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Thesis Summary 
 
No disease-modifying compounds are available to halt disease progression in Alzheimer’s 
disease (AD). Immunotherapy offers promising possibilities for the manipulation of Aβ levels 
which the amyloid cascade hypothesis proposes as the causative factor in AD. However, anti-
Aβ antibodies have caused inflammation in vivo. An alternative antibody (2B3) which targets 
the β-secretase cleavage site of the amyloid precursor protein (APP) from which Aβ is cleaved 
has been shown to downregulate Aβ in human cell lines. The approach is thought unlikely to 
cause inflammation as the immune system is not relied upon for Aβ clearance. It was 
hypothesised that the administration of 2B3 to aged transgenic APP mutation mice would 
lower Aβ levels through the inhibition of Aβ production, with an associated lowering of 
cognitive deficits. Two murine APP mutation models [London APP(V717I) and Indiana 
PDAPP(V717F)] were characterised in order to identify cognitive deficits against which the 
ability of 2B3 to reduce deficits could be assessed. APP(V717I) mice were assessed in the 
marble burying task, the elevated plus maze and a foraging task assessing spatial working 
memory at 3, 6 and 19 months of age. The radial arm water maze was carried out at 10 
months, before the T-maze non-matching to position task was administered at 11 months. 
Object recognition memory was assessed at 18 months. Similarly, PDAPP mice were assessed 
using the marble burying and elevated plus maze (9.5months), the T-maze (9-10 months), the 
foraging task (11 and 14 months) and the object recognition task (12 months). Whilst aged 
transgenic PDAPP mice displayed disrupted spatial working memory, no evidence of age-
related cognitive decline was observed in APP(V717I) transgenic mice despite increases in Aβ 
pathology with age. 2B3 did not alter Aβ levels or spatial working memory in PDAPP(V717F) 
mice in  a pilot study, whilst the in vitro downregulation of Aβ was successfully replicated in 
primary murine neurons. The findings indicate that transgenic models of neurodegenerative 
disease require thorough characterisation to optimise their use in pre-clinical research. 
Furthermore, the use of alternative immunotherapy in the treatment of AD remains a 
promising, but early stage avenue of study.      
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Chapter 1
 
Introduction 
 
1.1 Overview of the general introduction  
Currently available treatments for Alzheimer’s disease (AD) are symptomatic only, and are not 
able to halt neurodegeneration or the decline in cognitive function over time. Treatments 
which target the driving factors in disease progression are greatly needed. Transgenic mouse 
models of AD-like pathology are valuable tools for investigating the potential disease-
modifying characteristics of novel compounds. This introduction will summarise the 
neurobiological pathology and cognitive decline characteristic of AD, with a particular focus on 
Aβ, a 40-42 amino acid sized protein, and its role in the aetiology of AD. It is argued that Aβ is 
causal in AD progression, and is central in synaptic disruption and cognitive decline observed 
in patients and model systems. A range of other risk factors will be discussed, before 
presenting a short overview of transgenic mouse models of AD-like pathology. Following a 
presentation of the current treatments available for AD patients, a summary of the range of 
disease-modifying approaches currently under investigation is put forward. Whilst a range of 
steps in the Aβ cascade of pathology have been successfully targeted to lower Aβ levels in 
transgenic mouse models of AD, several of these approaches have not translated successfully 
to clinical trials or could have a number of side effects due to a lack of specificity in its targets. 
The concluding sections of the introduction will propose that an anti-APP β-secretase cleavage 
site antibody (2B3) which is able to reduce Aβ in vitro could provide a disease-modifying 
treatment with less of the side effects observed in pre-clinical studies and human trials. The 
introduction will hypothesise that the administration of this antibody will lower Aβ levels in 
transgenic APP mutation mouse models of AD-like pathology, and that such a reduction will 
reduce associated age-related cognitive deficits.     
 
1.2 AD prevalence and cost 
AD is a progressive neurodegenerative disease estimated to affect more than 493 000 people 
in the UK (Dementia UK report, 2010). It is the most common type of dementia, a class of 
disorders which reduce normal functioning of cognition and behaviour (Wimo & Prince, 2010). 
As a high number of patients are cared for by family members or friends in the community, 
the disease has far-reaching effects beyond that of the sufferers themselves. Carers report 
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high levels of strain, depression and distress (Marriot et al., 2000) and it is likely that the effect 
on carers of attending to an individual with AD in their home is highly underestimated (World 
Alzheimer Report, 2010). In addition to the disease being an emotional, cognitive and physical 
burden, it is estimated that the total annual cost of dementia in the UK is currently £23 billion 
(Dementia UK report, 2010). The problem is a growing one, as the number of people suffering 
from dementia is expected to rise by 154% over the next 45 years mirroring an expected 
increase in the proportion of aged members of the UK population (Dementia UK report, 2007). 
In line with this increase in patients, worldwide dementia costs are set to increase by 85% of 
current spending by 2030 (Wimo & Prince, 2010). With such a large scale health problem 
growing every year, there is a clear need for further understanding of the aetiology of the 
disease, the mechanisms of disease progression and potential treatments.  
 
1.3 Cognitive and behavioural impairments 
The earliest clinical manifestation of AD is subtle memory loss (Braak & Braak, 1995), affecting 
particularly semantic and episodic memory in 86-94% of patients (Dubois et al., 2007). 
Episodic memory impairment is also central feature of the core diagnostic criteria of the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (American Psychiatric 
Association, DSM-IV-TR, 2000).  This is followed by a progressive worsening of cognitive ability, 
which often targets specific functions such as language and perception (McKhann et al., 1984). 
Working memory and attentional control has been found to decline with disease progression 
(Becker, 1988; Baddley et al., 1991, Bellville, Chertkow & Gauthier, 2007), with short term 
memory deficits apparent with short and long delays (Grady et al., 2001). Impairments in 
recognition memory are apparent in a variety of domains including verbal, visual (facial, 
colours, patterns) and spatial stimuli (Moss, Albert, Butters & Payne, 1986). Non-cognitive 
changes are frequently observed in AD patients alongside cognitive decline. Firstly, 
behavioural changes including altered personality (Braak & Braak, 1995), outbursts of a verbal, 
emotional or physical nature and sexually inappropriate behaviour are common to varying 
degrees (McKhann et al., 1984). Secondly, neuropsychiatric symptoms and changes in 
emotional states are observed, such as depression, hallucinations and illusions (McKhann et 
al., 1984). Reports of 48% of AD patients suffering from increased anxiety, as well as frequent 
occurrences of emotional symptoms such as agitation, dysphoria and irritability highlight the 
wide range of behavioural and psychological problems in AD patients (Mega, Cummings, 
Fiorallo & Gornbein, 1996). Changes in sleep patterns are also frequent, with fragmented sleep 
during the night and increased tendency to sleep in daylight hours (Huitron-Resendiz et al., 
16 
 
2002), with some patients suffering from insomnia (McKhann et al., 1984). These symptoms 
are accompanied by a reduced ability to carry out activities of daily living (McKhann et al., 
1984). There have also been reports of increased seizures in AD patients (Amatinek et al., 
2006). 
 
1.4 Diagnosis of AD 
Diagnosis of AD is based on the DSM-IV-TR and the National Institute of Neurological Disorders 
and Stroke-Alzheimer Disease and Related Disorders working group (NINCDS-ADRDA; 
McKhann et al., 1984; Dubois et al., 2007). Whilst confirmation of a diagnosis of AD can only 
be made following post-mortem histological identification of both Aβ plaques and NFTs, a 
range of methods are employed to diagnose patients with AD in vivo with up to 90% accuracy 
in specialised clinics (Brodaty et al., 2011). The diagnostic process relies on a number of tools, 
including neuropsychological tests such as the Cambridge Neuropsychological Test Automated 
Battery (CANTAB; Fray & Robbins, 1996) in combination with dementia assessments such as 
the Mini-Mental Test and the Blessed Dementia Scale (McKhann et al., 1984) to assess a range 
of cognitive functions. Central to this is the identification of an episodic memory impairment 
which has been present over the last 6 months, and which is of a progressive nature (American 
Psychiatric Association, DSM-IV-TR, 2000). This is normally demonstrated as a recall deficit 
following effective encoding which persists despite being cued (American Psychiatric 
Association, DSM-IV-TR, 2000). Other behavioural disturbances, such as depressive features, 
irritability, apathy and aggression can be measured using tools such as the Behavioural Rating 
Scale for Dementia, but these are not considered a part of the diagnostic framework and are 
not specific to Alzheimer’s disease when compared to other dementias (Blazina et al., 1995).  
Medial temporal lobe atrophy and AD-specific patterns of activation are assessed using MRI 
and compared to controls. Finally, Aβ load measured using PET and alterations in CSF 
biomarkers, specifically low concentrations of Aβ42 with high phosphorylated or total tau, are 
used as AD-markers (Dubois et al., 2007; Brodaty et al., 2011). The emergence of biomarkers 
and use of imaging techniques in AD diagnosis have assisted an increase in diagnostic 
accuracy, which when using only the DSM-IV-TR and NINCDS-ADRDA guidelines to distinguish 
AD from other dementia cases was at an accuracy level of 23-88% (Dubois et al., 2007). 
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1.5 Pathology 
AD results in widespread neuronal loss and subsequent reduction in size of the temporal and 
frontal lobes in particular (Mattson, 2004). This is linked to extensive cognitive decline in 
patients, often couples with changes in personality (Mattson, 2004). The core pathology of AD, 
as discussed below, is characterised at a cellular level by extracellular plaques and intracellular 
tangles, which are aggregates of the proteins Aβ and tau respectively (Hardy & Higgins, 1992).  
 
1.5.1 Tau pathology 
As the focus of the experimental work in this thesis is on altered APP processing and 
downstream changes in Aβ and cognition, an extensive overview of the tau pathology 
literature will not be presented. Nevertheless, a short overview of the contributions of tau 
pathology to AD is given. 
The tau protein is a microtubule-associated molecule which is found in six different 
isoforms, ranging in size from 352 – 441 amino acids (Tolnay & Probst, 1999). The tau protein 
plays a central role in axonal transport through involvement in the assembly and stabilisation 
of microtubules (Tolnay & Probst, 1999). Once phosphorylated, tau is prevented from binding 
to microtubules, thus inhibiting microtubule functioning and normal axonal transport (Brion et 
al., 1991). As a pathological hallmark of Alzheimer’s disease, intraneuronal neurofibrillary 
tangles (NFTs) composed of predominantly paired (but also straight) helical filaments of 
hyperphosphorylated and abnormally phosphorylated tau are numerous in AD brain tissue 
(Tolnay & Probst, 1999). Braak & Braak (1991) characterised the predictable way in which NFT 
formation spreads through brain areas, dividing the progression into six neuropathological 
stages.  Pathology is initiated in the entorhinal cortex, progressing to the hippocampus with 
the emergence of mild cognitive impairment, and involves the neocortical association areas 
and severe dementia in the final stages (Braak & Braak, 1991).  
The aggregation of phosphorylated tau into NFTs has been shown to be linked to 
cognitive decline and neurodegeneration independently of Aβ pathology. In tauopathy 
disorders such as familial frontotemporal dementia and Parkinsonism linked to chromosome 
17 (FTDP-17), dementia is present in the absence of Aβ accumulation (Tolnay & Probst, 1999). 
This disorder is linked to mutations on the gene encoding tau, suggesting a central role for tau 
protein abnormalities in dementia (Tolnay & Probst, 1999). In support of this, the number of 
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NFTs in AD patients is correlated with cognitive impairment, as well as with neuronal loss 
(Tolnay & Probst, 1999; Gomez-Isla et al., 1997; Giannakopoulos et al., 2003).  
 
1.5.2 Aβ pathology  
Aβ is a 39-43 amino acid sized protein cleaved from amyloid precursor protein (APP), and is 
partly made up of the hydrophobic transmembrane domain of the APP COOH-terminal (Hardy 
& Higgins, 1992). Aβ protein monomers aggregate into oligomers, composing dimers, trimers 
and tetramers, before further aggregating into Aβ insoluble fibrils (Ward et al., 2000). These 
aggregates are evident in AD tissue as Aβ plaques, one of the classical pathological hallmarks 
which forms part of post-mortem diagnosis (McKhann et al., 1984). Aβ plaques are mainly 
made up of Aβ42, and are deposited in the extracellular space (Selkoe, 2001). Whilst the 
pattern by which Aβ pathology progresses through the brain is not as predictable as that of 
NFTs, there is nevertheless a general coherence in the development of pathology between 
patients.  As characterised by Thal et al. (2002), Aβ pathology progresses through five stages, 
initiating in the neocortex. Phase 2 sees the CA1 area of the hippocampus, the entorhinal 
cortex, the amygdala and the occipital lobe develop Aβ plaques, progressing to subcortical 
regions such as the thalamus, striatum, hypothalamus, caudate nucleus and white matter by 
phase 3. Phase 4 and 5 are similar in that previously observed areas of pathology are more 
heavily affected, with the addition of regions such as substantia nigra and areas of the pons.  
Whilst Aβ is a molecule which accumulates during normal aging, individuals with AD 
show elevated levels either due to overproduction, a failure of clearance, or a combination of 
the two (Klein, Krafft & Finch, 2001; Seubert et al., 1992; Shoji et al., 1992), with extensive 
data supporting the notion that Aβ plays a central role in the pathogenesis of AD (e.g. Selkoe, 
2001; see Chapter 1, Section 1.5.2). The dominance of Aβ42 over Aβ40 in plaques and the 
observation that it aggregates more rapidly in vitro than Aβ40 (Jarrett & Lansbury, 1993) has 
led to the idea that Aβ42 may play the more central role in amyloid pathology, although both 
species have been shown to be neurotoxic in vitro (King et al., 2003; Mucke et al., 2000).  
 
1.5.3 The interaction of tau and Aβ 
In addition to the independent contributions of tau and Aβ aggregation to neurodegeneration, 
there is growing evidence of interactions between Aβ and NFT pathology. Whilst this interplay 
is not yet defined, NFT pathology in AD is increasingly seen as one of a number of cellular 
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responses to the increased levels of Aβ (Selkoe, 2001), an idea in line with the amyloid cascade 
hypothesis of AD (see Chapter 1, Section 1.5.2). In support of this, Aβ and tau colocalise in 
neurons with tangle pathology (Guo et al., 2006) and the exposure of hippocampal neurons to 
Aβ or fragments of Aβ increases phosphorylation of tau (Busciglio et al., 1995; Takashima et 
al., 1996). Indeed, a single intracerebroventricular infusion of an Aβ-clearing antibody has 
been found to clear both tau and Aβ pathology (Oddo et al., 2006), but this is specific to early 
stage, unphosphorylated tau (Oddo et al., 2004). The mechanism linking upstream Aβ to 
downstream tau in the cascade of pathological events could be tau-dependent disassembly of 
microtubule proteins initiated by soluble Aβ specifically, as such disassembly is not observed 
through exposure to insoluble Aβ or in tau-free model systems (King et al., 2006). Strong 
support for the importance of Aβ/tau interactions in the development of cognitive deficits 
comes from a study where endogenous tau knockout (KO) mice were crossed with human APP 
(hAPP) mutation mice. When tested in the Morris water maze at 4-7 months of age, hAPP mice 
with either one or two alleles of endogenous tau showed impaired acquisition of the task. In 
accordance with the hypothesis that Aβ/tau interaction is a central aspect of AD pathology, 
mice that carried either hAPP without endogenous tau, or the reverse, acquired the task 
successfully (Roberson et al., 2007). A recent study by Bush and colleagues (Lei et al., 2012) 
which demonstrated the emergence of behavioural deficits and Parkinsonism in tau-KO mice 
may offer indications of the mechanisms which link the hyperphosphorylation of tau and 
tangle formation to Aβ pathology. They propose that the main cargo of tau-dependent 
trafficking is APP, and that a reduction in the level of soluble tau results in lower levels of APP 
transported to the cell surface. As APP has been shown to play a role in iron export from the 
cell (Duce et al., 2010), an inhibition of this function could result in toxic intraneuronal iron 
accumulation.  
 
1.5.4 Amyloid precursor protein (APP) processing 
Aβ is cleaved from the single transmembrane polypeptide APP (Selkoe, 2001). There are 3 
isoforms of 695, 751 and 770 amino acid residues, all of which are expressed throughout 
various cell types in the body (Selkoe, 2001). Neuronal cells express higher levels of the 695 
isoform, however, and the levels of this form of APP are low in non-neuronal cells (Mattson, 
2004). The N-terminal of the molecule protrudes into the extracellular space, whilst the 724-
770 amino acids of the COOH-terminal of the protein are positioned intracellularly.  
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APP can be processed by two different pathways (see Fig. 1), with altered APP 
processing being central to AD (Mattson, 2004). The majority of APP is subject to proteolytic 
cleavage by α-secretase at residues 15 and 17 within the Aβ amino acid domain, producing the 
83 amino acid sized C-terminal fragment of APP (C83) in addition to the N-terminal fragment 
sAPPα (Tanzi & Bertram, 2005). The enzymes responsible for α-secretase activity are likely to 
be the ADAM family of proteases, such as TACE, ADAM9 and ADAM10 (Buxbaum et al., 1998; 
Asai et al., 2003; O’Brien & Wong, 2011; Mattson, 2004). C83 can be further processed by γ-
secretase to produce P3 and the APP intracellular domain (AICD; Cao & Sudhof, 2001 as cited 
in Tanzi & Bertram, 2005). This pattern of cleavage does not produce Aβ.  
Alternatively, APP can be sequentially cleaved by the enzymes β- and γ-secretase, 
respectively. β-secretase has been identified as the transmembrane protein BACE1, whilst γ-
secretase has been identified as a complex comprised minimally of the presenilins, γ-
secretase, nicasterin, aph-1 and pen-2 (Edbauer et al., 2003; Francis et al., 2002). The 
sequential cleavage of APP results in the release of the N-terminal fragment sAPPβ and the C-
terminal fragment C99. Importantly, cleavage of C99 by γ-secretase produces the 40-42 amino 
acid-sized Aβ protein, depending on the exact location of γ-secretase cleavage within the 
transmembrane domain, in addition to AICD.  
The current model of APP processing proposes that APP can either be processed at the 
cell surface, or internalised through endocytosis and processed in endosomal compartments 
(O’Brien & Wong, 2011). This view of APP processing proposes that cell surface proteolysis 
involves α-secretase and γ-secretase, and does not result in Aβ production. In contrast, the 
processing of APP in endosomal compartments containing β-secretase and γ-secretase does 
lead to Aβ release. In support of this, inhibiting internalisation of APP lowers Aβ release by 
80% (Koo & Squazzo, 1994). Furthermore, BACE1 is predominantly found in the Golgi 
apparatus, supporting the belief that β-secretase-cleavage of APP occurs following endocytosis 
(Luo & Yan, 2010). It is currently unclear what regulates whether APP is processed at the cell 
surface or following endocytosis, but a shift in this regulation could be instrumental in altering 
AD pathology.  
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Fig. 1.1: A simplified schematic representation of APP processing by α-, β- and γ-secretase with 
the release of subsequent protein products as presented in Mattson (2004).  
 
1.5.5 Neuronal loss and cerebral Aβ angiopathy (CAA) 
The pathology of AD involves hallmarks beyond that of increased levels and deposition of Aβ 
and hyperphosphorylated tau, as neuronal loss and vascular damage caused by amyloid 
plaque formation are also common (Hardy & Higgins, 1992). Deposits of mainly Aβ40 are 
observed in small arterioles and capillaries in the cerebral cortex, but are rarely seen entering 
the white matter in subcortical layers (Selkoe, 2001). The contribution of CAA to cognitive 
decline or disease progression is unclear, as Aβ plaque load has not been found to correlate 
well with levels of angiopathy (Selkoe, 2001). In terms of neuronal loss, the hippocampi are 
heavily affected in AD patients (West, Coleman, Flood & Troncoso, 1994). Using imaging 
techniques, the hippocampal neural atrophy has been estimated to be 38% compared to age-
matched healthy controls, with atrophy of the frontal lobes and the amygdalae at 15-16% of 
normal volume (Laakso et al., 1995).  
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1.6 Aetiology of AD  
There are a number of hypotheses regarding the cause of AD. As the focus of the current work 
is on altering APP processing to downregulate Aβ production, the emphasis will be on the Aβ 
cascade hypothesis. Nevertheless, it is important to note that a variety of alternative 
hypotheses of AD aetiology have been put forward, highlighting the role of tau (Braak, Braak & 
Mandelkow, 1994; Rapoport, Dawson, Binder, Vitek & Ferreira, 2002), cholinergic dysfunction 
(Bartus, Dean, Beer & Lippa, 1982), oxidative stress induced DNA damage (Lu et al., 2004),  
mitochondrial dysfunction (Blass & Gibson, 1999; Castellani et al., 2002) and increased 
inflammation (McGeer & Rogers, 1992). The degree to which these are independent driving 
factors in aetiology, or act in combination with Aβ pathology (Mattson et al., 1992; Bush, 
2003) is unclear.   
 
1.6.1 AD risk 
Age is a serious risk factor for AD, as patients are rarely diagnosed in the first 40 years of life 
with the exception of individuals with Down’s syndrome. There are two subgroups of AD 
patients based on the age of onset of disease. The majority of AD patients suffer from the late 
onset form, defined as age of onset above 65 years. Only 1-5% of cases have an onset age 
below 65 years of age, referred to as the early onset form of AD (Tanzi & Bertram, 2005; 
McMurtray et al., 2006).  
The risk of familial AD (FAD), which typically manifests itself as early onset AD, is 
dominated by genetic predisposition. A series of autosomal dominant mutations on several 
AD-linked genes inevitably lead to early onset AD in carriers. The first FAD APP mutation was 
identified by Goete et al. in 1991, but 31 other autosomal APP mutations have been identified 
since (O’Brien & Wong, 2011). In addition, 179 presenilin1 (PSEN1) and 14 presenilin2 (PSEN2) 
autosomal dominant mutations have been identified. Generally, these mutations have in 
common that they increase production of Aβ42 compared to Aβ40 (O’Brien & Wong, 2011).  
By comparison, sporadic AD (SAD) is not linked to autosomal dominant mutations, but 
risk is nevertheless estimated to be 50-70% genetically determined (O’Brien & Wong, 2011). 
This is typically associated with late onset AD. The ε4 allele of the APOE gene has been 
strongly linked to AD, with a 3- to 15-fold risk increase with hetero- and homozygous carriers 
respectively (O’Brien & Wong, 2011; Harold et al., 2009). A group of smaller risk genes have 
been recently been identified using genome wide association studies (GWAS), which allow for 
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risk genes of smaller effect to be detected through the use of large sample sizes. These include 
variations on the CLU and PICALM genes (Harold et al., 2009), and underline the emerging 
complex genetic risk picture linked to SAD. GWAS studies with further increases in sample size 
are underway, opening up the possibility of further small risk genes to be identified. Mutations 
in these genes may not be sufficient to put an individual at risk when at low numbers, but may 
act together to increase the risk sufficiently to initiate AD pathology when in larger numbers. It 
is noteworthy that the pathology of SAD is very similar to that of FAD (O’Brien & Wong, 2011; 
Hernandez & Avila, 2008). This provides support to the idea that Aβ is central in the disease, 
despite potentially varying etiological triggers and genetic contributions. 
A variety of lifestyle factors have also been identified to play a role in SAD risk, with 
medical conditions such as vascular disease, hypertension, obesity and stroke increasing AD 
risk (Breteler, 2000, Brodaty et al., 2011), as well as socioeconomic factors including low levels 
of education. Protective life style factors involve high levels of physical and mental exercise 
(Fratiglioni, Paillard-Borg & Winblad, 2004), with some indication that dietary elements such 
as wine consumption can reduce risk of AD by up to 50% (Lindsay et al., 2002). Not only do 
these studies provide a more balanced picture of the risk factors involved in the development 
of AD beyond genetic risk, but they indicate that there is potential for risk-reducing behaviour 
to influence AD prevalence.  
 
1.6.2 The Aβ cascade hypothesis  
The most influential theory of AD aetiology is the Aβ hypothesis (Hardy & Higgins, 1992). The 
hypothesis proposes that Aβ deposition is causative in the disease, and that other pathological 
characteristics associated with the disease, such as NFTs, neuronal loss, CAA and behavioural 
and cognitive deficits characteristic of dementia, are a result of this deposition.  
The initial focus on Aβ as a central protein to disease progression was based on two 
sets of findings, beyond the identification of Aβ as the main component of plaques (Selkoe, 
2001). Firstly, it was observed that individuals with Down’s syndrome who live to 50 years of 
age have a higher incidence rate of AD than age-matched controls (Hardy & Higgins, 1992; 
Mann & Esiri, 1989). This combined with the discovery that the gene encoding APP is located 
on chromosome 21 of which individuals with Down’s syndrome have an extra copy, indicated 
that Aβ may play a role in the initiation and/or progression of AD (Mann et al., 1989; Rumble 
et al., 1989; Hardy & Higgins, 1992).  
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The proposed mechanism by which Aβ induces tangle formation is through disruption 
of calcium homeostasis (Hardy & Higgins, 1992). Aβ is known to increase intracellular calcium 
levels, which plays a role in the phosphorylation of tau (Baudier & Cole, 1987). With 
abnormally high intracellular calcium levels driven by Aβ, abnormally high levels of 
phosphorylated tau protein may be produced, which may in turn aggregate into the paired 
helical filaments found in neurofibrillary tangles. 
The amyloid cascade hypothesis has gained a substantial amount of support since 
being proposed in 1992, whilst remaining controversial (Tanzi, Moir & Wagner, 2004; Terry, 
1996). The support for the central role of Aβ in AD comes from a variety of sources. Firstly, the 
identification of a number of autosomal dominant APP and the presenilins (PSEN) mutations in 
families with high numbers of AD sufferers implicated changes associated with APP and Aβ as 
critical elements in the development of AD (St George-Hyslop et al., 1987; Goete et al., 1991; 
Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995). Secondly, the generation 
of transgenic mouse models of AD-like pathology by the introduction of identified APP and 
PSEN mutations to the mouse genome demonstrated a causal link between alterations in APP 
processing and increased levels of Aβ (Games et al., 1995; Hsiao et al., 1996; Moechars et al., 
1999b). Thirdly, the demonstration that immunisation with Aβ in transgenic mouse models 
which reproduce Aβ pathology similar to that seen in AD can not only lower Aβ levels and clear 
plaques, but improve cognition, suggests Aβ to be causally involved in the progression of 
dementia (Janus et al., 2000; Morgan et al., 2000; Wilcock et al., 2004; Rakover et al., 2007). 
Further evidence to suggest that Aβ pathology lies upstream of NFT pathology are the 
observations that the JNPL3 transgenic mouse line, which expresses a human tau mutation 
linked to frontotemporal dementia with parkinsonism-17 (FTDP-17), develops NFTs with age 
with no evidence of Aβ deposition (Lewis et al., 2000 as cited in Schwab et al., 2004). When 
crossing JNPL3 mice with Tg2576 mice, which develop Aβ plaques in the absence of NFTs 
based on the double Swedish APP mutations, the offspring develop comparable Aβ pathology 
to Tg2576 mice with exaggerated NFT pathology compared to the JNPL3 mice (Lewis et al., 
2001). This indicates that NFT deposition is influenced by the presence of Aβ, whilst the NFT 
pathology does not influence Aβ plaque numbers significantly (Schwab et al., 2004).  
As demonstrated by Pike et al. (1991), an early focus of the AD field was the 
neurotoxic properties of aggregated, fibrillar Aβ leading to neuronal death, with soluble Aβ 
considered less neurotoxic or in some instances, to have a trophic effect (Whitson et al., 1989; 
Whitson et al., 1990). Growing evidence has since demonstrated that the soluble, prefibrillar 
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forms of Aβ are more neurotoxic than insoluble, fibrillar Aβ (Klein, Krafft & Finch, 2001; Ashe, 
2009; Teller et al., 1996). This modified version of the amyloid cascade hypothesis suggests a 
connection between non-fibrillar Aβ and neuronal apoptosis (Sponne et al., 2003). Aβ has 
been demonstrated to directly interfere with plasma membrane functioning, disrupting 
calcium homeostasis and causing neuronal death when in its pre-aggregated form (Pillot et al., 
1999; Rhee et al., 1998; Lin et al., 2001). Non-fibrillar Aβ40 at low concentrations has also 
been shown to induce disruption of microtubule functioning through the generation of 
reactive oxygen species, leading to caspase activation and neuronal death (Sponne et al., 
2003). Importantly, Walsh et al. (2002) identified Aβ oligomers as synaptotoxic in vivo, and 
found no such role for either Aβ monomers or fibrils. The observed disruption of long term 
potentiation (LTP), a proposed neuronal basis of learning (Bliss & Lømo, 1973), was found to 
be reversed if hippocampal slices were subjected to an anti-oligomeric Aβ antibody (Kayed et 
al., 2003). In 1996, Hsiao et al. showed that age-related deficits in spatial memory correlated 
with elevated levels of soluble Aβ40 and Aβ42 in transgenic mouse models of disease at 9-10 
months of age. Similarly, a comparison between a series of APP overexpressing transgenic 
mouse lines found correlations between soluble Aβ42 levels and reduced numbers of 
presynaptic terminals, but no such correlation existed if soluble Aβ42 was substituted for 
either APP levels or plaque load in the analysis (Mucke et al., 2000). Oligomeric Aβ may also be 
driving memory deficits in AD patients (Klein, Krafft & Finch, 2001), and importantly, several 
groups have identified Aβ oligomers in tissue from AD patients (Roher et al., 1996; Enya et al., 
1999; Pitschke et al., 1998).  
The idea that soluble Aβ could be the predominantly neurotoxic form of the peptide 
fits with findings that point to strong correlations between soluble Aβ and cognitive decline 
(McLean et al., 1999; Oddo et al., 2006; Naslun et al., 2000) and synaptic loss (McLean et al., 
1999; Lue et al., 1999). This addresses a controversial issue with the original amyloid cascade 
hypothesis (Klein, Krafft & Finch, 2001), namely the weak correlations observed between 
plaque load and cognitive deficits (Mucke et al., 2000; Cummings et al., 1996; Terry, 1996; 
Bartoo et al., 1997; Thal et al., 2002; Gomez-Isla et al., 1997; Lue et al., 1999; Holmes et al., 
2008; McLean et al., 1999; Davis et al, 1999). Together, these studies have led to a refocusing 
of the Aβ cascade hypothesis in which soluble Aβ species are widely appreciated as disease-
relevant, with fibrillar, insoluble Aβ formations potentially acting as a neutraliser of this 
toxicity as opposed to inducing neurotoxicity in themselves.  
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 A second shift in the field to acknowledge is the growing awareness of intraneuronal 
Aβ as contributing to AD pathology in addition to extracellular Aβ, on which the focus has 
traditionally been. Oddo et al. (2006) found Aβ could be detected intracellularly prior to any 
extracellular presence, corroborating evidence from other groups observing intracellular 
accumulations of Aβ42 in vitro (Echeverria & Cuello, 2002; Tabira et al., 2002) and in 
transgenic mouse models of Aβ pathology (Wirths et al., 2001; Sheng et al., 2003). An 
interaction between the two pools of Aβ has also been reported, with extracellular Aβ42 
leading to intracellular increases in Aβ42 (Glabe et al., 2001), as well as exchanges in the 
opposite direction (DeMattos et al., 2001; 2002b, Oddo et al., 2004; 2006). Aging transgenic 
Tg2576 mice which model Aβ pathology leads to intraneuronal accumulation of Aβ42 in 
synaptic compartments and neuronal processes (Takahashi et al., 2004), and intracellular Aβ 
has been linked to behavioural deficits in the APP/Tg mouse model of AD (Billings et al., 2005).  
 
1.6.3 Synaptic disruption 
Whilst the amyloid cascade hypothesis focused the attention of the field on Aβ being causative 
in disease progression (Hardy & Higgins, 1992), it was not in a position to provide detailed 
hypotheses regarding the mechanisms involved in the pathological cascade leading to 
neuronal death. There is increasing support for the idea that synaptic damage is both an early 
and important pathological event in AD patients (Mattson, 2004; Tanzi, 2005; Synder et al., 
2005). This development is separate to the traditional “cholinergic hypothesis” which suggests 
that the impairment in cholinergic transmission following degeneration of the basal forebrain 
nuclei coupled with a reduction in the number of nicotinic receptors is an early and central 
part of AD pathology and disease progression (Scarpini, Scheltens & Feldman, 2003). There is 
controversy regarding whether this pathology is a driving force in the progression of the 
disease based around results suggesting that levels of acetylcholinesterase and choline 
acetyltransferase are stable during the early stages of AD (Scarpini, Scheltens & Feldman, 
2003). 
Aside from the role of acetylcholine in AD, extensive evidence supports the view that 
synaptic disruption is a central feature of AD. Brain regions which exhibit Aβ plaque pathology 
in patients frequently have a reduced number of synapses as well as display neuritic damage 
(Mattson, 2004; Dickson et al., 1995; Masliah et al., 1994), and synaptic loss correlates well 
with cognitive decline in patients (Terry et al., 1991; Sze et al., 1997; Lue et al., 1999; Tanzi, 
2005). In PDAPP and Tg2576 transgenic mice, synaptic impairments are observed prior to 
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plaque deposition (Larson et al., 1999; Jacobsen et al., 2006) suggesting an early role for 
synaptic disruption. As APP is transported to synaptic terminals following endoplasmic 
reticulum and Golgi sorting (O’Brien & Wong, 2011; Koo et al., 1990), the synapse is a location 
with the potential for high levels of soluble Aβ (Gong et al., 2003; Buxbaum et al., 1998) and is 
thus at high risk for Aβ induced damage. In addition, synaptic activity has been found to 
regulate APP processing (Kamenetz et al., 2003), carrying with it the possibility that altered 
synaptic function could increase pathogenic processing of APP through an Aβ-mediated 
feedback loop.  
Furthermore, there is evidence for the ability of Aβ oligomers to disrupt LTP in APP 
mutation mice in vitro (Lambert et al., 1998) and in vivo (Walsh et al., 2002), with the reversal 
of this effect observed in the presence of an anti-oligomeric Aβ antibody (Kayed et al., 2003). 
In addition, temporary disruption of a learned behaviour in Tg2576 transgenic mice using Aβ 
oligomers supports the idea that Aβ can disrupt synaptic functioning (Cleary et al., 2005). 
Snyder et al. (2005) found that application of Aβ42 to cultured neurons reduced the number of 
NMDA-receptors at the synapse, reducing sensitivity to glutamate. In support of this, a similar 
reduction in NDMA receptors can be seen in Tg2576 mice neurons (Snyder et al., 2005). AD 
patients have been found to have altered patterns of synaptic proteins, with changes in both 
the concentration, location and recycling of individual protein groups in regions vulnerable to 
AD pathology (Masliah et al., 2001).  
There is evidence that the presence of Aβ at the synapse increases the vulnerability of 
the synapse to oxidative stress and excitotoxicity in addition to altering calcium homeostasis 
and energy metabolism (Mattson, 2004). Such changes are linked to activation of apoptotic 
signalling cascades, potentially offering pathways through which Aβ production can lead to 
neuronal death (Mattson, 2004). As neuronal apoptotic signalling pathways are predominantly 
initiated at the synapse, it emerges as a likely location for Aβ induced apoptosis (Mattson, 
2004).  
The growing evidence pointing to synaptic dysfunction and apoptosis induced at the 
synapse leads to the question of reversibility (Tanzi, 2005). There is need to investigate both 
whether cognitive function be restored in neurons which have been exposed to Aβ-induced 
impairments, and at what time point intervention is necessary to inhibit the initiation by Aβ of 
apoptotic signalling cascades (Tanzi, 2005).   
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1.7 Modelling AD: Transgenic mouse models of AD pathology and phenotype  
An in-depth review of the two APP mutation mouse models utilised in this project will be 
described in their relevant experimental chapters. As an initial introduction, however, an 
overview of the role of transgenic mouse models in AD research will be presented. Whilst it is 
recognised that models based on mutations in the presenilins and tau genes are highly useful 
in a variety of contexts, the overview focuses on APP mutation models due to their central role 
in the current work. As the therapeutic approach to be assessed is based on altering APP 
processing to reduce Aβ production, models in which Aβ pathology is driven by APP mutations 
were a natural choice.      
The aim of transgenic approaches to modelling Alzheimer’s disease, or any other 
disease process, is to capture accurately a minimum of one feature of the disorder to allow for 
detailed investigation (Loring, 2000). Transgenic mouse models are created through the 
introduction of human genetic material into the mouse genome using site-directed 
mutagenesis of the gene of choice (Capecchi, 1989). Although this approach can be successful 
in a number of other species, the mouse is a commonly used species due to the large overlap 
between the human and mouse genomes (Mouse Genome Sequencing Consortium, 2002).  
Whilst there are a number of transgenic mouse models of Alzheimer’s pathology, no 
current model recapitulates all aspects of AD pathology as well as the typical cognitive deficits 
(Ashe & Zahs, 2010). Neuronal loss is a feature of AD which has been particularly challenging 
to recapitulate in model systems, whilst Aβ pathology in comparison is convincingly 
reproduced in a number of transgenic mouse models. Nevertheless, the introduction of 
transgenic mouse models of AD pathology to the field has been highly valuable. Whilst post-
mortem examination of brain tissue from AD patients has tremendous value in classifying and 
characterising the pathological hallmarks of AD, transgenic mouse models of the disease 
pathology offers an insight into the temporal development of such hallmarks, as well as the 
association between different pathological key stages and cognitive deficits. Increased 
understanding of the temporal nature of pathological developments has helped dissociate Aβ 
plaque load and cognitive deficits, aiding the refocusing of the field’s attention on soluble Aβ 
species. Nevertheless, it is important to critically evaluate the degree to which observations of 
transgenic mouse models of Aβ pathology are comparable to the human condition, given the 
differences in species as well as in the methods employed to assess cognitive function and 
behavioural change. This will be discussed in more detail in the relevant experimental 
chapters.   
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1.7.1 APP mutation mouse models  
APP mutation mouse models of AD pathology are based on autosomal dominant mutations in 
APP isolated from FAD patients. Thirty-one mutations of APP have been identified (O’Brien & 
Wong, 2011), such as the Swedish double mutation around the β-secretase cleavage site 
(K670M/N671L, Mullan et al., 1992), the Arctic mutation (E693G, Kamino et al., 1992; Nilsbeth 
et al., 2001; Basum et al., 2008) in the middle of the Aβ fragment as well as the Indiana 
(V717F, Murrel et al., 1992) and London mutations (V717I, Goete et al., 1991), both around 
the γ-secretase cleavage site. These mutations have given rise to a range of APP mutation 
models based on different mutations using varying genetic background strains and genetic 
promoters, with the common outcome of elevation of Aβ (see Table 1). 
Model Transgene 
mutation and 
promoter 
Promoter Aβ plaque 
pathology 
Cognitive deficit Reference 
Tg2576 APP Swedish 
(K670N/M671L)  
Hamster 
PrP 
Aβ plaques 
from 9-11 
months, 
reduced 
synaptic 
density 
Impaired spatial 
reference and working 
memory, object 
recognition memory 
(episodic like) 
Hsiao et al. 
(1996) 
PDAPP APP Indiana 
(V717F) 
PDGFβ  Aβ plaques 
from 6-8 
months, loss 
of synaptic 
density, 
hippocampal 
atrophy 
Impaired spatial 
reference and working 
memory, object 
recognition memory, 
cued fear conditioning 
Games et 
al. (1995) 
APP 
(V717I) or 
APP/Ld/2 
APP London 
(V717I) 
Murine 
Thy1 
Aβ plaques 
from 10-12 
months of age, 
altered 
synaptic 
functioning 
and c-fos 
expression 
Impaired spatial 
reference memory 
and object recognition 
memory at 3-6 
months,  increased 
anxiety from 1 month 
Moechars 
et al. 
(1999b) 
TgAPP22 APP Swedish 
(K670N/M671L), 
London (V717I) 
Murine 
Thy1 
Aβ plaques 
from 18 
months 
n/a Andra et al. 
(1996) 
TgCRND8 APP Swedish 
(K670N/M671L), 
Indiana (V717F) 
Syrian 
hamster 
PrP 
Aβ plaques 
from 2 months 
Impaired spatial 
reference and working 
memory 
Chishti et 
al. (2001) 
TgAPP23 APP Swedish 
(K670N/M671L) 
Murine 
Thy1 
Aβ plaques 
from 6 
Impaired spatial 
reference memory, 
Struchler-
Pierrat et 
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months, 
neuronal loss 
in CA1 
seizures and 
stereotypic behaviour 
al. (1997) 
TgAPP/Sw
/1 and 3 
APP Swedish 
(K670N/M671L) 
Murine 
Thy1 
Aβ plaques 
from 18-25 
months 
Increased anxiety and 
impaired spatial 
reference memory 
Moechars 
et al. 
(1999b) 
TgAPP/ 
WT 
No mutation, but 
WT APP over-
expression 
Murine 
Thy1 
No Aβ plaques Increased anxiety and 
spatial reference 
memory 
Moechars 
et al. 
(1999b) 
TgAPP/Fl 
TgAPP/Du 
APP Flemish 
(A692G), Dutch 
(E693Q) 
Murine 
Thy1 
No Aβ plaques  Increased aggression, 
seizures 
Kumar-
Singh et al. 
(2000) 
J20 APP Swedish 
(K670N/M671L), 
Indiana (V717F) 
PDGFβ Aβ plaques 
from 5-7 
months of 
diffuse nature, 
neuritic 
plaques from 
8-10 months  
Impaired reference 
memory 
Mucke et 
al. (2000) 
TgAPP 
SweArc 
APP Swedish 
(K670N/M671L), 
Indiana (V717F), 
Arctic (E693K 
(E22G) 
PDGFβ Aβ plaques 
from 2-3 
months 
n/a Cheng et 
al. (2004) 
TgAPP/ 
PS1 
APP Swedish 
(K670N/M671L), 
PSEN1 (M146L) 
PDGFβ 
and 
hamster 
PrP 
Aβ plaques 
from 6 months 
Impaired reference 
and working memory 
Holcomb et 
al. (1998) 
TgAPP/ 
PS1 
APP Swedish 
(K670N/M671L), 
PSEN1 
(A246E/TgPSEN1
5) 
 
PDGFβ 
and 
hamster 
PrP 
Aβ plaques 
from 9 months 
Impaired reference 
and working memory, 
auditory trace fear 
conditioning 
Borchelt et 
al. (1996) 
3xTg-AD APP Swedish 
(K670N/M671L), 
PS1 (M126V), 
Tau (P301L) 
Murine 
Thy-1 
Aβ plaques 
from 6 
months, NFTs 
from 9 months 
Impaired spatial 
reference memory  
Oddo et al. 
(2003) 
5xFAD APP Swedish 
(K670N/M671L), 
London (V717I), 
Florida (I716V), 
PSEN1 (M146L/ 
L286V) 
Murine 
Thy-1 
Aβ plaques 
from 2 
months, 
reduced 
synaptic 
density  
Impaired spontaneous 
alteration 
Oakley et 
al. (2006) 
Table 1.1: Summary table of transgenic models of AD-like pathology adapted from Eriksen & 
Janus, 2007. 
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1.8 Currently available treatments  
All available treatments for AD target the symptoms of the illness as opposed to the 
underlying causes, providing at best short-term improvements in cognition and behaviour 
(Schenk, 2002).  Two types of pharmacological treatments are used in AD patients. Firstly, the 
acetylcholinesterase inhibitors donepezil hydrochloride (Aricept), rivastigmine (Exelon) and 
galantamine (Reminyl) enhance acetylcholine levels in an attempt to counteract the reduced 
levels of the neurotransmitter and its receptors (Scarpini, Scheltens & Feldman, 2003). 
Galantamine also increases cholinergic neurotransmission by increasing acetylcholine release 
and transmission pre- and post-synaptically respectively (Scarpini, Scheltens & Feldman, 
2003).  
These drugs are used in mild to moderate stage AD patients and provide similar 
benefits in terms of behavioural, functional and cognitive symptoms (Scarpini, Scheltens & 
Feldman, 2003). The response of individual patients to treatment is variable however, 
resulting in small average benefits across patients (Scarpini, Scheltens & Feldman, 2003). A 
newly available treatment for advanced AD, memantine (Ebixa), is a NMDA channel blocker 
designed to inhibit glutamate-driven disruption of calcium homeostasis and excitotoxicity 
(Scarpini, Scheltens & Feldman, 2003). Whilst these treatments can temporarily halt cognitive 
decline, they do not offer long term relief of symptoms and have a limited period of 
effectiveness within individual AD patients (Mayeux & Sano, 1999).  
 
1.9 Treatment avenues under investigation 
The wide range of data generated following the identification of mutations in APP, PSEN1, 
PSEN2 and APOE collectively suggest that any disease-modifying treatment is likely to be more 
effective if levels of Aβ can be manipulated in some way (Tanzi & Bertram, 2005). This section 
will discuss the potential therapeutic targets in the Aβ cascade hypothesis which could be 
manipulated to alter the progression of AD beyond symptomatic treatment. Whilst no such 
treatment is currently available to AD patients, a wide range of possibilities are being explored 
in the scientific community, with several compounds proceeding to clinical trials.  
Whilst treatments which targets causal factors involved in AD disease initiation and 
progression are greatly needed, improvements in treatment offers could be provided without 
fully halting or reversing the disease. As the majority of AD cases are SAD with an onset age 
above 65 years (McMurtray et al., 2006) involving years of neurodegeneration, a delay in 
onset or a slowing of disease progression could be sufficient to avoid late stage AD in a 
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number of patients. An analysis by Brookmeyer et al. (2007) predicted that a one year delay in 
onset and progression would result in a reduction in 9.2 million cases of AD by 2050.  
Nevertheless, the growing evidence that AD-associated changes occur years prior to 
the emergence of clinical symptoms indicates that early intervention is likely to be most 
effective if a disease-modifying compound is to be used (Dubois et al., 2007). This is 
particularly relevant in the context of the amyloid cascade hypothesis, which would predict 
that an inhibition of Aβ levels and its associated toxicity will inhibit the development of 
downstream AD pathology. Based on this argument, several research groups have investigated 
forms of treatments designed to modify Aβ levels. These have included reducing Aβ 
production by selective increase or decrease in enzyme activity or enhancing Aβ clearance by a 
number of other strategies (Monsonego & Weiner, 2003). A short overview is provided of the 
research avenues investigated to date.  
 
1.9.1 Secretase inhibition 
The critical role of β- and γ-secretase in the production of Aβ makes these enzymes 
therapeutic candidates, in which reducing the activity of either secretase could prove 
beneficial in the aim of reducing Aβ levels.  
 APP is cleaved by β-secretase prior to γ-secretase cleavage, making it a suitable target 
to intervene in early Aβ production. In addition, β-secretase knockout (KO) mice produce 
virtually no Aβ whilst being generally healthy (Cai et al., 2001; Luo et al., 2001; Roberds et al., 
2001; Scarpini, Scheltens & Feldman, 2003;  Zouh et al, 2011). However, inhibition of β-
secretase (BACE1) may result in the inhibition of similar enzymes such as BACE2 and cathepsin 
D, and later studies of BACE1 KO mice have suggested abnormalities such as shortened 
lifespan, hypomyelination and indications of schizophrenia-like behaviour (Dominguez et al., 
2005; Hu et al., 2006; Willem et al., 2006; Savonenko et al., 2008). This is likely related to the 
fact that BACE1 has a number of other substrates in addition to APP, such as neuregulin-1 
(Nrg-1), a neurotrophic factor which is essential in synaptic and neurotransmitter function, as 
well as neuronal migration and myelination (Luo & Yan, 2010). Thus, it is likely to be 
problematic to inhibit BACE1 as this inhibition will not be APP specific (Rakover et al., 2007; 
Van Dooren et al., 2005, De Strooper et al., 2010).   
 Despite β-secretase being a highly challenging target (De Strooper et al., 2010), at 
least 18 different β-secretase inhibitors have been developed (Luo & Yan, 2010). Several of 
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these have successfully lowered Aβ levels in transgenic mouse models of AD (Asai et al., 2006; 
Ghosh et al., 2007; Ghosh et al., 2008; Hussain et al., 2007; Iserloh et al., 2008), but none 
measured the effect of the inhibitor on behavioural or cognitive measures. One of these, CTS-
21166 (CoMentis), has recently completed a phase I clinical trial demonstrating up to 80% 
reduction in plasma Aβ levels following intravenous administration (Luo & Yan, 2010). 
Similarly, May et al. (2011) reported significant reductions in plasma and CSF Aβ levels 
following administration of LY2911376, a non-peptidic orally available BACE1 inhibitor, to 
healthy volunteers. However, due to evidence from toxicology studies in rats showing an 
accumulation of unidentified biological material in the retinal epithelium and intracellularly 
within neurons and glia cells, the phase II clinical trial will not proceed with this compound. 
Thus, whilst BACE1 inhibition remains an interesting target for investigation, it is likely that the 
selectivity of the approach will need to be improved to ensure that side-effects are minimised. 
Inhibition of γ-secretase is a therapeutic target due to its role in determining the 
length of the Aβ peptide (Scarpini, Scheltens & Feldman, 2003; De Strooper et al., 2010). As 
with strategies to target β-secretase, γ-secretase inhibitors have an innate challenge in  that γ-
secretase has a number of substrates besides APP, such as Notch (Scarpini, Scheltens & 
Feldman, 2003; Bermans & De Strooper, 2010; Tanzi & Bertram, 2005) and Nectin (Kim et al., 
2002). Blocking Notch signalling is embryo-lethal, and a number of sources are indicating a 
role for γ-secretase in processing a number of transmembrane proteins (Kopan & Ilagan, 
2004). Thus, successful inhibition of γ-secretase relies on it being APP-specific.  
At least six γ-secretase inhibitors have been developed and are being tested in clinical 
trials or small scale human testing (Imbimbo, 2008). Semagacestat (LY-450139) progressed 
furthest of these (Bateman et al., 2009; Imbimbo, 2008, Siemers et al., 2007), but clinical trials 
and further development was halted in 2010 due to adverse effects in treated patients. These 
include accelerated cognitive decline and elevated levels of melanoma. A recent follow up of 
patients who were treated for 32 weeks prior to the disruption of the trial suggests irreversible 
acceleration of cognitive measures and a decreased ability to perform activities of daily living 
in treated patients compared to controls. The observation that Semagacestat negatively 
affects cognitive functioning in AD patients has received pre-clinical support from Bittner et al. 
(2009) who found the drug induced an irreversible loss of dendritic spines in wild type mice. 
These results suggest that blanket inhibition of APP secretases is likely to have unacceptable 
side effects, and that more specific approaches need to be considered. A subgroup of the 
currently available γ-secretase inhibitors appear not to affect Notch signalling (Petit et al., 
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2003; Albright et al., 2008; Mayer et al., 2008), and thus could offer alternatives to 
Semagacestat with reduced side-effects. 
 
1.9.2 Aggregation modulators 
Aβ oligomers have been identified as synaptotoxic, whilst Aβ monomers show no such effect 
(Walsh et al., 2002). Therefore, inhibiting Aβ aggregation or β-sheet formation may provide 
sufficient neuroprotection to be used as a disease treatment (Tanzi & Bertram, 2005, Citron et 
al., 2004). Utilising aggregation-blocking compounds could attenuate Aβ toxicity and 
subsequently may inhibit neuroinflammation (Caughey & Lansbury, 2003). Efforts to limit 
neuroinflammation alone, such as through the use of non steroidal anti-inflammatory drugs, 
may also provide therapeutic benefits (Rogers & Lahiri, 2004). Aggregation of Aβ is dependent 
on interactions with heavy metals such as zinc and copper, and can be inhibited through 
administration of metal-complexing drugs such as clioquinol (Tanzi et al., 2004, Ritchie et al., 
2003).  
 
1.9.3 Increased clearance of Aβ 
Apart from the use of antibody-mediated clearance, there are two pathways through which Aβ 
can be cleared from the brain, namely through proteolytic degradation or receptor-mediated 
transport to the periphery (Tanzi et al., 2004). The low-density lipoprotein receptor-related 
protein (LRP) has been found to be involved in transporting Aβ from the CNS to the plasma 
across the blood brain barrier (BBB), whilst the receptor for advanced glycation end products 
(RAGE) transports Aβ in the opposite direction. Modulation of their activity could aid clearance 
of Aβ from the CNS and potentially lead to degradation in sites such as the liver (Zlokovic, 
2004). Indeed, LRP antagonists can lower efflux of Aβ from the CNS by 90% in mice models 
(Tanzi et al., 2004).  
Alternatively, Aβ degradation can be increased within the CNS through enhancing the 
activity of zinc metalloendopeptidases such as insulin degrading enzyme (IDE) and neprilysin 
(NEP; Tanzi et al., 2004). These peptidases have a range of other substrates, however, 
including insulin, glucagon, β-endorphin, amylin, transforming growth factor, neuropeptide Y, 
enkephalin and substance P (Tanzi et al., 2004), indicating that upregulation of their activity is 
likely to produce noticeable side-effects. Despite these concerns, mouse models which either 
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overexpress IDE or are IDE-deficient provide in vivo support for an Aβ lowering or increase, 
respectively (Leissring et al., 2003; Farris et al., 2003), without reported side effects. 
 
1.9.4 Immunotherapy 
Immunotherapy involves the use of antibodies in the treatment of disease, and often relies on 
the activation of the immune system as an integral part of the treatment strategy. In the field 
of AD, immunotherapy has received much attention for its disease-modifying potential.  
There are three main areas of anti-Aβ antibody-based immunotherapy (Schenk, 2002). 
Firstly, active immunisation with synthetic Aβ42 leads to the uptake of the peptide by antigen-
presenting cells, followed by the activation of T-cells and B-cells, resulting in the production of 
anti-Aβ42 antibodies. These then activate the immune system in order to clear Aβ42 peptides. 
Secondly, active immunisation with a fragment of the Aβ42 peptide conjugated to a carrier 
protein leads to much the same sequence of events, with the exception of activation of T-cells 
by the carrier protein itself rather than the Aβ42 fragment. Thirdly, passive immunisation 
involves introduction of anti-Aβ42 antibodies, without the host being required to produce the 
antibodies itself.  
The first demonstration of successful in vivo reduction in Aβ using immunotherapy 
was in 1999, when Schenk et al. passively immunised PDAPP transgenic mice with full length 
Aβ42. They treated mice either before AD pathology onset (6 weeks) or after (11 months) 
monthly for 11 months. Studying the effectiveness of disease-modifying treatment in aged 
mice is particularly clinically relevant, as evidence suggests that disease-related changes in the 
CNS are likely to be initiated years prior to clinical manifestation of symptoms (Dubois et al., 
2007). Whilst aged mice showed reductions in Aβ pathology, a near total prevention of plaque 
deposition and associated gliosis was observed in young mice. This suggests that passive 
immunisation with Aβ42 has potential as both an early stage, preventative treatment as well 
as a late stage, disease-slowing alternative to acetylcholinesterase inhibitors. A drawback of 
the study is its lack of cognitive measures, thus making it impossible to infer whether a change 
in Aβ plaque load resulted in a corresponding change in cognitive function. Aβ lowering effects 
following active immunisation with Aβ42 have since been demonstrated by a number of other 
groups, as well as demonstrations that successful lowering of Aβ can be achieved using a non-
toxic fragment of Aβ42 conjugated to polylysine in the Tg2576 model (Sigurdsson et al., 2001).  
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Importantly, there have also been reports of improved performance on spatial 
memory tests such as the Morris Water Maze following active immunisation with Aβ42 in 
TgCRND8 transgenic mice (Janus et al., 2000) and APP/PS1 mice (Morgan et al., 2000), as well 
as in Tg2576 mice on the radial arm water maze (Wilcock et al., 2004) and object recognition 
(Rakover et al., 2007). In the study conducted by Janus et al. (2000), a reduction in spatial 
reference memory deficits was observed in conjunction with a reduction in Aβ plaque load, 
but with no change in the overall Aβ levels, suggesting that functional improvements can be 
observed following small, potentially undetectable changes in overall Aβ levels. Such an 
interpretation would be in accordance with the synaptic deficit theory of AD, where synaptic 
dysfunction may be induced by high levels of Aβ at the synapse. Similarly, Morgan et al. (2000) 
saw inhibition of the development of a spatial reference memory deficit in the mice 
immunised over 8 months, whilst the reduction in Aβ plaque load was small. These data 
indicate that elevated Aβ levels and deposition can be tolerated to some extent, and leave 
cognitive function relatively unaffected. Similar observations have been seen in the human 
literature, where individuals who present with Aβ plaque pathology post-mortem were 
cognitively healthy individuals during life (Davis et al., 1999). 
 Passive immunisation studies with anti-Aβ antibodies have paralleled the success seen 
in active immunisation studies. Peripheral administration of anti-Aβ antibodies to PDAPP mice 
has also been shown to reduce Aβ plaque load by 81-93% depending on the antibody used 
(Bard et al., 2000) with only antibodies recognising the 1-16 amino acid sequence of Aβ being 
effective. Wilcock et al. (2004) treated Tg2576 mice weekly for either 3 or 5 months ending at 
the age of 28 and 22 months respectively. This led to a reversal of cognitive deficits as tested 
in the radial arm water maze. In contrast, 1 or 2 months of passive immunisation in 22 month 
old mice was not sufficient to alter spatial reference memory performance. Reductions in Aβ 
diffuse plaque load was observed after 5 months of treatment only, a pattern which was 
coupled with increased angiopathy and microhemorrhages. Reductions in cognitive deficits 
have also been observed despite a lack of Aβ change, with passive immunisation with m266, 
an antibody targeting Aβ13-28, in PDAPP mice improving performance on both the object 
recognition and holeboard learning and memory task (Dodart et al., 2002). Whilst passive 
immunisation in transgenic mice has not resulted in major side effects, there is evidence to 
suggest an increase in cerebral haemorrhages in APP23 mice (Pfeifer et al., 2002).  
The majority of the immunisation studies conducted in transgenic mouse models of 
AD pathology use intraperitoneal injection as a means to deliver compounds to the CNS. The 
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following success in targeting both Aβ levels and improving cognition is surprising given the 
low permeability of antibodies to the BBB. Other studies have used passive immunisation 
through direct intraparenchymal infusion into the hippocampus and frontal cortex of Tg2576 
mice (Wilcock et al., 2003). By using a direct delivery method where a controlled 
concentration of anti-Aβ is delivered, it is possible to investigate short term changes following 
administration. No changes were observed after 4 hours, but a reduction in diffuse Aβ 
emerged after 24 hours. Reductions in thioflavine-S-positive staining indicative of neuritic 
plaque load was not apparent until 3 days post-infusion, which coincided with staining for 
microglia activation. This suggests that anti-Aβ42 antibody-mediated clearance of Aβ consists 
of two phases focusing firstly on diffuse plaques, followed in the later stage by neuritic Aβ 
plaques clearance mediated by microglical activation.   
The mechanisms by which immunisation with Aβ or anti-Aβ antibodies is effective are 
unclear. It has been suggested that reduced Aβ plaque burden is achieved through stimulation 
of microglial activity (Bard et al., 2000), the inhibition of Aβ aggregation (Solomon et al., 1996; 
Solomon et al., 1997; Frenkel, Katz & Solomon, 2000) or a combination of the two (Schenk, 
2002). In support of microglial activation, it has been found that Aβ plaques are subjected to 
phagocytosis triggered by the Fc region on anti-Aβ antibodies bound to the plaques (Bard et 
al., 2000).      
A third alternative for the mechanisms by which immunisation targets Aβ pathology is 
the “peripheral sink” hypothesis (Tanzi et al., 2004; DeMattos et al., 2004). This describes the 
idea that anti-Aβ antibodies bind and clear Aβ in the periphery rather than in the CNS, creating 
a concentration gradient across the BBB. The concentration of Aβ in the CNS is thereby 
reduced by passing from the CNS to the plasma. In support of this, DeMattos et al. (2001, 
2002) demonstrated that PDAPP mice which were peripherally immunised with m266 showed 
reductions in plaque burden without any evidence of the antibody binding to plaques. This 
was paralleled by an increase in Aβ levels in the plasma.   
Despite the promising results from immunisation studies in the animal literature, it 
has to date proved difficult to translate these findings to a clinical setting. Initially, a single 
dose phase I study actively immunising mild to moderate stage AD patients with AN1792, 
consisting of aggregated human Aβ42, reported good tolerability (Schenk, 2002). This was 
followed by a multiple dose study with similarly positive results and an antibody response in 
approximately half of the treated participants (Bayer et al., 2005). Whilst there were reports of 
two incidences of meningoencephalitis, these were either not related to the treatment or 
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occurred over 7 months following the last treatment. A second multiple dose study with over 
70 treated patients was conducted successfully, before proceeding to a phase IIa clinical trial 
with 300 mild to moderate stage AD patients being treated with AN1792. After receiving 
between 1-3 doses over up to 3 months, dosing was terminated following reports of 
meningoencephalitis in 18 treated patients (6%), with no such incidences in the placebo group 
(Orgogozo et al., 2003). With the exception of 6 of these cases who developed permanent 
cognitive or neurological side effects, the majority of cases experienced no long term 
consequences. Despite good tolerability in the phase I trials, the side effects observed in the 
phase IIa trial show similarities to reports of cerebral haemorrhage and immune system 
activation in immunisation studies in mouse models (Pfifer et al., 2002). Follow up analysis of 
the interrupted trial revealed a developed antibody response in 19.7% of treated patients 
(Gilman et al., 2005). There was no evidence of a beneficial effect of antibody response on a 
battery of cognitive assessments with the exception of minor superior performance by 
responders on a neuropsychological test battery (Gilman et al., 200; Holmes et al., 2008).  
A follow up of the 70 patients who took part in a phase I trial was concluded 6 years 
following treatment, of which 8 AD patients who received AN1792 underwent post-mortem 
histological analysis. The study showed that β-amyloid immunisation over time reduced the 
number of plaques in patients, but there was no evidence of an accompanying slowing of 
cognitive decline, as placebo and treatment groups had reached comparable levels of 
dementia at the terminal stages of life (Holmes et al., 2008). This result has been interpreted 
as a failing of preclinical data to translate into the clinical domain, as well as a failure of the Aβ 
cascade hypothesis, which would predict a reduction in Aβ plaque load to be beneficial in 
terms of rate of cognitive decline. Others have argued that the study provides further 
evidence that the destruction of Aβ plaques may not offer cognitive benefit if soluble, 
oligomeric Aβ is not also targeted, or may exacerbate conditions if it results in the release of 
pre-fibrillar Aβ from plaques to the extracellular space (Holmes et al., 2008).  
Whilst active immunisation with AD patients has not been widely assessed, passive 
immunisation could be a viable alternative if adverse reactions such as meningoencephalitis 
persist. Passive immunisation may induce less side effects as the immune system is not called 
upon for antibody production, and provides a more reversible treatment should side effects 
emerge (Wilcock et al., 2004). Furthermore, passive immunisation sidesteps the issue of 
potential direct toxicity associated with particular residues of Aβ (Wisniewski & Koniezko, 
2008). In addition, reports of variable antibody responses in the elderly population further 
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point to passive immunisation as potentially preferable as a treatment strategy in elderly AD 
patients (Wilcock et al., 2004). However, cerebral haemorrhage has also been observed in 
transgenic mice treated using passive immunisation (Pfeifer et al., 2002), suggesting that 
antibodies targeting Aβ through either passive or active immunotherapy could activate the 
immune system in a detrimental fashion. The unresolved issue of potentially increasing the 
level of toxic species of Aβ if using plaque-targeting antibodies, in association with the 
inflammatory issues observed when activating the immune system to clear Aβ, points to a 
need to develop alternative or more selective therapeutic strategies.  
A potential reason for the lack of successful translation of disease-ameliorating 
strategies in mouse models of Alzheimer’s disease pathology to human patients could be 
differences in the stage the pathology has progressed to at the time of compound 
administration. This was highlighted by Zahs & Ashe (2010), where the authors argue that the 
current mouse models of AD pathology model the early, asymptomatic stages of the disease 
specifically. Therefore, it could be more appropriate to classify preclinical treatment studies as 
preventative rather than initiated following the emergence of clinical symptoms, as would be 
more clinically relevant. In early stage drug trials, mild to moderate cognitive impairment 
patients AD patients are used, in which the disease process may have progressed beyond that 
modelled in transgenic mice. These treatments may prove more effective if tested 
longitudinally on pre-symptomatic individuals with a biomarker profile suggestive of early AD-
associated changes. This highlights a need in the field for models which focus more specifically 
on the later stages of the disease, one that without doubt involves extensive cell loss, a 
feature which has not been successfully incorporated into current models.   
 
1.9.5 Alternative immunotherapy to anti-Aβ antibodies 
Whilst the focus of immunotherapy in AD research has been on anti-Aβ antibodies which bind 
various sites of Aβ42, there are groups which have utilised antibodies with alternative targets 
with the aim of lowering Aβ levels in the CNS. The benefit of such an approach is several-fold. 
Firstly, selecting alternative targets in the Aβ cascade results in valuable opportunities to test 
the Aβ cascade hypothesis. Secondly, using antibodies which do not bind Aβ may result in less 
activation of the immune system, as antibodies would not be bound to Aβ plaques. This could 
result in therapeutic strategies which are able to lower Aβ with limited medical side effects. 
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One alternative target in the Aβ cascade is BACE1. Monoclonal antibodies have been 
developed which bind to loops D and F, which are removed from the active site of the enzyme, 
but inhibits its ability to cleave APP (Zhou et al., 2011). This approach has been shown to 
reduce Aβ40 and Aβ42 production in vitro and in vivo, following stereotactic injection to the 
hippocampus and cortex of APPDutch mice at 3 months of age (Zhou et al., 2011). This 
approach has also been utilised by Atwal et al. (2011), who produced a monoclonal antibody 
with loop C, D and F of BACE1 as its substrates. In addition, a bispecific version of the antibody 
was created where half of the molecule was made up of the anti-BACE antibody and the other 
half a low affinity anti-transferrin receptor antibody. As transferrin receptors are present at 
the BBB, the merging of these two antibodies allows the molecule up to 10-fold higher 
penetration of the BBB as compared to the anti-BACE1 antibody in its original form (Yu et al., 
2011). This type of antibody engineering may open possibilities for increased delivery of 
peripherally administered antibodies to human patients.  
Focusing on altering APP processing, Thomas et al. (2006), Arbel et al. (2005) and 
Boddapati, Levites & Sierks (2011) developed antibodies which bind to the β-secretase 
cleavage site of APP rather than Aβ itself. The strategy is based on inhibiting BACE1 access to 
the cleavage site through steric hindrance, reducing the amount of APP processed by β-
secretase cleavage, thereby lowering the production of Aβ (Thomas, Liddell & Kidd, 2011). APP 
can then undergo proteolytic cleavage by α-secretase as an alternative to amyloidogenic 
processing. This approach has several advantages. Firstly, it avoids issues relating to which 
form of Aβ to target in terms of neurotoxicity, as the production of the molecule itself is 
hindered. Secondly, given that the APP molecule is highly preserved through evolution, is 
present in most cells and tissues within humans and mice, and has a gene promoter region 
with characteristics of housekeeping genes (Salbaum et al., 1988), it is likely that the variety of 
molecules formed from processed APP serve important functions (Selkoe, 1991). It is therefore 
an advantage for a treatment strategy to minimise interference with the general processing of 
APP, avoiding only the production of Aβ40/42 specifically. Lastly, by avoiding enzyme 
inhibition, the approach will not interfere with ability of BACE1 to process other substrates 
aside from APP, an approach which has been problematic (Rakover et al., 2007; Van Dooren et 
al., 2005, Boddapati et al., 2011).  
 The potential of this approach for therapeutic treatment has been investigated by the 
two groups using both in vivo and in vitro assessments. Thomas et al. (2006) demonstrated 
that an antibody (2B12) against the β-secretase cleavage site reduced Aβ40 in a time- and 
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concentration dependent manner by up to 50% in human neuroblastoma (MOG-G-UVW) and 
astrocytoma (SH-SY5Y) cell lines expressing normal levels of APP, without binding Aβ itself. A 
similar antibody (2B3) with a higher specificity and affinity to the β-secretase cleavage site 
than 2B12 has demonstrated an ability to further reduce Aβ levels compared to 2B12 (Thomas 
et al., 2011). The characterisation of these antibodies has demonstrated that they remain 
bound to APP after 60 min incubation at pH 4.0 in vitro, suggesting that they will be unaffected 
by the similar pH level found in the endosomal/lysosomal system in which β-secretase 
cleavage of APP occurs (Thomas et al., 2011). Supporting the idea that the reduction in Aβ 
levels is based on inhibition of β-secretase cleavage is the finding that levels of the C-terminal 
fragment of APP (C99) produced following β-secretase cleavage are reduced if 2B3 is present 
(Thomas et al., 2011). Using hamster ovary cells overexpressing human APP, Arbel et al. (2005) 
showed that a similar antibody, BBS1, reduced secreted and intracellular levels of Aβ. Such 
demonstrations of effective downregulation of Aβ production in vitro are a first step in the 
evaluation of the antibody’s therapeutic value. These results must be replicated in vivo using 
pre-clinical models of AD-like pathology in order to start building a convincing case for 
investing further research effort into anti-APP β-secretase cleavage site antibodies.  
To date, Rakover et al. (2007) offers the only insight into the in vivo effect of anti-APP 
β-secretase cleavage site antibodies. Female transgenic Tg2576 mice received IP injections of 
BBS1 (or PBS) every two weeks from 6 to 12 months of age, at which point object recognition 
memory was assessed using the novel object recognition task. Whilst no differences in 
insoluble Aβ levels were observed as measured by both ELISA and immunohistochemical 
staining, BBS1 treated mice demonstrated a significantly higher discrimination ratio compared 
to PBS treated mice. Furthermore, the authors reported a reduction in microhemorrhages 
following BBS1 treatment. The effect of BBS1 on neuroinflammation was investigated using 
staining for F4/80 and GFAP, but BBS1 administration lowered F4/80 staining only.    
Whilst these results are encouraging in the sense that an anti-APP β-secretase 
cleavage site antibody showed effects on biochemical and behavioural markers in a disease-
limiting direction, there are a number of reasons why further research using this form of 
immunotherapy is desirable. Firstly, the lack of a reduction in any measure of Aβ pathology 
opens the possibility that the BBS1-linked reduction in microhemorrhages, neuroinflammation 
and object recognition memory could be related to a secondary effect of the antibody 
presence as opposed to the result of a significant downregulation of Aβ. Based on the Rakover 
et al. (2007) paper alone, the behavioural changes appear to have a stronger link with 
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alterations in vascular and inflammatory markers than with insoluble Aβ pathology. This link 
may be driven by changes in soluble Aβ, a measure thought to be more relevant in the context 
of cognitive deficits in transgenic APP mutation models. As soluble Aβ levels were not 
successfully measured in Rakover et al. (2007), further investigation of the role soluble Aβ 
species play in possible alterations in cognitive function would be beneficial.  
Secondly, there is dispute in the literature regarding whether transgenic Tg2576 mice 
display deficits on the task used to assess the effect of BBS1 on cognitive function in Rakover 
et al. (2007). Whilst several groups have reported deficits using delay intervals between 5 min 
and 24 hours (Ribes et al., 2011; Yuede et al., 2009; Taglialetela et al., 2008; Bardgett et al., 
2011), opposing patterns of results indicate that transgenic mice up to 16 months of age can 
discriminate between a novel and familiar object when there is no requirement to form a 
coherent representation of an object and its spatial location (Hale & Good, 2005; Good & Hale, 
2007; Ognibene et al., 2005). A dispute regarding the presence of an object recognition deficit 
in Tg2576 mice used in Rakover et al. (2007) calls into question the utility of this task as a 
measure of changes in cognitive function following BBS1 treatment. Indeed, no wild type mice 
are included to indicate the baseline level of performance to be expected from healthy mice, 
making it difficult to determine the degree to which the BBS1 treatment reduced object 
recognition memory deficits. This is problematic due to the demonstration that PBS treated 
Tg2576 mice show a preference for the familiar over the novel object rather than equal 
exploration as expected if subjects have no memory of a previous encounter, indicating the 
interference of an additional factor such as anxiety or object bias on normal novelty seeking 
behaviour. Given that the increase in the discrimination ratio for mice treated with the high 
dose of BBS1 is significantly higher than the PBS treated mice, but not the mice treated with a 
low dose of BBS1 who are at chance level, it is likely that had PBS treated mice performed at 
chance level, no significant changes in cognitive function would have been observed.  
Furthermore, the Rakover et al. (2007) paper provides no evidence that the BBS1 
antibody penetrates the blood brain barrier after being administered in the periphery. It is 
therefore possible that the antibody did not arrive at its target, making it unable to lower 
neuronal Aβ levels. The changes in inflammatory and microhemorrhage markers may be 
driven by effects of the antibody in the periphery as opposed to interference with APP 
processing in the CNS.  
Finally, it is worth noting that a single demonstration of in vivo effects of an anti-APP 
β-secretase cleavage site antibody will benefit from the parallel investigation of similar 
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processes. In addition, mice were treated from 6 months to 12 months of age in Rakover et al. 
(2007), demonstrating that early intervention using this approach can be beneficial, but 
providing little information of the effect of halting Aβ production once Aβ pathology is 
established. For the reasons listed, the current work set out to expand on the current 
knowledge of the effect of an anti-APP β-secretase cleavage site antibody as outlined further 
in the section below.   
 
1.10 Thesis summary and aims 
In this chapter, an overview of AD as a cognitive and biochemical disorder has been presented, 
as well as a discussion of immunotherapy as a treatment strategy in clinical AD research. The 
anti-β-secretase cleavage site antibody 2B3 and the use of transgenic mice to model AD have 
been introduced. Despite considerable focus of disease modifying treatments targeting the 
factors driving pathology in AD, limited success has translated to clinical trials. With AD 
growing in prevalence and only symptomatic treatments with limited effectiveness currently 
available, further efforts to identify effective compounds which translate successfully to a 
clinical setting are needed. There have been encouraging results of using anti-APP β-secretase 
site antibodies to reduce Aβ production in vitro (Thomas et al., 2006; 2011; Arbel et al., 2005; 
Rakover et al., 2007; Boddapati et al., 2011), but no such demonstration has been made in 
vivo. Importantly, a beneficial effect of antibody administration on cognitive functioning was 
reported (Rakover et al., 2007), although further exploration of the degree of cognitive 
improvement, biochemical change and antibody delivery to the CNS would be valuable. As 
such, the current work has several aims.  
Firstly, the thesis aims to characterise two transgenic APP mutation mouse models of 
AD-pathology in terms of the behavioural and biochemical phenotype in order to establish 
baseline levels against which to assess whether the introduction of 2B3 to aged transgenic APP 
mice leads to a reduction in Aβ production and associated behavioural deficits. In addition, the 
thesis aims to replicate the in vitro reductions in Aβ levels following treatment with anti-APP 
β-secretase cleavage site antibodies (Thomas et al., 2006; Arbel et al., 2005; Boddapati et al., 
2011) for the first time using a novel neuronal cell line. The work expands on Rakover et al. 
(2007) by treating mice at a clinically relevant late time point in terms of disease progression, 
as opposed to a preventative intervention starting at a young age. Furthermore, the use of a 
spatial working memory task for the evaluation of the cognitive benefit of 2B3 treatment 
expands assessments beyond object recognition memory allowing for an indirect evaluation of 
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the specificity of anti-APP β-secretase cleavage site antibodies in vivo. In addition, in order to 
understand the mechanism of action of a potential change in cognitive performance, it is 
desirable to obtain a measure of the effect of such a treatment on both soluble and insoluble 
Aβ levels.  
Thus, Chapter 2 and 3 present behavioural characterisation work focused on the 
London APP(V717I) mutation model of AD, with parallel biochemical work presented in 
Chapter 4. In Chapter 5, behavioural characterisation of a second APP mutation model, the 
PDAPP(V717F) model is presented, followed by Chapter 6, where both in vitro and pilot in vivo 
attempts at reducing Aβ production and behavioural deficits using 2B3 are investigated.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Chapter 2 
 
Anxiety Phenotype of the London APP(V717I) Model 
 
2.1 Introduction 
This chapter investigates the onset and progression of anxiety-related behaviour in the London 
APP(V717I) mouse model of Aβ pathology. The main rationale for these studies was to 
establish whether transgene-related changes in anxiety could interact with assessment of 
learning and memory. Whilst information regarding the anxiety phenotype is available in the 
published literature, it was necessary to reassess the effect of the APP(V717I) mutation on 
anxiety behaviour because of the change in the genetic background strain. The first section of 
this chapter provides a brief outline of the pathology expressed by the APP(V717I) model. 
Experiments 1a and 1b therefore assessed the performance of (male and female) APP(V717I) 
mice at 3, 6 and 19 months on a marble burying task and the elevated plus maze (EPM) 
respectively.   
 
2.1.2 The London mutation APP(V717I) model   
In order to assess the ability of 2B3 to lower Aβ production in vivo, it was essential that a 
suitable model was selected. As described in Chapter 1, Section 1.9.5, the antibody treatment 
evaluated in this thesis was designed to lower Aβ production by blocking access to APP at the 
β-secretase cleavage site through steric hindrance. The Tg2576 mouse model of amyloid 
pathology (Hsiao et al., 1996) is one of the most widely used transgenic murine models in the 
field (Eriksen & Janus, 2007). It has been thoroughly characterised both in terms of 
biochemical pathology and learning and memory deficits (Hsiao et al., 1996; Morgan et al., 
2000; Kawarabayashi et al., 2001; Irizarry et al., 1997a; Arendash et al., 2001; Kotilinek et al., 
2002; Westerman et al., 2002: Zhuo et al., 2007; Barnes et al., 2004; Lesne et al., 2006; 
Chapman et al, 1999; Corcoran et al, 2002; Ognibene et al., 2005; Hale & Good, 2005; Good, 
Hale & Staal, 2007, Eriksen & Janus, 2007). Although this model is commercially available (and 
bred at Cardiff University), the two hAPP mutations in the Tg2576 model are located at the β-
secretase cleavage site (K670M/N671L, Mullan et al., 1992), which results in enhanced 
cleavage of APP via this route. It is important to note that this is also the location to which 2B3 
binds. As antibodies are highly specific in the recognition of their binding site, a change in 
amino acids within this sequence could greatly affect their ability to successfully bind to their 
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target molecule. In support of this, pilot Western blotting work suggested binding of 2B3 to 
APP from Tg2576 transgenic tissue was limited (Thomas & Kidd, unpublished data).  
Given the potential limitation of using a mouse model with mutations at the β-
secretase cleavage site, an alternative APP model was used. The selection of the London 
APP(V717I) mouse line was governed firstly by the fact that the APP(V717I) mutation is located 
at the γ-secretase cleavage site (and should therefore not interfere with the ability of the 
antibody to bind to the β-secretase cleavage site). Secondly, published work indicated that 
these mice display an early behavioural phenotype, in addition to a robust biochemical profile 
(Moechars et al., 1999b; Bronfman, Moechars & Van Leuven, 2000; Dewachter et al, 2000; 
Masliah et al., 2000; Dewachter et al., 2002; Van Dorpe et al., 2002; Postina et al., 2004; Van 
Dooren et al., 2005; Tanghe et al., 2010).  
The heterogeneous APP(V717I) mouse model of Aβ pathology carries a single point 
mutation in APP, resulting in the substitution of valine for isoleucine at residue 717 (770 
isoform), close to the γ-secretase cleavage site. Expression of this mutant allele is driven by 
the neuronal specific mouse Thy1 promoter with expression levels of human APP 2 fold that of 
endogenous APP (Tanghe et al., 2010), with an increase in hAPP protein levels from 3 to 15 
months of age (Dewachter et al., 2000). The mutation results in preferential cleavage of the 
APP molecule by γ-secretase closer to the C-terminal of the protein, thus increasing the levels 
of soluble Aβ42 compared to that of Aβ40 (Moechars et al., 1999b; Tanghe et al., 2010). An 
overview of Aβ pathology in the transgenic APP(V717I) mice obtained from published work is 
displayed in Table 2.1. As can be seen, there is considerable variation both with regards to the 
levels of Aβ reported at certain ages, as well as the relationship between levels of Aβ40 and 
Aβ42.  Nevertheless, mice with the APP(V717I) mutation display an age-related increase in Aβ  
levels. As the cleavage of the APP protein is not thought to be dependent on age, it is believed 
that the accumulation of Aβ40-42 that accompanies aging in this model is due to the failure of 
clearance or degradation of the protein isoforms as opposed to increases in the overall levels 
produced (Dewachter et al., 2000, Tanghe et al., 2010). 
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Age 
(months) 
Soluble 
Aβ40 
Soluble 
Aβ42 
Total SDS 
extracted 
(soluble) 
Aβ(40+42) 
Insoluble 
Aβ40 
Insoluble 
Aβ42 
Total FA 
extracted 
(insoluble) 
Aβ(40+42) 
3 2.5 0 0 0 0 0 
4.5 1.7/5 1.3/0.6 n/a n/a n/a n/a 
5 7 n/a n/a n/a n/a n/a 
6 2 5 n/a n/a n/a n/a 
6-9 2.5 0 5 0 ~0 5 
12 n/a n/a 7000 n/a n/a 125 
15 15 10 21000 2000 750 310 
16 25 12 n/a 4500 5000 n/a 
16-18 4.6 0.5 n/a n/a n/a n/a 
22 150 100 n/a 16000 14000 n/a 
      
Table 2.1: Summary table of reported approximated soluble and insoluble Aβ40 and Aβ42 
(ng/g of tissue) values in transgenic APP(V717I) mice as measured using ELISA based on 
Dewachter et al. (2000), Dewachter et al. (2002), Etcheberrigaray et al. (2004), Postina et al. 
(2004), Willem et al. (2004), Van der Auwera et al. (2005) and Tanghe et al. (2010). N/A = not 
available. If two studies indicated different values at the same age, values were included side 
by side. SDS = sodium dodecyl sulfate, FA = formic acid.  
 
In terms of the anatomical pattern of Aβ deposition, plaques develop first in the entorhinal 
cortex and subiculum before becoming evident in the frontal cortex (Tanghe et al., 2010). Aβ 
plaques appear from 10-12 months of age (Tanghe et al., 2010), although earlier reports from 
this group indicate a slightly later profile (12-15 months of age; Dewachter et al., 2000). Both 
diffuse and senile plaques are observed, which are surrounded by neuritic processes including 
hyperphosphorylated tau (Tanghe et al., 2010). In addition, neuroinflammation can be 
detected in association with plaques using immunostaining for activated astrocytes and 
microglia (Tanghe et al., 2010). In terms of vascular deposits, the Aβ deposits are similar in 
morphology, structure and localisation to that observed in human AD tissue (Van Dorpe et al, 
2000; Tanghe et al., 2010).  
The London V717I mutation was originally bred into the FVB/N background strain, and 
this strain has been used in the majority of behavioural work on this mutation (Moechars et 
al., 1999b; Dewachter et al., 2002; Van Dooren et al., 2005; Dewachter et al., 2009). These 
mice displayed a number of problematic physical and behavioural characteristics such as 
premature death, seizures and increased levels of anxiety (Moechars et al., 1999b; Ashe, 
2009). These aspects of the phenotype clearly make the transgenic mice less suited for 
behavioural testing. Recently, the APP(V717I) mutation has been bred into the C57Bl/6 line, in 
which APP mutations do not result in the problems described above (Moechars et al., 1999b; 
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Ashe, 2009). Furthermore, C57Bl/6 mice are considered to be a good background strain for 
studies of learning and memory (Crawley et al., 1997). 
In considering the published work on mice with the V717I mutation, much of the focus 
has been on characterisation of the biochemical changes, with little attention directed 
towards the assessment of the behavioural and cognitive phenotype. Indeed, the effect of the 
APP(V717I) mutation on changes in cognitive function with age is unknown. A summary of the 
behavioural profile of the APP(V717I) model is presented in Table 2.2, highlighting the changes 
in genetic background the V717I mutation was maintained on. Important to the current 
experiments are reports that transgenic APP(V717I) mice display an age-independent increase 
in anxiety compared to wild type mice from 4-8 weeks onwards when on the FVB/N 
background (Moechars et al., 1999b). Thus, it is necessary to assess whether a change in the 
genetic background influences the anxiety phenotype in these mice. It is also worth noting 
that whilst deficits in spatial memory have been reported at 3-6 months of age, the effect of 
the V717I mutation on cognitive functioning with age is unknown.  
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Type of 
assessment 
Genetic 
back-
ground 
Construct 
assessed 
Age Deficit 
Open Field FVB/N Anxiety 1-2, 3-4 and    
5-12 months 
 
Tg mice show increased anxiety 
compared to WT mice. 
Morris water 
maze 
F1 hybrid 
(C57Bl/6 
& FVB/N) 
 
Spatial 
reference 
memory 
3-6 months Tg mice show inferior 
performance compared to WT 
mice. 
Novel object 
recognition  
FVB/N Object 
recognition 
memory 
 
3-6 months Tg inferior performance 
compared to WT after a 3 hour 
sample-test delay 
Fear conditioning n/a c-fos expression 
following cued 
and contextual 
fear 
conditioning 
n/a Reduced increase in C-fos 
expression in the hippocampal 
CA1 and basolateral amygdalae 
of Tg mice compared to WT 
mice. Behavioural parameters 
not reported. 
 
Electrophysiology 
(in vitro) 
n/a NMDA-
dependent long 
term 
potentiation 
and NMDA 
receptor 
responses 
n/a Reduced NMDA receptor 
response in CA1 of Tg mice 
compared to WT mice.  
Impaired long term potentiation 
in CA1 of Tg mice compared to 
WT mice. 
Table 2.2: Summary table of reported behavioural deficits as reported in Moechars et al. 
(1999b), Dewachter et al. (2002), Postina et al. (2004) and Dewachter et al. (2009). N/A = not 
available. Tg = transgenic, WT = wild type.  
 
There is clearly a need to assess the behavioural profile of the APP(V717I) mice for several 
reasons. Firstly, the current behavioural analysis has been conducted within one research 
group only. In order to verify results, it would be beneficial to see the pattern of results 
replicated across laboratories. Secondly, due to the change in the genetic background that the 
mutation is maintained on from FVB/N to C57Bl/6, it is necessary to assess whether this 
change has altered the behavioural phenotype of the model.  
The aim of the experiments presented in this chapter is to provide a developmental 
profile of potential changes in anxiety-related behaviour of London APP(V717I) mice. This was 
done to establish whether changes could interact with assessment of learning and memory, 
rather than as an attempt at establishing a behavioural phenotype against which to assess the 
effect of reducing Aβ through 2B3 administration. Anxiety in AD patients is measured using 
subjective report by the patient, or behavioural observation by carers or clinicians (Kogan, 
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Edelstein & McKee, 2000). This differs from the direct manipulation of rodent assessments of 
anxiety, in which animals are placed in an unfamiliar, exposed environment for behavioural 
observation. Furthermore, anxiety in AD patients is thought to be related to difficulties arising 
from cognitive deficits and confusion (Fisher & Noll, 1996 as cited in Kogan et al., 2000). It is 
therefore argued that the anxiety construct as measured in rodents holds limited translational 
value in terms of disease understanding, and therefore best serves as a feature of transgenic 
phenotyping, potentially independent of increases in Aβ levels with age. The experiments 
presented test the hypothesis that the APP(V717I) mutation would lead to age-independent 
disruption to anxiety-related behaviour. Experiments 1a and 1b assessed anxiety behaviour in 
wild type and transgenic APP(V717I) mice longitudinally at 3, 6 and 19 months in a marble 
burying task and the elevated plus maze (EPM) respectively.  
The marble burying task is an unconditioned anxiety task based on the natural 
neophobic response mice exhibit when exposed to novel objects, and has been widely used to 
assess anxiety in mice (Thomas et al., 2009; Archer et al., 1987). When faced with negative 
stimuli such as food shock or noxious food, rodents will engage in burying behaviour referred 
to as “defensive burying” (Thomas et al., 2009). Whilst rodents also bury non-aversive objects 
such as marbles, it is traditionally thought that anxiogenic aspect of these objects is their 
novelty.  
The EPM is an unconditioned anxiety task where an animal’s unconditioned avoidance 
response to high, exposed locations is utilised to measure levels of anxiety (Pellow, Chopin, 
File & Briley, 1985; Walf & Frye, 2007). This anxiety-like response is expressed through a 
greater reduction in exploratory behaviour in exposed locations compared to non-exposed 
locations. Anxiety related to the exposed nature of the area is thought to contribute to 
anxiety-like behaviour rather than neophobia when faced with a novel space (Pellow et al., 
1985). Support for the EPM being sensitive to behaviour related to anxiety comes from 
pharmacological manipulations showing sensitivity to anxiolytic and anxiogenic agents (Pellow 
et al., 1985, Belzung & Griebel, 2001). In addition, the task is considered an ethologically valid 
task due to the use of novel and exposed locations as anxiety inducing environmental 
elements which could be encountered in a natural setting (Walf & Frye, 2007, McHugh, 
Deacon, Rawlins & Bannerman, 2004). When wild type mice are exposed to the EPM, they are 
typically observed to spend approximately 25% of their time in the open, anxiogenic arms 
(Dawson & Tricklebank, 1995).  
51 
 
This study also considered whether gender influenced the emergence of a behavioural 
deficit or, indeed, the degree of disruption (c.f. McLean & Anderson, 2009; Johnston & File, 
1991). As no gender information is available on this model, no predictions were made 
regarding the effect of gender on anxiety. However, transgenic mice were predicted to display 
higher levels of anxiety than wild type mice at all ages tested.  
 
2.2 General method: Maintenance and breeding 
All animals were health-checked weekly and maintained according to UK Home Office 
regulations and the Animal (Scientific Procedures) Act (1986). Standard cage material included 
a cardboard tube and a wooden gnawing block and approved nesting martial. Holding rooms 
were kept on a 12 hour light/dark cycle, with stable temperature and relative humidity levels 
at around 21oC ± 2oC and 60 ± 10% respectively. Mice were maintained on ad libitum access to 
food and water unless specified in the experimental protocol in the relevant chapters.  
The APP(V717I) London mutation (Moechars et al., 1999b) is maintained on the inbred 
C57Bl/6 background. Wild type C57Bl/6 females (Cathays Park transgenic production unit, 
Cardiff University) were bred with heterozygous transgenic APP(V717I) males, a generous gift 
from Prof. Fred van Leuven, to produce an approximate 1:1 ratio of wild type and 
heterozygous transgenic offspring. Litter size is typically between 3-9 pups. Mice were weaned 
at 5 weeks and either group housed according to gender within a litter, or singly housed. In 
our hands, attrition rates were < 2%, and no observations of elevated aggression or general 
health issues were made. Average body weights did not differ between wild type and 
transgenic mice at any age. Locomotor activity was measured in an open arena at 3, 6 and 18 
months, with no differences between transgenic and wild type mice in the percentage of time 
spent moving [3 months: (F (1, 36) = 2.28, p > .05); 6 months: (F (1, 36) = 2.80, p > .05); 18 
months: (F (1, 36) = 3.34, p > .05)].    
 
Genotyping of APP(V717I) mice 
A tail or ear sample less than 2mm in size was obtained from mice at approximately 5 weeks of 
age or following culling and was stored at -20. DNA was digested (0.2% Proteinase K, 1M Tris 
HCl, 0.5M EDTA, 10% SDS) and extracted using 5M ammonium acetate followed by 
centrifugation at 14000rpm. Isopropanol was added to the supernatant followed by 
52 
 
centrifugation and two washes with 70% ethanol. DNA samples were incubated in 55oC TE 
buffer (1M Tris Chloride, 0.5M EDTA) and stored at -20oC until use. 
 
Polymerase Chain Reaction (PCR) for APP(V717I) 
The sense primer (Eurofins, MWG Operon, Ebersberg, Germany) NE1075 (5’-
CCGATGGGTAGTGAAGCAATGGTT-3’) and antisense primer NE1076 (5’ –
TGTGCCAGCCAACAGAGAAAAC-3’) were utilised to target the APP(V717I) mutation. The 
master mix solution consisted of 1.25µl of 10x buffer (BIOTAQ Red DNA Polymerase, Bioline, 
London, UK), 0.625µl of 50x MgCl2 (Invitrogen, Paisley, UK), 0.625µl of 10mM deoxynucleotide 
triphosphates (dNTPs; GE Healthcare, Little Chalfont, UK), 0.125µl of NE1075 and NE1076 at a 
concentration of 15pmol each, 0.75µl of Taq Red (Bioline), 8.5µl of DNAse- and RNAse-free 
H20 was combined per sample, with 0.5µl of DNA. The thermocycling conditions were the 
following: 72oC for 2 minutes, 36 cycles at 94oC for 1 minute, 60oC for 1 minute, 72oC for 2 
minutes, with 2 seconds added to the elongation step per cycle. Samples were stored at 4oC. 
The DNA product was separated on a 1.5% agarose gel electrophoresis using TAE buffer 
(40mM Tris-acetate, 1mM EDTA). Products were visualised using SYBR Safe (Invitrogen) and 
sized against a DNA ladder of product sizes 50, 150, 300, 500, 750 and 1000 base pairs (bp;  
(Promega, Southampton, UK). The APP(V717I) transgene DNA product is approximately 500bp, 
and appears in the transgenic samples only. This is depicted in Figure 2.1, visualised with a UV-
transilluminator using Gel Doc 2000 Gel Documentation System (Bio-Rad Laboratories, 
Hercules, USA).  
  
Fig. 2.1: Representative image displaying an electrophoresis gel of amplified genomic material 
from APP(V717I) transgenic and wild type mice. Lane 1 = DNA ladder displaying bp 1000 to 50. 
Lanes 2 – 4 = ~500bp fragment representing the hAPPV717I transgene in sample transgenic 
mice. Lane 5 = known wild type control sample. Lane 6 = known transgenic control sample. 
Lane 7 = nuclease free water control.  
53 
 
 
Samples which did not produce a DNA band for APP(V717I) were analysed for beta-globin to 
confirm DNA presence using the sense primer 1 (5’-
CCAATCTGCTCACACAGGATAGAGAGGGCAGG-3’) and the antisense primer 2 (5’–
CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG-3’) giving a 500bp fragment. The master mix 
solution consisted of 2.5µl of 10x PCR buffer (Invitrogen), 0.75µl of 50x MgCl2 (Invitrogen), 4µl 
of 10mM dNTPs (GE Healthcare), 1.25µl of primer 1 and 2 (Eurofins MWG Operon) at a 
concentration of 10pmol each, 0.0625µl of Taq DNA Polymerase (Invitrogen), 14.6875µl of 
DNAse- and RNAse-free H20 was combined per sample, with 0.5µl of DNA. The thermocycling 
conditions were as follows: 35 cycles of 94oC for 30 seconds, 60oC for 90 seconds, 72oC for 120 
seconds, followed by 10 minutes at 72oC and storage at 4oC. The amplified DNA product was 
separated and visualised in an identical manner to that described above. The visualised DNA 
products can be seen in Fig. 2.2.  
  
Fig. 2.2: Representative image displaying an electrophoresis gel of amplified genomic material 
from an APP(V717) transgenic and a wild type mouse. Lane 1 = DNA ladder displaying bp 1000 
to 50. Lane 2 = ~500bp fragment representing the endogenous beta-globin gene in a known 
transgenic mouse sample. Lane 3 = known wild type control sample. Lane 4 = nuclease free 
water control. 
 
Design 
A longitudinal study of the level of anxiety-like behaviour exhibited by transgenic and wild 
type APP(V717I) mice at age points 3, 6 and 19 months was conducted. The assessment of 
anxiety using the elevated plus maze was conducted in parallel with measure of neophobia 
using the marble burying task. The order of administration of the EPM and the marble busying 
task was counterbalanced across subject groups. Both male and female mice were included at 
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all age points as a means of assessing whether the potential genotypic differences in marble 
burying performance were influenced by gender.  
 
Subjects 
A total of 21 heterozygous transgenic and 22 wild type London APP(V717I) mice on a C57Bl/6 
inbred background strain were used (Moechars et al., 1999b), of which 19 were male (6 
transgenic, 13 wild type) and 24 were female (15 transgenic, 9 wild type). All mice were tested 
at each time point, with the exception of 4 transgenic females which were tested at 3 and 6 
months only. This was due to tissue collection and in one case, natural attrition of the colony. 
An experimental time line including sample size is presented in Figure 2.3. 
 
 
 
 
 
 
 
Fig. 2.3: Experimental time line indicating the age at which the marble burying (MB) and 
elevated plus maze (EPM) was carried out, as well as details of the sample sizes. The order of 
administration of the marble burying task and the elevated plus maze was counterbalanced at 
each age point. The overview is limited to the tasks discussed in the current chapter, and thus 
is not a full overview of the tasks administered to this cohort of mice.  
 
General procedure of behavioural testing  
All behavioural testing was carried out during the holding room light cycle. Mice were 
transported to test rooms in their home cages and allowed to acclimatise for at least 15 
minutes prior to test initiation. Running order was counterbalanced for gender and genotype 
for all tasks. A camera was mounted in the ceiling of each test room and recorded all trials on 
a DVD recorder and monitor (VM-904K, Shiba Electrics Ltd, Hong Kong). The testing rooms 
contained a number of salient extramaze cues, and were lit from the ceiling. At every test 
point, the anxiety tests were performed in rooms novel to the animal. When tests made use of 
sawdust in the apparatus, this was not replaced between each mouse, but animal droppings 
3 months: 
MB/EPM 
6 months: 
MB/EPM 
19months: 
MB/EPM 
M Tg = 6 
M WT = 13 
F Tg = 15 
F WT = 9 
 
M Tg = 6 
M WT = 13 
F Tg = 15 
F WT = 9 
 
M Tg = 6 
M WT = 13 
F Tg = 11 
F WT = 9 
 
Age and task 
N numbers 
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were removed and the sawdust raked by hand. In all other instances, the apparatus and test 
objects were wiped down with 70% ethanol wipes between trials.  
 
2.3 Experiment 1a: Marble burying 
2.3.1 Apparatus 
In the marble burying task, mice were tested in an opaque box 13cm deep, 17.5cm long and 
11cm wide. This was filled with 6cm of compacted sawdust on which 20 glass marbles (15mm 
diameter) were placed in a 4*5 pattern (see Figure 2.4). A transparent Plexiglas with 
ventilation gaps was placed over the box to avoid escape. 
 
Fig. 2.4: 1A shows the marble burying set up within the test room. 1B shows the distribution of 
marbles within one test box.  
 
Methods 
Four mice were tested at a time in four boxes placed next to each other on a surface raised 
1.1m above floor level for 30 minutes. The mice were placed in the middle of the box facing 
the eastern wall before the Plexiglas was fitted. None of the mice were able to see each other 
or the experimenter. Exposure times to the marbles were kept equal through initiating and 
completing trials in the same order. Marbles were not cleaned between trials unless obviously 
dirty.  
 
 
 
1A 1B 
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Scoring and data analysis  
Throughout the thesis, two-tailed significance testing was carried out with all data, with a 
significance value set at p ≤ 0.05. Assumptions of Analysis of Variance (ANOVA) were tested 
and dealt with as detailed in the specific sections. For non-parametric analysis involving 
multiple independent variables, the alpha level was adjusted using the Bonferroni correction 
to avoid Type I errors. 
In terms of Experiment 1a, the total number of buried and unburied marbles was 
recorded for each mouse upon their removal from the testing box. A buried marble was 
defined as at least two thirds of the marble covered with sawdust (Njung’e & Handley, 1991). 
The number of marbles buried was averaged across groups at each age point. The dependent 
variables at all ages were not normally distributed and violated the assumption of 
homogeneity of variance. As transformations did not aid in rectifying these violations, non-
parametric Mann-Whitney U and Friedman’s ANOVA analyses were used for data analysis. 
 
2.3.2 Results  
The average number of marbles buried by transgenic and wild type mice at the three different 
age points is presented in Fig. 2.5. Visual inspection suggests a lower number of buried 
marbles in the transgenic group compared to the wild type group. In order to test whether 
genotype affected the number of marbles buried at each age, a Mann-Whitney U test was 
carried out on the number of marbles at 3, 6 and 19 months with genotype as the 
independent variable. There was a significant effect of genotype at 3 months (U (21, 22) = 
110.5, p < .005), 6 months (U (21, 22) = 88.5, p < .0001) and 19 months of age (U (17, 22) = 
87.5, p < .005), with transgenic mice burying fewer marbles than wild type mice at all ages.  
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Fig. 2.5: The mean number of marbles buried for transgenic and wild type mice at ages 3, 6, 
and 19 months. ** = p<.005, *** = p<.001. Error bars ± 1 standard error of the mean (S.E.M.)  
 
The average number of marbles buried by male and female mice of each genotype across the 
three age points is presented in Table 2.3. To test the effect of gender on the number of 
marbles buried, a Mann-Whitney U test with gender as the independent variable was 
performed. This revealed a significant effect of gender at 3 months (U (19, 24) = 76.5, p 
<.0001), 6 months (U (19, 24) = 141.5, p <.05) and 19 months of age (U (19, 20) = 99.5, p <.01), 
with males burying more marbles than females at all ages.  
 
Age 
(months) 
Gender 
Wild Type           Transgenic 
Mean S.E.M. Mean S.E.M. 
3 Male     9.62 1.25 6.50 1.80 
3 Female      4.00  1.15  2.43  0.83 
6 Male      7.69  1.74  4.67  2.06 
6 Female      4.43  1.25   0.88  0.36 
19 Male      5.15  0.68  1.83  0.83 
19 Female      3.11  1.62  1.27  0.49 
Mean Male 
Female 
7.49 
3.85 
0.79 
0.76 
4.33 
1.53 
1.01 
0.36 
Table 2.3: The mean and S.E.M. values for the number of buried marbles across gender and 
genotype at each age interval.  
 
In order to assess the effect of genotype in the context of gender, the analysis was split by 
gender. In male mice, there was a significant effect of genotype at 19 months (U (6, 13) = 9.0, 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
3 months 6 months 19 months 
A
ve
ra
ge
 n
u
m
b
er
 o
f 
m
ar
b
le
s 
b
u
ri
ed
 
Transgenic 
Wild Type 
** 
*** 
** 
58 
 
p <.01), but not at 3 months (U (6, 13) = 21.5, p >.025) or 6 months of age (U (6, 13) = 32.0, p 
>.025), with transgenic males burying fewer marbles than wild type male at 19 months (see 
Fig. 2.6). 
 
Fig. 2.6: The mean number of buried marbles for male transgenic and wild type mice at 3, 6, 
and 19 months of age. ** = p <.01. Error bars  ± 1 S.E.M. 
 
In terms of female mice (see Fig. 2.7), there was no significant effect of genotype on the 
average number of marbles buried at 3 months (U (9, 15) = 34.5, p >.025) or at 19 months of 
age (U (9, 11) = 40.0, p >.025), but at 6 months of age, female transgenic mice buried fewer 
marbles than wild type female mice (U (9, 15) = 9.0, p <.0001).  
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Fig. 2.7: The mean number of marbles buried for female transgenic and wild type mice at ages 
3, 6, and 19 months. *** = p < .001 or more. Error bars ± 1 S.E.M.  
 
In order to assess the effect of age on marble burying performance in the context of both 
gender and genotype, the data was split according to gender and genotype. The average 
number of marbles buried at each age was used as dependent variables in the non-parametric 
Friedman ANOVA test of repeated measures. As can be seen in Table 2.3, there was no 
significant difference between age points for any group [male wild type mice: (χ2(2)=6.90, p > 
.0125); male transgenic (χ2(2)= 5.73, p > .0125); female wild type (χ2(2)= 2.53, p > .0125); or 
female transgenic mice (χ2(2)= 2.73, p > .0125)].  
 
2.4 Experiment 1b: EPM 
2.4.1 Apparatus 
The elevated plus maze consisted of four arms which are 70cm above floor level. The arms are 
39.5cm long and 6.5cm wide, with a connecting area (6.5cm*6.5cm) in the meeting point 
between the arms (see Figure 2.8). Two of the arms (referred to as “closed arms”) are 16.6cm 
high and of dark material, whilst the other two arms (referred to as “open arms”) are 3cm high 
and of clear Plexiglas. The two open arms are positioned directly across from each other, as 
are the two closed arms.  
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Fig. 2.8: The elevated plus maze free standing in testing room illustrating two open and two 
closed arms. 
 
Methods 
Mice were placed in the connecting area facing an open arm and left to explore the maze at 
their will for a period of 5 minutes based on literature suggesting this to be the optimum time 
period for detection of avoidance behaviours (Pellow et al., 1985). The experimenter was 
present in the room scoring the behaviour of the mice on a monitor facing away from the 
maze.  
 
Scoring and data analysis 
The level of anxiety each mouse exhibited was measured by the duration of time spent in the 
open and closed arms. This was manually scored whilst recording using EthoVision XT. An 
entry into an arm was defined as all four legs being positioned inside the arm. Similarly, exit 
out of an arm was defined as all four legs being positioned outside the arm. Information about 
the relationship between the amount of time spent in the open vs. closed arms of the elevated 
plus maze was captured by creating a composite variable expressing time spent in the open 
arms as a percentage of time spent in all arms using the formula [time in open arms/(time in 
open arms + time in closed arms)]*100. The data was analysed using repeated measures 
ANOVA.   
 
61 
 
2.4.2 Results 
The percentage of time spent in the open arms as a percentage of time spent in any arm is 
presented in Fig. 2.9, and shows a preference for the closed arms in wild type mice which is 
not present in transgenic mice. This interpretation was confirmed by statistical analysis 
revealing a main effect of genotype (F (1, 35) = 9.9, p < .005), in which transgenic mice spent 
more time in the open arms (as a percentage of total time) than wild type mice. There was no 
significant between-subject effect of gender (F (1, 35) = 0.25, p > .05) or a gender*genotype 
interaction (F (1, 35) = 0.001, p > .05).  
Fig. 2.9: The time spent in the open arms as a percentage of time spent in any arm for 
transgenic and wild type mice at ages 3, 6, and 19 months. Error bars ± 1 S.E.M. *** = p < .005. 
 
In terms of the within-subject effects, there was an effect of age (F (2, 70) = 3.5, p < .05) on the 
time spent in the open arms as a percentage of time spent in any arm, driven by an increase in 
time  spent in the open arms at 3 months compared to 6 months (F (1, 35) = 8.0, p < .01).  
The means and S.E.M. values for the time spent in the open and closed arms are 
presented in Table 2.4, and mirror the pattern in the percentage data of a preference for the 
closed over the open arms in the wild type mice which was not present in the transgenic mice.  
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  Time in open arms (s) Time in closed arms (s) 
                                          Wild Type Transgenic Wild Type Transgenic 
Age Gender Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
3 Male 59.9 8.4 105.0 19.6 158.5 9.9 72.4 22.7 
3 Female   92.9    16.4 102.8    12.2  139.9    16.3  114.6      9.0 
6 Male   46.4      6.1  89.9    29.6  188.3    11.1  108.5    26.9 
6 Female   42.9    16.7 104.0    10.9  183.5  22.7  112.8  12.1 
19 Male   82.8    10.9 109.2    28.2  149.9    10.9  146.3    30.2 
19 Female   93.6    17.0 104.5    10.0  151.4    18.6  148.3    10.7 
Mean Male 
Female 
62.9 
77.0 
5.5 
10.4 
101.4 
103.7 
14.3 
6.6 
165.7 
157.6 
6.6 
11.3 
109.1 
123.0 
16.3 
6.8 
Table 2.4: The mean and S.E.M. values for the time spent in the open and closed arms (s) 
across all gender and genotype groups at each age interval.  
 
2.5 Chapter Discussion 
The results from the longitudinal assessment of marble burying performance indicate a clear 
genotypic difference, with transgenic mice burying fewer marbles than wild type mice at 3, 6 
and 19 months. In addition, a gender difference was identified, with male mice burying more 
marbles than female mice across genotype. Thus, transgenic mice are less anxious than wild 
type mice, with female mice showing the same tendency for reduced anxiety relative to male 
mice.  
In terms of interactions between gender, genotype and age on marble burying 
behaviour, the general patterns of performance are stable across ages, despite only reaching 
statistically significant differences at certain age points. Female transgenic mice buried 
significantly fewer marbles than wild type mice at 6 months, but not 3 or 19 months of age. In 
contrast, male transgenic and wild type mice differed only at 19 months of age. The lack of 
significant genotypic differences within the genders at select age points may be influenced by 
a relatively high level of variance which appears to decrease with age. In addition, it is 
important to note the differences in sample size between gender/genotype groups, and the 
limitation this poses in terms of the conclusions one can draw regarding gender effects in the 
current study. Overall, transgenic mice display an anxiety-deficit compared to wild type mice 
of both genders, and this pattern of behaviour is present from 3 to 19 months of age with 
relatively little change (although see below for a discussion of the issue of repeated testing in 
anxiety assessments).  
Although the marble burying task has been used as an assay of anxiety, recent 
evidence indicates that mice do not reduce their marble burying activity following habituation 
to the marbles in the home cage, following repeat testing or when given the opportunity to 
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avoid the marbles (Njung’e and Handley, 1991; Thomas et al., 2009). Indeed, mice buried a 
similar number of familiar and novel objects when comparing marbles to food pellets from the 
home cage. It has therefore been proposed that marble burying may be related to 
perseverative, obsessive-compulsive behaviour (Londei, Valentini & Leone, 1998; Albelda & 
Joel, 2011) or regulated by genetic background related to general digging behaviour (Thomas 
et al., 2009). It has been repeatedly established however that anxiolytic drugs such as 
diazepam reduce the number of marbles buried (Broekkamp et al., 1986; Njung’e and 
Handley, 1991; Ichimaru et al., 1995; Nicolas, Kolb & Prinssen, 2006). This suggests that neural 
pathways that are involved in anxiety-related behaviour are implicated in this task. It is 
therefore possible that marble burying is related to a complex set of behaviours, including 
anxiety-like behaviour, but in a way that is not driven by object novelty per se. To provide 
another index of anxiety APP(V717I) mice were also tested on the elevated plus maze.    
The results from the EMP study show a clear genotypic difference with transgenic 
mice spending more time in the open arms than wild type mice. This indicates that transgenic 
APP(V717I) mice show reduced anxiety. This deficit was generally stable across age. There 
were indications of more variability in the wild type group, with an increase in anxiety from 3 
to 6 months, and a numerical decrease in anxiety from 6 to 19 months. There were no 
contributions of gender to anxiety behaviour in the EPM. The results from the EPM 
experiment are clearly in accordance with those observed in the marble burying experiment. 
The stability of the reduction in anxiety-like behaviour in transgenic mice compared to wild 
type mice across two types of anxiety tests suggests that the tasks are assessing overlapping 
constructs.  
The results of the behavioural characterisation of the APP(V717I) model contradict the 
published reports of increased anxiety APP(V717I) mice. Mutant mice showed a clear increase 
in anxiety behaviours across 1-12 months of age (Moechars et al., 1999b). The discrepancies 
between Moechars et al. (1999b) and the current experiments could be due to a number of 
factors. Elevated transgenic anxiety in Moechars et al. (1999b) was detected using an open 
field task to assess anxiety compared to the marble burying and EPM tasks used in the current 
study. Whilst the difference in tasks could account for the discrepancy, perhaps a more 
significant factor is the difference in the background strain (Moechars et al., 1999b; Crawley et 
al., 1997; Bucan & Abel, 2002; Wolfer & Lipp, 2000; Võikar et al., 2001). In Moechars et al. 
(1999b), the APP(V717I) model in maintained on an FVB/N background for the anxiety 
assessments, whilst a F1 hybrid generation of FVB/N and C57Bl/6 mice was used for the Morris 
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water maze task. When informally comparing the current cohort of APP(V717I) mice to 
Moechars et al. (1998; 1999b), it was notable that none of the reported aggression, seizures or 
premature death was observed in the current cohort of mice. It is therefore possible that the 
background change could have similarly affected the expression of anxiety phenotypes. 
Indeed, Võikar et al. (2001) found strain and gender differences on a battery of behavioural 
tests, including a stronger expression of anxiety in C57Bl/6 males than females when crossed 
into 129S2/SvHsd and tested in the elevated plus maze. Similarly, Holmes et al. (2003) report 
differential anxiety phenotype in serotonin transporter null mice when on different genetic 
backgrounds.  
It is important to note that the effect of age on anxiety behaviour was confounded by 
repeated testing. As anxiety tasks, it is desirable for subjects to be unfamiliar with the task at 
the time of testing. Any effect of repeat exposure to the test was minimised through the use 
of novel test rooms at each test stage, as well as the delay of 3, then 13 months between 
testing points. It is however possible that the numerical reduction in genotypic difference at 
19 months of age in both the marble burying and the EPM task is related to the higher level of 
handling and testing experience the cohort had undergone by this age in a series of other 
behavioural paradigms, in addition to potential habituation to the tasks themselves. However, 
there is a clear trend for the decrease in anxiety being stable both across age and tasks, 
suggesting that the transgenic anxiety deficit does not progress in parallel with Aβ pathology.  
The assessments of anxiety in APP(V717I) mice was carried out with the aim of 
achieving a fuller phenotype of the model, as well as to investigate whether differences in 
anxiety exists between transgenic and wild type mice which may influence assessments of 
cognition. In terms of the translational value of behavioural assessments in mouse models of 
AD, it can be argued that measurements of cognitive performance are more relevant to the 
human condition than assessments of anxiety. Human patients are frequently found to suffer 
from elevated anxiety, and a high percentage of patients are on anxiolytic drugs like 
benzodiazepines (Blazer et al., 1991, Ownby & Carmin, 1998). The lack of consistency between 
the higher anxiety levels observed in patients and lowered anxiety levels as assessed in the 
marble burying task and EPM in the APP(V717I) model indicates that the tasks used measure 
different psychological constructs. Expressions of anxiety in patients could be influenced by an 
awareness of the progression of their disease and their own cognitive decline which is not 
possible to recapitulate in rodent models. Indeed, Harwood et al. (2002) identified a positive 
relation between the degree to which patients were aware of their cognitive deficits and 
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instances of depression and anxiety. Related to this, a high degree of disease awareness is 
related to elevated reports of hopelessness and feelings of life having reduced worth 
(Harwood & Sultzer, 2002). This highlights the need to view anxiety as assessed in mouse 
models of Aβ pathology as an important element of characterising the behavioural phenotype, 
with limited direct translational value in the context of immunotherapy.    
When assessing transgene-related phenotypes in mouse models of AD-pathology, it is 
important to assess whether deficits are age-dependent or age–independent. As near zero 
levels of human Aβ can be detected at 3 months of age in this model (Dewachter et al., 2000), 
it is unlikely that the observed reduction in anxiety behaviour is related to an elevation in Aβ 
levels at this age. In addition, the anxiety deficit does not appear to exacerbate with age as Aβ 
levels increase. It remains possible therefore that the reduction in anxiety is related more to 
overexpression of hAPP than Aβ pathology. In this model, the thy1 promoter drives stable 
hAPP expression from 2 weeks of age. Indeed, when comparing mice expressing non-mutant 
hAPP to both wild types and mice expressing the human APP(V7I7I) mutation, mice expressing 
any form of APP displayed increased anxiety and spatial learning deficits compared to non-
transgenic mice (Moechars et al., 1999b). This underlines the ability of both non-mutant and 
mutant APP overexpression to affect anxiety-behaviours; although the mechanism(s) by which 
such overexpression of APP affects anxiety and cognition is unclear. Importantly, this 
phenotype is unlikely to be modified through a therapeutically induced change in Aβ levels, 
suggesting that anxiety-assessments may be unsuited to evaluate the effect 2B3 induced 
changes in behaviour mediated by reduced Aβ production. In order to identify an age-related 
cognitive phenotype in the APP(V717I) model which may be suited to assess the effect of 2B3 
on cognition, the aim of the experiments reported in Chapter 3 were to characterise the onset 
and progression of cognitive changes in the APP(V717I) model.  
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Chapter 3 
 
Spatial and Object Recognition Memory in the London APP(V717I) Model 
 
3.1 Introduction  
The experiments reported in this chapter investigated the onset and progression of changes in 
spatial learning and memory the London APP(V717I) mouse model of Aβ pathology. The 
experiments aimed to establish the nature and developmental profile of spatial learning and 
object recognition memory. 
As summarised in Table 2.2, Section 2.1.2, Chapter 2, APP(V717I) mice display a deficit in 
the Morris water maze at 3-6 months of age and a visual recognition deficit at the same age 
range (Dewachter et al., 2002). One interpretation of these results is that they may reflect 
structural or functional alterations in areas such as the hippocampus (spatial memory) and the 
perirhinal cortex (object recognition memory; Bannerman et al., 2003; 2004; Gray & 
McNaughton, 2000; Aggleton & Brown, 2006; Davis, 1998).  
Given the results of the anxiety assessments, it is clear that in order to evaluate the effects 
of 2B3 on Aβ-related cognitive deficits it is first important to establish the cognitive profile of 
the V717I line. Earlier published reports of memory function in APP(V717I) mice have been 
conducted solely within the age range of 3 to 6 months. This relatively limited age range does 
not allow one to accurately pinpoint the age of onset and developmental profile of 
behavioural deficits. In addition, the discrepancies in anxiety-related behaviour between the 
published data and the findings reported in Chapter 2 raises the possibility that similar 
discrepancies could emerge in the cognitive phenotype. Similarly, the lack of information 
regarding the effect of gender on the APP(V717I) behavioural phenotype underlines the 
necessity of further characterisation of the model.  
The aim of the experiments presented in this chapter was to provide a developmental 
profile of putative changes in cognitive function in London APP(V717I) mice. The experiments 
tested the hypotheses that the APP(V717I) mutation would lead to age-related deficits in 
spatial and object recognition memory. Both male and female mice were utilised to assess 
whether gender influenced the time of emergence of behavioural deficits or the degree of 
disruption to normal functioning.  Moechars et al. (1999b) reported significant impairments in 
spatial learning in APP(V717I) transgenic mice using the Morris water maze at 3-6 months of 
age. In Experiment 3, spatial reference memory was examined using a radial arm water maze 
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task at 10 months of age, in which transgenic mice were hypothesised to display deficits in 
platform learning compared to wild type mice. The radial arm water maze was selected based 
on extensive evidence to implicate the hippocampus in successful performance in variations of 
spatial water maze tasks (Westerman et al., 2002; Hsiao et al., 1996; King et al., 1999). The 
hippocampus is throught to support episodic memory, an important cognitive process 
disrupted in AD patients (McKhann et al., 1984; Squire & Zola, 1998). Whilst the radial arm 
maze task does not directly assess episodic memory, the sensitivity of the task to hippocampal 
damage makes it relevant in the context of AD-related cognitive deficits. Furthermore, tasks 
sensitive to deficits in recognition of spatial locations in AD patients (Moss et al., 1986) have 
similiar task requirements to that of the radial arm maze task, although testing conditions vary 
significantly. In the context of preclinical work, the task has been used as a measure of 
cognitive dysfunction in APP mice (Gordon et al., 2001) that is sensitive to treatment 
intervention (Wilcock et al., 2004; 2006).  
Experiment 4 and 5 assessed spatial working memory using a foraging task and the forced 
choice alternation non-matching to position T-maze task respectively. Performance on the 
non-matching to position paradigm tested in the T-maze is disrupted by hippocampal lesions 
(Deacon et al., 2002), and the task is sensitive to cognitive impairment in APP mutation mouse 
models (Chapman et al., 1999; Lalonde et al., 2002; Wriths et al., 2008; Corcoran et al., 2002). 
In terms of the relevance of spatial working memory paradigms to the cognitive profile of AD 
patients, it has been repeatedly demonstrated that short term or working memory 
impairments are widespread in individuals with AD (Baddely et al., 1991; Becker et al., 1988; 
Bellville et al., 2007; Grady et al., 2001; Moss et al., 1986). These impairments are often 
measured using delayed non-matching to sample paradigms which are similar to tasks like the 
T-maze in that sample information must be retained over a delay, prior to being utilised to 
identify the novel option (Grady et al., 2001). , The focus on visual stimuli in AD patient testing 
differs from rodent work in which spatial locations are to be recalled. Nevertheless, given the 
extensive medial temporal lobe, and in particular hippocampal, dysfunction in AD patients, the 
use of a delayed non-matching to position paradigm based on spatial information is highly 
relevant to AD (Squire & Zola, 1998).  
In the foraging task (Pearce et al., 2005), mice were assessed longitudinally at 3, 6 and 19 
months of age. The task is an adaptation of the radial arm maze which has been used 
extensively to assess spatial working and reference memory deficits in APP models (Dodart et 
al., 1999; Gordon et al., 2001). As such, it falls within the test battery relevant to working 
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memory deficits and hippocampal dysfunction in AD patients as discussed previously. Based 
on Moechars et al. (1999b), transgenic mice tested in the foraging task in Experiment 4 were 
predicted to perform at similar levels to wild type mice at 3 months of age, with a progressive 
decrease in spatial memory related performance compared to wild type mice evident at 6, and 
19 months of age. In the T-maze at 11 months of age, transgenic mice were predicted to 
display a spatial working memory deficit. Object recognition memory at 18 months of age was 
assessed using novel object recognition in Experiment 6. Performance in the novel object 
recognition task relies on the perirhinal cortex (Aggleton & Brown, 1999), and offers an 
extension to the otherwise largely hippocampal-based task battery. Recognition memory 
deficits as observed in animal work has been suggested to be comparable to human semantic 
memory, defined as “knowledge for objects, concepts, faces and words” (Davies et al., 2004, 
p. 2441). AD patients have a well documented impairment in recognition memory, which 
applies to a variety of domains such as visual (including objects), spatial and verbal stimuli (Hof 
& Bouras, 1991; Moss et al., 1986), and perirhinal volume has been found to correlate 
positively with semantic performance (Davies et al., 2004). Experiment 6 tested the prediction 
that transgenic mice would show inferior discrimination of the novel and familiar objects after 
a 3 hour delay, but not after a 1 hour or 5 minute delay as demonstrated in Dewachter et al. 
(2002). An overview of the order of experiments and the sample size for APP(V717I) mice is 
presented in Fig. 3.1.  
 
 
 
 
 
 
 
Fig. 3.1: Experimental time line indicating the age at which each test carried out in APP(V717I) 
mice, as well as details of the sample sizes. The overview includes the tasks described in 
Chapter 2, and thus provides a full overview of the tasks administered to this cohort of mice. 
At 3 and 6 months of age, the anxiety tasks were administered before the foraging task. The 
hippocampal lesioned mice are not included, but were assessed on the RAWM prior to the T-
maze.  
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3.2 Experiments 3a and 3b: Hippocampal lesioned and APP(V717I) mice on the Radial 
Arm Water Maze 
The radial arm water maze (RAWM) is an alternative version of the widely used Morris water 
maze. In a pool divided into 6 arms, mice are released from varying start arms and are 
required to learn the location of a stable escape platform in one goal arm. The task has been 
used to test spatial reference memory in several transgenic AD mouse models (Gordon et al., 
2001; Wilcock et al., 2004; Wilcock et al., 2006) as well as in rats (Diamond, Park, Heman & 
Rose, 1999). As disruption to the hippocampus has been shown to disrupt spatial learning in 
C57Bl/6 mice in the Morris water maze and the radial arm maze (Aggleton & Brown, 1999; 
Logue, Paylor & Wehner, 1996; Cho, Friedman & Silva, 1998; Gerlai, 1998; Deacon, 
Bannerman, Kirby, Croucher & Rawlins, 2002), it is reasonable to predict that the RAWM is 
sensitive to hippocampal dysfunction. In order to confirm that the RAWM test procedure was 
sensitive to alterations in hippocampal function a preliminary study (Experiment 3a) was 
conducted with hippocampal lesioned mice prior to using the procedure on APP(V717I) mice 
(Experiment 3b). It was hypothesised that APP(V717I) mice would show impaired performance 
in the RAWM compared to littermate controls. In terms of gender, no direct information 
regarding male and female differences in APP(V717I) mice in spatial learning is available, but 
information from studies such as Clinton et al. (2007) suggest that female transgenic mice 
show poorer spatial learning in stressful conditions such as the Morris water maze compared 
to male 3xTg mice. It is therefore possible that APP(V717I) mice will show a similar impairment 
in spatial learning compared to males.   
  
3.2.1 Design 
Assessment of the effect of the APP(V717I) mutation on spatial reference memory was carried 
out at 10 months of age. Both genders were included in order to assess whether gender 
affects the expression of a transgenic phenotype in the RAWM. The effect of bilateral 
hippocampal lesions on spatial reference memory was established prior to evaluating 
APP(V717I) mouse performance.   
 
Subjects 
Experiment 3a: Fifteen male C57Bl/6 mice aged 5 months were tested in the RAWM, of 
which 7 mice had bilateral hippocampal excitotoxic lesions surgery 3 months prior to 
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behavioural assessment. Prior to administration of the RAWM task, mice had undergone 
extensive operant learning training to assess responding when cued ambiguously compared to 
unambiguously using Med Associates testing chambers. One mouse was excluded based on 
the histology indicating that the excitotoxic lesion to the hippocampus was restricted to 
unilateral damage. Thus, the behavioural data presented is based on 6 mice with bilateral 
hippocampal lesions and 8 non-surgical controls.    
 
Experiment 3b: The subjects were those described in Chapter 2, Section 2.2, with 14 female 
transgenic APP(V717I) mice. 
 
Apparatus 
The RAWM consisted of 6 dark Perspex arms connected by a 37cm wide central area elevated 
77cm above the floor (Figure 3.2). The maze was 28.3cm deep, with arms of 29cm length and 
17.3cm width. A platform with a weighted dark plastic base (11.5cm*8.9cm) with a clear 
Perspex platform (17cm*8cm, 1cm thick) elevated to the total height of 19cm by a clear plastic 
rod was provided as a means of escaping the water for the mice. A visual cue consisted of a 
laminated white card (16.8cm*8.2cm) attached to the back wall of the goal arm 0.5 cm above 
the water line. The maze was filled 21cm high with 25-29oC opaque water (~1% milk). The 
water was at approximately 1cm above the top surface of the platform to ensure that the 
platform was invisible to the mouse. Trials were video recorded.  
 
Fig. 3.2: Radial arms water maze apparatus without water and escape platform in A, with 
escape platform featured in B.  
A B 
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Method 
Surgery 
Mice were anaesthetised with Isoflurane [2-chloro-2-(difluromethoxy)-1, 1, 1-trifluoro-
(ethane)] in O2 during stereotaxic surgery. The skull was exposed by a scalp incision. Two holes 
were drilled on opposite sides of the midline at the appropriate coordinates (see Table 3.1). 
Three injections of 63mM ibotenic acid (IBO, Biosearch Technologies, USA) in PBS at a rate of 
0.3µl per minute were made in each hemisphere using a 30G cannulae microinjection 5µl 
Hamilton #75 syringe (Hamilton Company, Reno, USA). Following each infusion, the needle 
was left in place for 1 minute before being retracted slowly. Upon completion, the wound was 
sutured and the animal was given a subcutaneous injection of glucosaline to aid rehydration. It 
was then placed in a 30oC temperature controlled recovery chamber under monitoring until 
deemed alert and mobile. Once alert, the animal was place in the home cage with soaked diet 
and 500mg paracetamol added to the drinking water. Mice were perfused at 22 months.  
 
Perfusion 
Mice were given a 0.1ml intraperitoneal (IP) injection of 200mg/ml pentobarbital (Euthatal, 
Merial, Harlow, UK) to induce deep anaesthesia. Through the insertion of a cannula into the 
left cardiac ventricle, approximately 50ml of 0.1M PBS (pH 7.4) was pumped through the 
circulatory system. This was followed by approximately 100ml of 4% paraformaldehyde in 
0.1M PBS (formaldehyde, FA). Following extraction of the brain, it was post fixed in 4% FA at 
4oC for 8 hours before being transferred to 30% reagent grade sucrose in dH2O. The brain was 
left in sucrose until saturated indicated by it sinking (approximately 48 hours). Using a freezing 
microtome, 40µm coronal sections of brain tissue were cut and mounted on gelatinised slides 
in 0.1M PBS. 
Four colleagues at Cardiff University kindly assisted in this work. The bilateral 
hippocampal lesions described were performed by Prof. Good. Perfusions of lesioned mice 
and controls were carried out by Dr. Reichelt, whilst the histological processing was performed 
by Mr. Anderson. In addition, Ms. Peatson assisted with the behavioural testing.  
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 Stereotaxic coordinates  
Site Anterior-Posterior (-) Lateral (±) Ventral (-) Volume (µl) 
1     1.9     1.6     1.8     0.10 
2     2.5     3.0     3.0     0.15 
3 3.0 3.2 3.5 0.15 
Table 3.1: The stereotaxic coordinates for bilateral hippocampal lesions outlined as mm from 
bregma (anterior posterior), from the midline (lateral) and from the skull surface (ventral).  
 
Cresyl violet staining 
Sections were dried at 200C for 24 hours before being stained. Staining involved immersing 
sections in xylene for 4 minutes before descending concentrations of ethanol was applied for 2 
minutes each (100%, 90%, 70%) starting with 4 minutes in 100% alcohol. After 2 minutes in 
deionised water, 0.005% Cresyl violet was applied for 2 minutes, followed by 30 seconds in 
deionised water.  An ascending series of alcohol was applied for 2 minutes each (70%, 90%, 
100%), followed by an additional 2 minutes in 100% alcohol and two exposures to xylene, 
again of 2 minutes duration each. Slides were dehydrated in an ascending concentration of 
ethanol for 2 min each (50%, 70%, 90%, 100%, 100%) before being submerged in xylene for 4 
minutes. Finally, slides were coverslipped with DPX Mounting media and air dried for 48 hours 
before sections were visualised using a Leica DMRB microscope. Images were captured using 
an Olympus DP70 camera and the programme analySIS-D. 
 
Behavioural procedure 
The procedure was adapted from Wilcock et al. (2004; 2006). The mice were given 4 days of 
testing, with 12 trials on each day and an inter-trial interval of 10 minutes. On the first day of 
testing, the platform was visually cued with white card on half of the trials. Each trial required 
the mouse to swim to the centre of the maze following release from a start arm, before 
making a choice to swim into any of the 6 arms. If the mouse made an incorrect choice (i.e. an 
arm where the platform was not located), the experimenter gently pulled the mouse back to 
the start arm by the tail and then released the mouse. A trial was either concluded when the 
mouse located the platform, or when 1 minute had passed without the platform having been 
located. In the latter case, the experimenter guided the mouse to the platform and allowed 
the mouse 30 seconds on the platform to enable the animal to encode the extra maze 
environment. The mouse spent the inter trial interval in a heated box set at 37oC to avoid 
hypothermia. The location of the platform was kept constant for each mouse across all trials, 
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but was counterbalanced between two locations across groups. On each trial, the mice were 
released from a different start arm, all of which were counterbalanced across groups. On day 
5, a probe trial was administered where the platform was removed, and the mouse was 
permitted to explore the maze freely for 1 minute.  
   
Scoring and data analysis 
An error was defined as the mouse entering an arm that did not contain the platform. Entry 
into an arm was defined as the point at which the back of the mouse (excluding the tail) 
crossed into the arm. Errors were counted manually by the experimenter, and noted down at 
the conclusion of each trial. An additional error was awarded if the mouse failed to locate the 
platform in the 1 minute available. During the probe trial, the amount of time spent in each 
arm as well as the number of entries into each arm was scored manually from video 
recordings. The error score obtained on each trial was averaged across each test day for each 
mouse, before the scores were averaged across test days to create a composite variable of 
total error average. For the probe trial, a score was calculated to represent the time the 
mouse spent in the goal arm as a percentage of time spent in any arm.  
 
3.2.2 Results: Experiment 3a: Hippocampal lesioned mice 
Histology  
The maximum and minimum tissue damage obtained as a result of excitotoxic lesions is 
displayed in Fig. 3.3. In 4 lesioned animals, the entire hippocampus was removed. In 3 lesioned 
animals, the hippocampus was removed completely with the exception of the dorsal dentate 
gyrus bilaterally. There was also some (mostly unilateral) sparing of the ventral subiculum and 
CA1 in these 3 mice. Some cortical damage around the infusion site was evident in 5 out of 6 
lesioned mice, predominately in the somatosensory and retrosplenial cortex, with some 
damage to the visual cortex.  No hippocampal damage was present in any non-surgical control 
mice. Some cortical damage was evident, but as this was not focused around the craniotomy 
site, it is likely to be related to mechanical damage during tissue sectioning.   
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Maximum and minimum lesion size 
 
 
 
 
Fig. 3.3: The level of damage to the hippocampus and cortical areas around the infusion sites 
in hippocampal lesioned mice is summarised by the shading of the largest and smallest lesions 
in the cohort. Maximum sized lesion is indicated in striped grey, with the minimum sized lesion 
in dark grey. Each section is denoted as the distance from posterior from bregma (mm).  
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Behavioural results 
Visually cued trials in hippocampal lesioned mice 
There were no significant differences between lesioned and non-lesioned mice in the average 
errors on visually cued trials (F (1, 13) = 2.87, p > .05, see Fig. 3.4A) or in the average latency to 
complete visually cued trials (F (1, 13) = 2.50, p > .05; see Fig. 3.4B).  
   
Fig. 3.4: Mean error (A) and latency (B) across visually cued trials on test days 1 – 4 for 
hippocampal lesioned and non-surgical control mice on the RAWM task. Error bars are ±1 
S.E.M.  
 
Error and latency in hippocampal lesioned mice 
There was a significant main effect of test day (F (3, 39) = 9.51, p < .0001) in addition to 
hippocampal lesioned mice making significantly more errors across test days than non-
lesioned mice (F (1, 13) = 27.23, p < .0001; see Fig. 3.5A). Hippocampal lesioned mice had 
higher latency scores than non-lesioned mice (F (1, 13) = 6.37, p < .05; see Fig. 3.5B). 
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Fig. 3.5: Mean error (A) and latency in seconds (B) across trials on test days 1 – 4 for 
hippocampal (HPC) lesioned and non-surgical control mice on the RAWM task. The first test 
day does not include visually cued trials and is thus half the number of trials as the subsequent 
days. Error bars are ±1 S.E.M.  * = p < .05, *** = p < .0001.  
 
Results: Experiment 3b: APP(V717I) mice 
Visually cued trials 
On visually cued trials (see Fig. 3.6), there was no significant difference between transgenic 
and wild type mice on error scores (F (1, 38) = 0.02, p > .50), no effect of gender (F (1, 38) = 
0.002, p > .50) and no gender*genotype interaction (F (1, 38) = 0.02, p > .50). This pattern was 
upheld when analysing latency scores on visually cued trials [genotype (F (1, 38) = 0.19, p > 
.05), gender (F (1. 38) = 1.49, p > .05), genotype*gender (F (1, 38) = 0.66, p > .05)]. 
  
Fig. 3.6: Mean error and latency across cued trials for transgenic and wild type mice. Error bars 
± 1 S.E.M. 
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Error and latency 
Fig. 3.7A indicates that wild type and transgenic mice acquired the water maze task at the 
same rate. Indeed, ANOVA analysis confirmed that there was no significant main effects of 
genotype (F (1, 38) = 0.03, p > .50) or gender (F (1, 38) = 0.63, p > .50) on average latency 
across test daysAn effect of test day (F (3, 114) = 20.48, p < .0001) indicates learning across 
sessions. Additionally, there was no effect of genotype (F (1, 38) = 0.01, p > .50) or gender (F 
(1, 38) = 1.09, p > .50) on error scores across test days. Genotype and gender did not 
significant interact on either measure [latency (F (1, 38) = 2.04, p > .50), error (F (1, 38) = 2.04, 
p > .50)].  
 
Probe trial 
Fig. 3.7B shows the percentage time spent in the goal arm during the probe trial. This figure 
indicates that there was no difference between wild type and transgenic mice. This was 
confirmed by an ANOVA that revealed no significant main effects of genotype (F (1, 38) = 0.29, 
p > .50) or gender (F (1, 38) = 1.58, p > .50) and no significant interaction between these 
factors (F (1, 38) = 2.0, p > .50).  
 
Fig. 3.7: A displays the mean errors made by transgenic and wild type within each test day. B 
displays the mean percentage of time spent in the goal arm during the probe trial. Error bars ± 
1 S.E.M. 
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Due to the lack of effect of gender on these measures, the data presented in Fig. 3.7 have 
been collapsed across gender. For information however, average values split by gender and 
genotype is presented in Table 3.2 
                                          Mean error Mean latency           Probe trial (%) 
Genotype Gender Mean S.E.M. Mean S.E.M. Mean S.E.M. 
Transgenic Male  3.58 0.38 28.10 1.39   27.10 3.89 
Transgenic Female    3.07     0.14 24.77 0.84    27.92 3.85 
Wild Type Male    3.22 0.25     31.78 1.47    31.74 5.17 
Wild Type Female    3.35     0.21 28.17 2.15    19.24 4.45 
Mean Transgenic 3.38 0.31 26.84 1.07 25.73 3.48 
Wild Type 3.43 0.28 30.33 1.30 23.57 3.68 
Table 3.2: The mean and S.E.M. values for the mean latency and errors made across test days 
and the percentage of time spent in the goal arm during the probe trial presented split by 
gender and genotype.   
 
3.2.3 Discussion 
The performance of C57Bl/6 mice with bilateral hippocampal lesions compared to controls 
indicate that intact hippocampal functioning is necessary in order to acquire the platform 
location in the RAWM. Whilst the error scores of control mice decline with training, the error 
score of hippocampal lesioned mice is comparable on day 1 and day 4 of testing. The deficit in 
RAWM performance in hippocampal lesioned mice compared to controls is not present when 
the platform is cued, suggesting that the deficit is specific to the spatial learning requirements 
of the task. Therefore, the lack of deficit observed in APP(V717I) transgenic mice at 10 months 
compared to littermate controls indicates intact spatial reference memory and 
uncompromised hippocampal function.  
 This latter finding is in contrast to previous reports of a spatial reference memory 
deficit at 3-6 months of age (Moechars et al., 1999b; see Chapter 2, Section 2.5 for a 
discussion of the role genetic background may play). The lack of evidence of a spatial memory 
deficit in transgenic mice at 10 months of age suggests that this aspect of cognitive function is 
not affected by either APP over-expression or elevation of Aβ levels at this age. It is unclear 
what levels of soluble and insoluble Aβ are detectable in the central nervous system (CNS) of 
transgenic APP(V717I) mice by 10 months of age, but there is some evidence of soluble Aβ at 
younger ages indicating that at least trace levels are present (see Chapter 2, Section 2.1.2, 
Table 2.1). The absence of a behavioural deficit on this task may be due to insufficient Aβ 
pathology. Alternatively, it is equally possible that the task may be insensitive to subtle 
alterations in Aβ-induced synaptic deficits in APP(V717I) mice. The following set of 
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experiments was conducted to assess whether transgenic APP(V717I) mice display deficits on 
other spatial procedures, such as age-related deficits in spatial working memory using a 
foraging task (Experiment 4) and a forced choice non-matching to position T-maze task 
(Experiment 5).  
 
3.3 Experiment 4: APP(V717I) mice assessed using the foraging task 
3.3.1 Introduction  
The foraging task is a spatial working memory task (Pearce et al., 2005), where a series of 
spatial locations are baited with rewards that can be retrieved in any order. Each location is 
always baited at the start of each trial. Efficient completion of the task requires the use of 
continuously updated information regarding which locations have been depleted of rewards at 
any given time during testing. The task is an adaptation of the 8-arm radial arm maze where 
animals are required to visit the baited half of the arms to obtain reward, but avoid the half of 
arms which are never baited (Olton & Samuelson, 1976; Olton & Papas, 1979; Floresco, 
Seamans & Phillips, 1997). 
 
3.3.2 Method 
Design 
The longitudinal assessment of spatial working memory as measured in the foraging task was 
conducted in order to assess whether the presence of the APP(V717I) mutation led to higher 
error scores for transgenic mice than wild type mice, and whether such a deficit was age-
dependent.  
 
Subjects 
The subjects were those described in Chapter 2, Section 2.2. 
 
Apparatus 
A 102cm*102cm sized arena with 45cm high walls painted a dark grey was filled with loose 
sawdust to a depth of approximately 2cm. The arena was placed on the floor, and contained 
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eight 3.5cm high circular pots with a diameter of 7.7cm placed in an hour-glass formation (Fig. 
3.8). The pots were filled 3cm high with sawdust, and a coco pop reward [Kellogg’s; rice, sugar 
and chocolate (4%)] placed in the centre of the pot, 1 cm from the bottom. Trials were DVD 
recorded and tracked using EthoVision XT (Noldus).  
 
Fig.3.8: The foraging task arena with 8 baited pots arranged in the standard pattern.  
 
Method 
Pretraining and habituation 
Testing was carried out in the same test room at each longitudinal testing point. Mice were 
food deprived to 90% of their body weight over approximately 2 weeks prior to testing in the 
arena. During this time, mice were individually trained to forage a baited pot in cages identical 
to their home cage. Each mouse was given three such attempts daily until proficient. The mice 
were habituated to the empty arena through 10 minutes of free exploration, followed by 
habituation involving exposure to the arena with two baited pots. Mice were habituated to 
the two pots until successfully foraging in both within 2 minutes. The number of habituation 
days required at 3 months of age was 4 days, whilst 2 days of habituation was sufficient at 6 
and 19 months of age. On the first two days, the habituation duration was fixed at 10 minutes, 
regardless of when the pots were foraged. On any additional habituation days following that, 
habituation trials were terminated upon both pots being foraged.  
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Test phase 
At test, the mice were placed in the middle of the arena facing north side of the maze. Mice 
were required to visit all pots and retrieve the reward in order for the task to be completed. If 
the task was not completed within 10 minutes, the experimenter ended the trial. Mice were 
tested over 4 consecutive days, with one trial on each day. The experimenter was present in 
the room scoring the performance on a monitor, facing away from the arena.  
 
Scoring and data analysis  
The dependent variable recorded in the test phase included the number of errors, return 
errors and consecutive errors. The detail regarding the coding of these errors is summarised in 
Table 3.3. Following testing, mice had individual data points excluded if during that trial, a pot 
was foraged in a way where the reward fell onto the arena surface.  
Outcome 
measure 
Definition Example (error highlighted in bold) 
Error Jumping onto the edge of a 
pot from which the reward 
has previously been 
consumed and displacing 
sawdust through digging 
Consume reward in pot 2, leave pot 2, return 
to pot 2 and make an error 
   
Repeat 
error 
Making an error as 
described above in a pot 
where (an) error(s) 
has/have previously been 
made 
Consume reward in pot 2, leave pot 2, return 
to pot 2 and make an error, consume reward 
in pot1, return to pot 2 and make an error 
   
Consecutive 
error 
Making an error as 
described in “return error” 
in the same pot two or 
more times without 
making errors in other pots 
in the intervals between 
those errors 
Consume reward in pot 2, leave pot 2, return 
to pot 2 and make an error, return to pot 2 
and make an error, return to pot 2 and make 
an error (this would be counted as two 
consecutive errors) 
Table 3.3: Overview of the types of errors recorded in the foraging task in terms of definitions 
and examples of implementation.  
 
Perseveration, the repeated responding despite a lack of initial and/or further reinforcement, 
has been linked to hippocampal dysfunction (Dalland, 1976) and is commonly observed in 
Alzheimer’s patients (Pekkala et al., 2008) as well as transgenic APP mutation mice models 
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(Kobayashi & Chen, 2005). Spatial perseveration was measured by identifying the subset of 
errors in which returns to an incorrect location were made (see Table 3.3). The number of 
each type of error made by individual mice was averaged across test days, before being 
averaged across gender/genotype groups at each age point. In addition to these “total” task 
error scores, it is possible to analyse the error scores made in the first half of the task as an 
indication of performance under simplified test conditions, in which task difficulty is lowered 
due to the high likelihood of encountering a baited pot by chance. The end of the first half of 
the task was defined as the point at which the 4th reward out of 8 was retrieved, at which 
point engaging with a baited pot was above 50% (the “first half of the trials”). In contrast, the 
more challenging phase of the trial was defined from the 4th reward consumption until task 
completion, where the probability of engaging with a baited pot was below 50% (the “second 
half of the task”.  
 
3.3.3 Results  
A repeated measures ANOVA was used to analyse the number of errors as defined in Table 
3.4. Repeat and consecutive error measures were analysed using Mann Whitney U and 
Wilcoxon Signed Ranks for between and within-subject analyses respectively, as these 
variables violated the assumptions of normality and heterogeneity of variance. These 
violations were not successfully rectified following transformation. For simplicity of 
presentation, only data for which significant group differences were observed are graphically 
presented. Mean and S.E.M. values for all conditions are presented in Tables 3.5-3.7.   
 
Error 
The overall number of errors averaged across test trials is shown in Fig. 3.9 (and Table 3.4). A 
repeated measures ANOVA conducted on the data from which these means were derived 
revealed a significant within-subject effect of age (F (2, 68) = 3.44, p < .05), reflecting an 
overall increase in error scores across groups from 3 to 19 months of age. There were no 
within-subject interactions between age, gender and genotype [Age*Gender; F (2, 68) = 1.07, 
p > .05; Age*Genotype; F (2, 68) = .56, p > .05; Age*Gender*Genotype; F (2, 68) = .24, p > 
.05)]. There was a significant between-subjects effect of gender (F (1, 34) = 6.75, p < .05) with 
females making more errors than males, but no main effect of genotype (F (1, 34) = 3.40, p > 
.05) or a gender*genotype interaction (F (1, 34) = 1.36, p > .05).  
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Fig. 3.9: Mean error across test days for transgenic and wild type mice of both genders at ages 
3, 6 and 19 months. Error bars ±1 S.E.M.  
 
  Error across trials  Error in the first half of the trials 
                                          Wild Type Transgenic Wild Type Transgenic 
Age Gender Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
3 Male 6.16 0.17 6.53 0.79 0.45 0.02 0.86 0.02 
3 Female 6.27 0.26 7.25 0.24 0.67 0.03 0.56 0.02 
6 Male 6.85 0.55 7.25 0.28 0.55 0.02 0.83 0.05 
6 Female 6.58 0.21 9.78 0.10 0.69 0.02 0.76 0.04 
19 Male 5.39 0.06 6.00 0.17 0.46 0.03 0.58 0.02 
19 Female 7.50 0.15 9.00 0.12 0.49 0.02 0.84 0.01 
Mean Male 
Female 
6.13 0.24 6.59 0.21 0.49 0.02 0.76 0.05 
6.78 0.21 8.67 0.43 0.62 0.04 0.72 0.05 
Table 3.4: The mean error scores across trials and in the first half of the trials presented across 
age, gender and genotype with S.E.M. values.  
 
In terms of errors made in the first half of the trials, Mann Whitney U comparisons between 
transgenic and wild type mice at 3, 6 and 19 months (summarised in Table 3.7) revealed a 
significant difference in error made at 19 months of age, with transgenic mice making 
significantly more errors in the first half of the trials than wild type mice (U (20, 22) = 119.0, p 
< .05, see Fig. 3.10 and Table 3.4). This genotypic difference was evident only when the data 
were collapsed across gender [Male: U (6, 13) = 33.0, p > .025; Female: U (9, 11) = 26.5, p > 
.025)]. 
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.  
Fig. 3.10: Mean error in the first half of the trials of transgenic and wild type collapsed across 
gender at 19 months of age. Error bars ±1 S.E.M. * = p < .05.  
 
Repeat error 
An analysis of the average repeat errors across whole trials revealed a genotypic difference at 
6 months of age (U (20, 22) = 125.0, p < .05) with transgenic mice making more repeated 
errors than wild type mice (see Fig. 3.11A and Table 3.5). When analysing the effect separately 
for each gender, only transgenic female mice made significantly more repeat errors across 
trials than wild type female mice (U (9, 11) = 24.5, p < .025), with no differences between male 
mice of different genotypes (U (6, 13) = 34.0, p > .025). 
 
Fig. 3.11: Mean total repeat error (A) and repeat error in the first half of the trials (B) across 
test days for transgenic (Tg) and wild type (WT) mice of both genders (M = male, F = female) at 
ages 6 months of age only. Error bars ±1 S.E.M. * = p < .05. 
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Equally, in the first half of the trials, 6 month old transgenic mice made significantly more 
repeat errors (U (20, 22) = 139.5, p < .05; see Fig. 3.11B and Table 3.5). When analysed by 
gender, neither transgenic male nor transgenic female mice made more repeated errors in the 
first half of the trials than their wild type control group [male: (U (6, 13) = 22.0, p > .025); 
female: (U (6, 13) = 46.0, p > .025)].  
  Repeat error across trials  Repeat error in the first half of the 
trials 
                                          Wild Type Transgenic Wild Type Transgenic 
Age Gender Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
3 Male 2.39 0.09 2.53 0.41 0.02 0.01 0.09 0.03 
3 Female 2.26 0.11 2.87 0.11 0.31 0.10 0.10 0.01 
6 Male 2.46 0.10 2.50 0.11 0.02 0.01 0.17 0.03 
6 Female 2.44 0.10 5.03 0.04 0.08 0.02 0.32 0.07 
19 Male 1.63 0.04 2.25 0.17 0.04 0.01 0.00 0.00 
19 Female 3.02 0.14 3.84 0.13 0.00 0.00 0.07 0.01 
Mean Male 
Female 
2.16 0.26 2.43 0.09 0.03 0.01 0.09 0.03 
2.58 0.23 3.91 0.63 0.13 0.05 0.16 0.05 
Table 3.5: The mean repeat error scores across trials and in the first half of the trials presented 
across age, gender and genotype with S.E.M. values.  
 
Consecutive error 
In the first half of the trials, 6 month old transgenic mice made significantly more consecutive 
errors (U (20, 22) = 155.0, p < .05; see Fig. 3.12B and Table 3.6) compared to wild type mice. 
When analysed by gender, no genotypic differences emerged within each gender [male: (U (6, 
13) = 26.0, p > .025); female: (U (9, 11) = 49.0, p > .025); Table 3.7)].  
  
Fig. 3.12:  Mean total consecutive error (C) and consecutive error in the first half of the trials 
(D) across test days for transgenic (Tg) and wild type (WT) mice of both genders (M = male, F = 
female) at ages 6 months of age only. Error bars ±1 S.E.M. * = p < .05. 
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  Consecutive error across trials  Consecutive error in the first half of 
the trials 
                                          Wild Type Transgenic Wild Type Transgenic 
Age Gender Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
3 Male 0.06 0.01 0.17 0.02 0.00 0.00 0.00 0.00 
3 Female 0.18 0.02 0.28 0.01 0.03 0.01 0.07 0.001 
6 Male 0.30 0.01 0.29 0.04 0.00 0.00 0.08 0.02 
6 Female 0.17 0.01 0.51 0.03 0.00 0.00 0.12 0.03 
19 Male 0.23 0.02 0.38 0.04 0.04 0.01 0.00 0.00 
19 Female 0.31 0.03 0.39 0.03 0.00 0.00 0.02 0.01 
Mean Male 
Female 
0.20 0.07 0.28 0.06 0.01 0.01 0.03 0.03 
0.22 0.04 0.39 0.07 0.03 0.02 0.07 0.03 
Table 3.6: The mean consecutive error scores across trials and in the first half of the trials 
presented across age, gender and genotype with S.E.M.  
 
Variable (mean across test days) 
Genotype difference Genotype 
difference 
(collapsed 
across gender) 
Male Female 
U p U p U P 
3 month  
  
Error first half of the trials 16.5 0.045 66.5 0.952 182.5 0.233 
Repeat error 33.3 0.598 49.5 0.282 201.5 0.473 
Repeat error first half of the trials 29.0 0.166 64.5 0.823 191.0 0.188 
Consecutive error 33.5 0.531 51.0 0.286 163.0 0.063 
Consecutive error first half of the trials 39.0 1.000 57.0 0.374 197.5 0.143 
6 month  
  
Error first half of the trials 22.5 0.141 55.5 0.631 167.5 0.179 
Repeat error 34.0 0.660 24.5 0.015 125.0 0.017 
Repeat error first half of the trials 22.0 0.036 46.0 0.219 139.5 0.013 
Consecutive error 37.0 0.854 27.5 0.021 152.0 0.075 
Consecutive error first half of the trials 26.0 0.032 49.0 0.252 155.5 0.017 
19 
month  
  
Error first half of the trials 33.0 0.581 26.5 0.074 119.0 0.047 
Repeat error 29.5 0.401 40.5 0.494 131.5 0.115 
Repeat error first half of the trials 33.0 0.323 36.0 0.098 171.0 0.664 
Consecutive error 32.0 0.516 48.0 0.906 165.5 0.523 
Consecutive error first half of the trials 33.0 0.323 45.0 0.366 171.0 0.434 
Table 3.7: The test statistic and exact significance for the effect of genotype on variables from 
the foraging task is presented at each age time point both split by gender and collapsed across 
gender. Significant values are highlighted in bold (p = .05 for genotypic differences collapsed 
across gender, p = .025 for genotypic differences within each gender).   
 
The effect of gender 
To evaluate the effect of gender on measures of spatial working memory function in the 
foraging task, the data was collapsed across genotype. As can be observed from Table 3.8, the 
significant gender differences were limited to female mice having higher consecutive error 
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scores than males across the task at 3 months of age (U (19, 20) = 151.00, p < .05), as well as 
higher repeat error scores across the task at 6 (U (19, 20) = 137.00, p < .05) and 19 months of 
age (U (19, 20) = 115.00, p < .05). When analysed separately for each genotype, there were no 
significant gender differences.  
Variable (mean across test days) 
Gender difference Gender 
difference 
(collapsed 
across 
genotype) 
WT Tg 
U p U P U P 
3 month  
  
Error first half of the trials 50.00 0.58 27.50 0.18 227.00 0.99 
Repeat error 47.50 0.48 31.00 0.29 206.50 0.61 
Repeat error first half of the trials 49.00 0.34 43.00 0.91 191.50 0.23 
Consecutive error 43.00 0.23 33.50 0.36 151.00 0.04 
Consecutive error first half of the trials 52.00 0.41 33.00 0.28 180.50 0.05 
6 month  
  
Error first half of the trials 53.00 0.74 39.50 0.86 197.00 0.59 
Repeat error 51.00 0.63 18.50 0.05 137.00 0.04 
Repeat error first half of the trials 49.50 0.44 41.50 1.00 176.50 0.21 
Consecutive error 43.00 0.29 26.50 0.22 195.00 0.55 
Consecutive error first half of the trials 52.00 0.41 40.00 0.89 182.50 0.19 
19 
month  
  
Error first half of the trials 56.50 0.89 21.00 0.24 145.00 0.20 
Repeat error 38.00 0.18 21.50 0.27 115.00 0.04 
Repeat error first half of the trials 49.50 0.49 24.00 0.27 181.50 1.00 
Consecutive error 49.50 0.57 33.00 1.00 170.00 0.57 
Consecutive error first half of the trials 49.50 0.49 30.00 1.00 179.50 0.61 
Table 3.8: The test statistic and exact significance for the effect of gender on variables from 
the foraging task is presented at each age time point both split by genotype and collapsed 
across genotype. Significant values are highlighted in bold (p < .05 for gender differences 
collapsed across genotype, p < .025 for gender differences within each genotype).   
 
The effect of age 
Within-subject analyses were carried out to assess the effect of age on spatial working 
memory function in transgenic and wild type mice separately. As seen in Table 3.9, there were 
no significant within-subject changes as a function of age on any measure of performance.  
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Variable (mean across test days) 
Within-subject changes (across age 
points) 
WT Tg 
Χ2 p Χ2 P 
Error first half of the trials 0.94 0.63 0.03 0.98 
Repeat error  1.45 0.51 3.52 0.18 
Repeat error first half of the trials 0.29 1.00 2.58 0.29 
Consecutive error 3.65 0.17 2.98 0.23 
Consecutive error first half of the trials 0.50 1.00 4.75 0.09 
Table 3.9: The test statistic and exact significance for within-subject analysis of variables of 
transgenic and wild type performance from the foraging task is presented. WT= wild type, Tg = 
transgenic.   
 
3.3.4 Discussion 
The results from the longitudinal foraging task study indicate that there are few differences in 
spatial working memory performance between transgenic and wild type APP(V717I) mice at 3 
months, with one of six measures of performance showing a significant transgenic deficit 
compared to wild type performance in male mice only.  
At 6 months, more genotypic differences were evident, with transgenic mice making 
more repeat and consecutive errors than wild type mice, particularly in the first half of the 
trials. This finding suggests an effect of age on errors, with a general increase in errors 
between 3 and 6 months of age. However, when analysing within-subject changes in 
transgenic and wild type mice, no evidence of changes in performance as a function of age 
was obtained with the exception of an increase in overall error scores between 3 and 6 
months. By 19 months of age, the majority of these genotype differences were no longer 
evident, with the exception of the emergence of transgenic mice making more errors than wild 
type mice in the first half of the trials when collapsing across gender. 
Across age and genotype, female mice were observed to make significantly more 
errors than male mice, with a subset of performance measures indicating general differences 
between male and female mice at 3, 6 and 19 months of age. Thus, male mice appear to 
outperform female mice on a selection of variables in a manner that is not dependent on age 
or genotype. This trend does not uphold across the task measures however. More 
interestingly, genotypic differences in performance are influenced by gender, although the 
effect is limited to 2 measures of female performance at 6 months of age. This indicates that 
there are differences in the way males and females respond to the spatial working memory 
task, and raises the possibility that the phenotypic expression of the APP(V717I) transgene 
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may be different in male and female transgenic mice. Such an interpretation should be taken 
with caution however, as the effects of gender on spatial working memory in the foraging task 
are neither consistent across measures nor widespread in the data set. In addition, the 
unequal sample sizes between male and female APP(V717I) mice further encourages caution.   
Overall, the APP(V717I) mutation leads to a subtle disruption of spatial working 
memory in transgenic mice. However, it is clear that these effects do not generalise across the 
variety of measures. Moreover, transgenic performance improved from 6 to 19 months of age 
in contrast to the expected pattern in a putative model of age-related Aβ-induced cognitive 
decline. This is despite 19 months being a relatively high age for transgenic mice, as well as an 
age where extensive Aβ plaque pathology has been reported (Dewachter et al., 2000). As 
spatial working memory has not been previously assessed in the APP(V717I) model, it is 
unclear how far these results generalise across laboratories and testing conditions.  
 Due to the subtle nature of the identified transgenic APP(V717I) deficit in spatial 
working memory, it is difficult to conclude that these transgenic mice show a robust memory 
deficit.  In an effort to determine whether subtle changes in spatial working memory are 
manifested by this model in other tasks, Experiment 5 assessed memory function using a T-
maze forced choice alternation paradigm. This task has well-replicated sensitivity to deficits in 
APP mutation models (Chapman et al., 1999; Lalonde et al., 2002; Wriths et al., 2008; Corcoran 
et al., 2002).  
 
3.4 Experiment 5a and 5b: Hippocampal lesioned and APP(V717I) mice on the T-maze 
3.4.1 Introduction  
The T-maze forced choice alternation (FCA) task is a spatial working memory task where the 
mouse is placed in an elevated maze shaped as a T with a start arm and two goal arms. If given 
a choice between an already visited arm and a previously unexplored arm, a normal mouse 
tends to choose the unexplored arm (Deacon & Rawlins, 2006). This task is sensitive to 
hippocampal dysfunction (Deacon & Rawlings, 2006; Deacon et al., 2002), and APP mutations 
in mice (Chapman et al., 1999; Lalonde et al., 2002; Wriths et al., 2008; Corcoran et al., 2002). 
Experiment 5a investigated the effects of the APP mutation on the T-maze alternation task and 
Experiment 5b established that the procedure was sensitive to disruption of hippocampal 
function in mice. Transgenic APP mutation mice were hypothesised to show impaired delayed 
non-matching to position performance at 11 months of age. 
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3.4.2 Method 
Design 
APP(V717I) mice were tested at 11 months of age in order to assess whether the introduction 
of the APP(V717I) mutation is related to decreased performance in the T-maze FCA non-
matching to position paradigm. Both genders were included in this study, as results from the 
foraging task (Experiment 4) indicate spatial information processing may be more sensitive to 
the APP mutation in female than male transgenic mice.   
 
Subjects 
Experiment 5a 
The hippocampal lesioned and non-lesioned mice utilised were the same as those described in 
Chapter 3, Section 3.2. 
 
Experiment 5b 
The subjects were those described in Chapter 2, Section 2.2 assessed at 11 months of age.   
 
Apparatus 
The T-maze consists of one long start arm (52cm*8.5cm) and two shorter goal arms 
(26cm*8.5cm; see Fig. 3.13). The walls are made of clear Plexiglas (height 12.7cm). Two 
removable stop doors were used of either light or dark grey Plexiglas (13.5cm*8.6cm).  At the 
end of each test arm was a well (8cm long, 2.3cm wide and 1.3cm high, with a groove of 
dimensions 7cm length, 1.5cm width and 1cm depth) of dark plastic material. These allowed 
for the use of a liquid reward of sweetened, condensed milk mixed 50:50 with distilled water 
without being visible from the choice point at the beginning of the goal arms. The T-maze was 
situated on a table (75cm*118cm) elevated 80cm above from the floor.  
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Fig. 3.13: The T-maze apparatus with two unbaited reward wells in place.  
 
Method  
Habituation 
Mice were water deprived with daily access to water limited to 2 hours. The mice received 3 
days of habituation. The mice were placed in the beginning of the start arm, facing into the 
maze. Both goal arms were baited with one drop of reward solution (approximately 30µl) in 
the wells. On day 1 and 2, the mice were given 10 minutes to explore the maze freely and 
consume the rewards. On day 3, the mice were given two habituation sessions of 5 minutes 
with baited wells in each session to ensure all mice were consistently consuming both 
rewards.  
 
Test phase 
The mice received 8 days of testing. On each day, the mice received a sample trial and a test 
trial. On the sample trial, both wells were baited, and a light grey door prohibited access to 
one of the goal arms. The mouse was placed at the beginning of the start arm, released, and 
was allowed to consume the reward in the only accessible goal arm. The mouse was then 
placed into the home cage whilst the maze and the visited well were cleaned. The light grey 
stop door was then removed, leaving both goal arms open. The mouse was placed in the start 
arm and was required to make a choice between the previously visited arm and the previously 
unvisited arm. The light grey door was then removed, leaving both goal arms open. The mouse 
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placed in the start arm and was required to make a choice between the previously visited arm 
and the previously unvisited arm. Mice were rewarded for visiting the unvisited goal arm. If 
the mouse entered the previously visited arm, a dark grey door was placed at the arm entry, 
confining the mouse to the goal arm for approximately 15 seconds before being returned to its 
home cage. If the mouse entered the previously unvisited arm, it was allowed to consume the 
reward before being returned to the home cage. Each mouse received 6 sets of trials per day 
with an inter-trial interval of approximately 20 minutes.  
 
Scoring and data analysis 
Entry into an arm was defined as the moment the back legs of the mouse crossed the entry 
line to the arm. Following each trial, the experimenter manually noted whether the mouse 
made a correct or incorrect choice. Mice were excluded from testing if they did not engage 
with the task, defined as requiring more than 5 minutes to move from the start arm on 8 or 
more trials. One female transgenic mouse was excluded during test day 2 on such grounds. For 
each test day, a percentage correct score across the six trials was calculated for each individual 
mouse. The percentage correct scores were then averaged across groups for each test day, 
before being averaged across test days.  
 
3.4.4 Results  
Experiment 5a: Hippocampal lesions  
There was a significant differences between lesioned and non-lesioned mice in the average 
errors across test days (F (1. 13) = 39.00, p < .0001, see Fig. 3.14). 
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 Fig. 3.14: Mean error across trials for hippocampal lesioned and non-surgical control mice on 
the T-maze. Error bars are ±1 S.E.M. ****= p < .0001. 
 
Whilst there was no effect of test day on performance (F (7, 91) =1.37, p > .05), there was a 
significant interaction between test day and lesion status (F (7, 91) =4.14, p < .001; see Table 
3.10). Simple effects analysis revealed that non-surgical control mice performed significantly 
better than hippocampal lesioned mice on the majority of test days [Day1: (F (1, 13) =36.83, p 
< .0001), Day2: (F (1, 13) =13.88, p < .005), Day3: (F (1, 13) =30.52, p < .0001), Day 5: (F (1, 13) 
=6.32, p < .05), Day 7: (F (1, 13) =13.17, p < .005)]. In contrast, control and lesioned mice did 
not differ on Day 4 (F (1, 13) =1.64, p >.05), Day 6 (F (1, 13) =4.46, p > .05) or Day 8 (F (1, 13) 
=4.18, p > .05).   
  Test 
day 
Hippocampal Control 
Mean S.E.M. Mean S.E.M. 
1 42.84 5.36 85.41 4.91 
2 45.26 10.91 85.41 4.91 
3 35.70 4.69 75.00 5.45 
4 54.76 5.14 64.59 5.84 
5 57.14 5.35 70.85 2.72 
6 57.14 5.35 72.93 5.39 
7 54.77 3.33 74.99 4.45 
8 50.00 3.94 64.58 5.83 
Mean 49.70 6.29 74.22 5.44 
Table 3.10: The mean percentage correct scores and S.E.M. values for hippocampal lesioned 
mice and non-surgical control mice presented by test day and averaged across test days.  
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Experiment 5b: APP(V717I) mice 
An ANOVA assessing the effect of gender and genotype on the average percentage correct 
across trials revealed a significant main effect of genotype (see Fig. 3.15), with transgenic mice 
showing higher correct scores than wild type mice (F (1, 37) = 11.5, p < .005). A comparison of 
the average percentage correct score of wild type  mice against chance using Mann Whitney 
U, due to violations of the assumptions of homogeneity of variance and normality, confirmed 
that wild type  mice performed significantly above chance (U (22, 22) = 11.00, p < .0001). 
There was also a main effect of gender (F (1, 37) = 5.3, p < .05), with males showing a higher 
percentage correct score than females. However, there was no significant gender/genotype 
interaction (F (1, 37) = .33, p > .50).   
 
Fig. 3.15: Mean percentage correct across test days displayed for transgenic and wild type 
mice for both genders at 11 months of age. Error bars ±1 S.E.M. **= p < .005. 
 
The pattern of performance in transgenic and wild type mice did not appear to be affected by 
test day (see Table 3.11). Using the Greenhouse-Geisser control for violations of the 
assumption of sphericity, there was no effect of test day on performance (F (7, 196.1) =1.96, p 
> .05), or any interaction between test day and genotype (F (7, 196.1) =1.03, p > .05), test day 
and gender (F ( 7, 196.1) =.57, p > .05) or test day, gender and genotype (F ( 7, 196.1) =.46, p > 
.05).   
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Test 
day 
Wild Type  Transgenic 
Female Male Female Male 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
1 57.42 6.87 69.23 5.61 64.10 6.77 72.23 7.02 
2 57.40 7.91 74.35 5.54 73.08 4.02 75.02 13.43 
3 57.41 5.64 67.95 3.98 82.05 4.79 86.10 5.12 
4 66.67 7.86 73.06 4.82 73.08 6.41 88.88 5.55 
5 68.56 6.49 73.08 4.02 83.32 4.22 80.55 7.95 
6 61.12 5.56 69.23 3.70 74.35 4.85 75.00 7.13 
7 55.56 5.56 64.10 4.15 74.35 4.47 80.55 7.95 
8 57.41 4.90 70.52 4.28 66.67 4.62 80.57 9.04 
Mean 60.19 3.78 70.19 1.66 73.87 3.26 79.86 7.93 
Table 3.11: The mean percentage correct scores and S.E.M. values for wild type and transgenic 
mice at 11 months of age presented by test day and averaged across test days.  
 
3.4.4 Discussion 
The results from the T-maze FCA non-matching to position paradigm show superior spatial 
working memory performance in 11 month old transgenic mice compared to wild type 
controls. Experiment 5b confirmed that this task was sensitive to extensive cell loss in the 
hippocampus of C57B/6 mice. The lack of disruption in APP mutation mice is surprising and 
indicates that the presence of the APP(V717I) mutation does not disrupt spatial working 
memory processes, despite such indications from the foraging task, but rather improved 
performance. It can be concluded that transgenic APP(V717I) acquire the spatial alternation 
task and in contrast to other APP mutation models (Chapman et al., 1999) appear to display 
improved performance.  
 In terms of gender, the T-maze data suggests that male mice regardless of genotype 
outperform female mice. This pattern is in line with the gender pattern from the foraging task, 
suggesting that female APP(V717I) show a spatial working memory deficit compared to males 
irrespective of the presence of the APP(V717I) mutation, as well as data from the 3xTg-AD 
model in which female mice are outperformed by males in the Morris water maze task at 12 
months (Clinton et al., 2007). This has been shown to be due to female mice being more 
affected by stress than males, specifically at 12 months of age but neither at a younger nor 
older age (Clinton et al., 2007). As such, differences in stress-sensitivity could be involved in 
the gender differences detected in APP(V717I) mice the T-maze and the foraging tasks. It is 
worth noting however that the Morris water maze task is considered a more stressful 
paradigm due to the use of aversive rather than appetitive motivation. Furthermore, no 
evidence of a gender difference was found in the RAWM, indicating that the gender 
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differences in APP(V717I) mice are unlikely to be explained wholly by stress-sensitivity. 
Overall, the difficulty level of the tasks used needs to be appropriate for the control group 
used when assessing cognitive function. Thus, this gender information is important in guiding 
task selection and task difficulty manipulations, as the use of female APP(V717I) mice may 
require a lower task difficulty level than the use of males in order to be sensitive to genotypic 
differences. In addition, this pattern of cognitive differences may indicate that female 
transgenic APP(V717I) mice have more extensive Aβ pathology than males. 
Overall, transgenic APP(V717I) mice do not show a strong, age-dependent decline in 
spatial working memory as assessed in the foraging task. With the T-maze results showing 
improved performance in transgenic mice compared to wild type mice, there is little evidence 
of a general spatial working memory deficit in this model. With evidence from two spatial 
working memory task and one watermaze navigation task suggesting a lack of clear spatial 
deficits in transgenic APP(V717I) mice at 3, 6, 10, 11 and 19 months of age, there appears to 
be little support for utilising these mice to assess the effects of 2B3 on spatial cognition. 
Dewachter et al. (2002) provided evidence that APP(V717I) mice were impaired in a 
novel object recognition paradigm at 3-6 months of age. As there was a clear absence of a 
memory deficit associated with hippocampal pathology, the final experiment assessed non-
spatial recognition memory in APP(V717I) mice, allowing for a wider assessment of cognitive 
function through the investigation of a perirhinal cortex-dependent task (Aggleton & Brown, 
1999; Brown & Aggleton, 2001; Brown, Warburton & Aggleton, 2010). 
 
3.5 Experiment 6: Assessment of novel object recognition in APP(V717I) mice 
3.5.1 Introduction  
Object recognition memory refers to the ability to recognise and respond to an object or 
situation in a way which indicates that it has been encountered previously, and has been 
found to be impaired in AD patients (Aggleton & Brown, 1999). Single novel object recognition 
when presented simultaneously with a familiar object has been shown to rely on the perirhinal 
cortex in monkeys (Meunier et al., 1993) and rats (Mumby & Pinel, 1994; Winters & Bussey, 
2005), a structure which anatomically is located close to the hippocampus in the temporal 
lobe. Aggleton & Brown (2001) proposed a dissociation of hippocampal and perirhinal cortex 
functioning, with the perirhinal cortex supporting single object recognition, and the 
hippocampus processing more complex stimuli integrating features of objects, as well as the 
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temporal and spatial aspects of an encountered scene. This analysis raises the possibility that 
object recognition memory may be impaired in the absence of spatial memory deficits in the 
APP(V717I) model.  
The novel object recognition task assesses object recognition memory function by 
allowing mice to explore a set of two identical objects. This is followed by a delay, after which 
the mice are presented with one copy of the previously encountered object and one novel 
object. Wild type mice preferentially explore a novel object over a familiar object unless the 
inter-trial interval is of a sufficient duration to disrupt recognition memory of the previously 
encountered object.  
 
3.5.2 Method 
Design 
Assessment of the effect of the APP(V717I) mutation on object novelty detection as a 
characteristic of object recognition memory was carried out at 18 months of age. Both genders 
were included in order to assess whether gender affects the expression of a transgenic 
phenotype in the novel object recognition task. APP(V717I) transgenic mice are reported to 
display deficits in object recognition memory expressed as novelty preference after a 180 
minute delay between sample and trial, but not after a 60 minute or 5 minute delay 
(Dewachter et al., 2002). Identical delay parameters were adopted in the current study in 
order to order to replicate the findings of Dewachter et al. (2002).   
 
Subjects 
The subjects were those described in Chapter 2, Section 2.2 assessed at 18 months of age.   
 
Apparatus 
Mice were tested in an 82cm*82cm arena with 40cm high walls of clear Perspex which were 
covered externally with white card. The laminate plywood base was painted white and divided 
into 16 equally sized 20.5cm*20.5cm squares, arranged in a 4*4 design (see Fig. 3.16). The 
arena was situated on a table (80cm*80cm) elevating it to 80cm above floor level.  
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The objects used for testing were a variety of household objects of materials such as 
glass and plastic. Examples include a tape measure, a funnel and a door stop and hair gel 
bottle. Objects were chosen based on pilot studies with C57Bl/6 mice and were explored 
equally. To minimise odour cues guiding the behaviour of the subjects, three copies of each 
object (two for the sample phase and one for the test phase) were used. Trials were recorded 
whilst the experimenter recorded the respective contact time of each object using an 
electronic dual timer.  
 
Fig. 3.16: Object recognition arena with two identical objects in place in the sample phase.  
 
Method 
Habituation 
The mice were habituated to the arena over three days. On days 1 and 2, the mice were 
permitted to explore the empty arena freely for 10 minutes. On habituation day 3, a single 
object that was not used in future testing was placed in the centre of the arena to assess 
whether mice had habituated to the novel environment sufficiently to explore an unknown 
object. The experimenter was visible throughout testing. 
 
Sample and test phase 
Counterbalancing was conducted for both spatial location of objects and the objects 
themselves, in addition to gender and genotype. In the sample phase, the mice were placed in 
the middle of the arena containing two identical objects and allowed to freely explore for 10 
minutes. The objects were placed diagonally opposite each other in two of the middle 4 
squares of the arena (see Fig. 3.16). After 10 minutes, the mice were returned to their home 
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cage for the duration of the delay (5 minutes, 60 minutes or 180 minutes). The objects and the 
arena were wiped with 70% ethanol wipes and the familiar object (identical to the two in the 
test phase) and the novel object (never before seen object) replaced the objects of the sample 
phase. The test phase was carried out in an identical fashion to the sample phase, the only 
difference being the presence of one familiar and one novel object. These objects are placed in 
the same spatial locations in both the sample and test phase. The type of object used in the 
sample phase and as a novel object, in addition to the spatial location of the novel object, 
were counterbalanced across groups. Hence, if a mouse encountered the novel object on the 
left in trial 1, it would encounter it on the right in trial 2. At each delay interval, two trials were 
run across two days, with each mouse tested at each delay interval (a total of 6 test days for 
each individual mouse). A two day break was given between each set of test days in an 
attempt to avoid habituation to novelty.  
 
Scoring and data analysis  
The amount of time spent exploring each object in the habituation, sample and test phase was 
recorded electronically by the experimenter. Exploration was defined as the mouse being 
within 2 cm of the object and interacting with it either by sniffing, biting, pushing or moving its 
nose in contact with the object. Exploration was not scored if the mouse was within 2 cm of 
the object, but did not face it, or if the object was used as a means to explore the extramaze 
environment. An electronic timer was used to manually record the duration of exploration.  
For each delay interval, the time spent exploring the novel object on test day 1 and 2 
was averaged. The same was done for the total time spent exploring any object on each test 
day. Using these average test day scores, a discrimination ratio was created by dividing the 
average novel score by the average total exploration score, and multiplying this by 100. A 
score of 50 would indicate an equal amount of time spent exploring the novel and familiar 
object across test days and the higher the score, the stronger the preference for the novel 
object.  
 
3.5.3 Results  
The contact times averaged across the two identical objects in the sample phase are 
presented in Table 3.12. In order to assess whether there were any sampling bias between 
groups, a repeated measures ANOVA with gender and genotype as factors was carried out. 
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There were no differences between transgenic and wild type mice on sampling time across 
delay conditions (F (1, 35) = 1.13, p > .05), but there was a main effect of gender (F (1, 35) = 
11.31, p < .005) with female mice spending more time exploring the sample objects than male 
mice. Gender did not interact with genotype on this measure (F (1, 35) = 0.37, p > .05). 
 
 Contact time (s) in sample phase 
 Wild Type Transgenic 
 Male Female Male Female 
Delay Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
5 min 11.89 1.11 13.55 2.08 10.61 2.79 16.48 1.78 
60 min 11.40 1.44 17.10 2.33 8.12 1.08 15.92 2.17 
180 min 11.85 1.25 15.51 1.55 9.74 1.38 11.95 1.20 
Table 3.12: The mean contact time in seconds for transgenic and wild type mice of both 
genders when faced with a pair of novel objects over two habituation days (novel pairs 
presented on each day). Min = minutes.  
 
The mean contact time for the novel and familiar object at each delay interval is presented in 
Table 3.13. There was a significant within-subject effect of delay (F (2, 70) = 9.97, p < .0001), in 
which the contact time at 5 minutes delay was significantly higher than at 60 minutes ( p < .05) 
and 180 minutes (p < .0001). The effect of the difference in contact time at different test 
intervals is minimised however by the lack of interaction between delay and any other factor 
[delay*genotype: (F 2, 70) = 0.72, p > .05); delay*gender (F (2, 70) =0.62, p > .05); 
delay*genotype*gender (F (2, 70) = 0.76, p > .05)].  
 A significant main effect of object type revealed that novel objects were explored 
significantly more than familiar objects (F (1, 35) = 53.65, p < .0001). However,  neither 
genotype, gender nor delay influenced this effect [object*genotype: (F (1, 35) = 0.69, p > .05); 
object*gender: (F (1, 35) = 1.04, p > .05); object*genotype*gender: (F (1, 35) = 0.16, p > .05); 
object*delay: (F (2, 70) = 1.37, p > .05); object*delay*genotype: (F (2, 70) = 0.62, p > .05); 
object*delay*gender: (F (2, 70) = 1.68, p > .05); object*delay*genotype*gender: (F (2, 70) = 
0.95, p > .05)]. As in the sample phase, female mice were found to spend significantly more 
time exploring the objects in the test phase when collapsed across all other variables (F (1, 35) 
= 15.62, p < .0001).  
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Delay 
Novelty 
status 
Contact time (s) in test phase 
Wild Type Transgenic 
Male Female Male Female 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
5 min 
Novel 18.22 0.94 21.28 1.67 15.17 1.10 22.08 1.50 
Familiar 11.37 0.80 11.98 0.99 8.88 0.33 15.36 1.14 
60 min 
Novel 13.52 1.12 19.06 2.08 11.87 1.79 16.44 1.44 
Familiar 9.54 1.16 13.42 1.90 5.16 0.52 12.92 1.04 
180 min 
Novel 14.11 0.99 18.68 1.32 9.53 1.79 16.29 2.24 
Familiar 8.25 0.59 9.85 0.82 7.94 0.87 8.87 0.62 
Table 3.13: The mean contact time in seconds for transgenic and wild type mice of both 
genders when faced with a novel and a familiar object in the test phase (averaged across two 
trials). Min = minutes. 
 
Fig. 3.17 shows the discrimination ratios of transgenic and wild type mice at each delay 
interval. For simplicity of presentation, data is collapsed across gender. An ANOVA assessing 
the effect of delay interval on the discrimination ratios in transgenic and wild type mice of 
both genders established no within-subject effect of delay (F (2, 70) = .19, p > .05) or any 
within-subject interactions with delay (delay*genotype: F (2, 70) = 1.67, p > .05; delay*gender: 
(F (2, 70) = 3.07, p > .05; delay*genotype*gender: F (2, 70) = 2.43, p > .05). There was no 
between-subjects effect of genotype (F (1, 35) = .54, p > .05), gender (F (1, 35) = .01 p > .05) or 
a gender*genotype interaction (F (1, 35) = .61, p > .05).  
 
Fig. 3.17: Discrimination ratio (total time novel/total time any object*100) displayed for 
transgenic and wild type mice at delay intervals of 5 minutes, 60 minutes and 180 minutes. 
Error bars ±1 S.E.M.  
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3.5.4 Discussion  
The results from the novel object recognition experiment indicate that there are no genotypic 
differences in object recognition memory between transgenic and wild type APP(V717I) mice 
of either gender at 18 months of age. Whilst male mice were observed to show lower contact 
times than female mice across the task, this difference did not interact with genotype. In 
addition, all groups showed a pattern of novelty preference, indicating that at both transgenic 
and wild type mice can discriminate between a novel object and one previously encountered 
after up to 3 hours delay.  This indicates that the object recognition memory of transgenic 
APP(V717I) mice is not disrupted by Aβ pathology at 18 months of age, despite reports of 
extensive plaque pathology by this age (Dewachter et al., 2000; 2002).  
 It is worth noting that the object recognition task relies on novelty detection 
expressed as preferential exploration of a novel object over a familiar object. Thus, extensive 
exposure to novel objects may result in the cohort habituating to novelty, reducing the 
sensitivity of the paradigm to object recognition memory function. Whilst both transgenic and 
wild type mice in the current study demonstrated discrimination ratios above chance, it is 
possible that a cross-sectional design would enhance the sensitivity of the task in a manner 
which could preferentially benefit wild type performance. Furthermore, whilst pilot work was 
carried out to limit the potential variability introduced by objects of differential interest to 
subjects, a recent paper has highlighted the effect of the functional properties of objects 
(Heyser & Chemero, 2011). Specifically, objects that can be climbed were found to produce 
greater discrimination ratios in C57Bl/6 mice compared to those that can be touched only. As 
the current study utilised objects of both these categories, it is possible that this introduced 
further variability to the data. However, no systematic bias in wild type or transgenic 
performance would have resulted from the mixed use of objects due to careful 
counterbalancing of objects across genotype and gender groups, as well as delay conditions.   
 
3.6 Chapter discussion 
The aim of this chapter was to analyse the developmental profile of a range of cognitive 
processes in the APP(V717I) model in order to identify aspects of learning and memory in 
which transgenic mice show age-related deficits compared to littermate wild type controls. A 
secondary aim was the analysis of the effect of gender on the expression of the transgenic 
cognitive phenotype.  
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The results from a set of behavioural experiments assessing a range of cognitive 
constructs in APP(V717I) mice in this thesis largely point to a lack of a strong age-related 
behavioural phenotype in this model. This is in complete contrast with the published literature 
(Moechars et al., 1999b). In the RAWM test administered at 10 months (Experiment 3), no 
indications of a spatial navigation deficit observed.  In terms of the longitudinal assessment of 
spatial working memory, the results from the foraging task do not indicate a transgenic spatial 
deficit at 3 or 19 months, although differences emerge on a subset of measures at 6 months of 
age (Experiment 4). These results are not corroborated by the T-maze experiment conducted 
at 11 and 14 months of age, where transgenic mice outperformed wild type mice in measures 
of spatial working memory (Experiment 5). Thus, the transgenic deficits observed in the 
foraging task can be considered at best transient and possibly a task-specific phenomenon. In 
terms of object recognition memory, transgenic and wild type mice display comparable 
performance in novelty detection in the novel object recognition task at 18 months of age 
(Experiment 6). Importantly, the lack of genotypic differences is consistently due to an ability 
of transgenic mice to successfully complete the tasks as opposed to poor performance of wild 
type mice.  
In terms of gender, female mice made more spatial working memory errors than 
males regardless of genotype in both the T-maze and selected variables of the foraging task. 
This information is valuable when designing future experiments, as no previous information 
regarding gender is available in this model, and the task difficulty levels may need to be 
lowered for female mice compared to males. No such gender differences emerged from the 
RAWM or the object recognition task. Whilst it is not clear by which mechanisms gender 
influences performance, the emerging gender pattern raises the possibility that female 
transgenic mice display a more extensive Aβ pathology than transgenic males.  
APP(V717I) transgenic mice were found to display lower levels of anxiety compared to 
wild type mice (Chapter 2). Therefore, the lack of a strong spatial memory deficit in transgenic 
mice could be due to an advantageously lowered anxiety enabling enhanced learning about 
the spatial information necessary to successfully master each task. Whilst this explanation 
could apply to the RAWM data, it is less likely to explain the general lack of deficit observed in 
the foraging task and the T-maze, as these tasks rely on different motivational manipulations. 
Nevertheless, the lack of a spatial memory deficit in transgenic APP(V17I) mice could be 
related to general alterations in motivation which enhance learning compared to wild type 
controls.    
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The differences in genetic background as discussed in Chapter 2, Section 2.5 is a 
potential factor in the discrepancy in results compared to Moechars et al. (1999b) and 
Dewachter et al. (2000). Importantly, small variations in genetic background can also affect 
spatial memory performance, as illustrated in Savonenko, Xu, Price, Borchelt & Markowska 
(2003). Despite the reduction of differences in genetic background through the breeding of 
FVB/N transgenic males with C57Bl/6 females, the noncongenic nature of the C57Bl/6 
background has been shown to encourage the development of age-related spatial memory 
deficits in a manner not observed in congenic (more than 10 generations of sibling mating) 
strains of C57Bl/6 mice. Indeed, Savonenko et al. (2003) found that cognitive deficits evident 
in an APPswe model on a noncongenic C57Bl/6 background were abolished when compared to 
either a congenic line of the same mutation or downstream congenic generations of the 
original noncongenic line. This highlights the importance of genetic background in behavioural 
assessments of cognitive deficits in AD-like mouse models, and could aid to explain the lack of 
a strong spatial memory phenotype in the current cohort of APP(V717I) mice.  
There were a number of differences in the behavioural paradigms utilised between 
the current project and Moechars et al. (1999b) and Dewachter et al. (2002) that could 
contribute to differences in findings. These include both differences in the task themselves, as 
well as variations in testing protocol, such as under floor illumination in the object recognition 
task utilised only in Dewachter et al. (2002). The most important discrepancy in results 
between the groups in terms of age-related deficits is that of the water maze spatial 
navigation task. Here, two different versions of the water maze were used. Whilst Moechars et 
al. (1999b) utilise the standard water maze paradigm where a platform is located in a circular 
pool, the current study used a water maze with 6 arms which the animal has to discriminate 
between in order to locate the hidden platform. Thus, it could be argued that the RAWM has a 
higher difficulty level than the standard maze (Nilsson et al., 2004) as splitting the maze into 6 
distinct zones inhibits the use of non-spatial strategies such as circling the edges of the pool. 
The RAWM requires the commitment of a choice whilst in the centre of the arena, thus 
reducing the likelihood of coming upon the platform by chance. If adopting this approach, 
there is the possibility that a lack of a spatial deficit in transgenic APP(V717I) mice is due a 
higher task difficulty level in the RAWM where wild type mice make sufficient errors to mask 
any transgenic-wild type differences as compared to the Morris water maze. This is unlikely 
however, due to a relatively low number of errors in both transgenic and wild type scores, in 
addition to data from the probe trial indicating successful learning in both groups. Therefore, 
the contrasting data between the two laboratory groups is unlikely to be due to differences in 
106 
 
task difficulty. Overall, differences in testing paradigms are not sufficient to explain the large 
discrepancies between the published literature and the current findings. The experiments 
outlined in this chapter cover a range of behavioural tasks across 3 – 19 months of age in both 
male and female mice without the detection of a strong age-related cognitive phenotype. In 
addition, the adopted tasks were verified through the use of C57Bl/6 mice with bilateral 
hippocampal excitotoxic lesions, demonstrating that the paradigms used were sensitive to 
hippocampal damage. 
The lack of a recognition memory deficit in transgenic APP(V717I) mice may be due to 
insufficient delay between sample and test in the current work. The delay intervals were 
selected based on reports of an APP(V717I) transgenic deficit after a 3 hour delay, but not 
after 5 minute or 1 hour (Dewachter et al., 2002). An extension of the delay interval may have 
increased the task difficulty sufficiently for genotypic differences to emerge. It is worth noting 
however that whilst both transgenic and wild type performance on this task was above 
chance, mice did not show a strong novelty preference at the shortest delay of 5 minutes, 
suggesting that there is relatively little room for a decline in wild type performance as a 
function of increased task difficulty before they perform at chance level. The lack of a object 
recognition memory deficit is in line with data presented in Chapter 3 and 4 assessing both 
anxiety and spatial memory, demonstrating that the current cohort of APP(V717I) mice do not 
show a comparable phenotype to that reported in Dewachter et al. (2002) or Moechars et al. 
(1999b). 
Whilst the longitudinal study of cognitive ability is powerful in that it allows detection 
of within-subject decline in performance with age, there may be potential beneficial effects of 
repeated testing on cognition which may mask cognitive decline. There are two variants of this 
argument. Firstly, a lack of deficit at the aged time point could be due to procedural learning 
from repeated testing. Secondly, repeated testing could have beneficial effects of cognition 
through acting as an environmental enrichment. Thus, lack of age-related aggravation in 
cognitive deficits in transgenic APP(V717I) mice from 6 to 19 months of age in the foraging 
task (Experiment 4) could reflect the effect of repeated testing rather than the absence of 
spatial memory decline. Environmental enrichment is widely recognised to be beneficial both 
at a behavioural and neural level in rodents, and is often assessed as the effect of enriched 
cage conditions on cognition (van Praag, Kempermann & Gage, 2000). In humans, cognitive 
exercise has been shown to be positively linked to performance on neuropsychological 
assessments in aged healthy individuals (Valenzuela & Sachdev, 2009). Thus, the argument 
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suggests that repeated testing in a number of tasks (including the foraging task) could offer 
sufficient cognitive exercise and environmental stimulation to protect transgenic mice from 
developing age-related cognitive deficits. The best way to control for this is through the use of 
parallel longitudinal and cross-sectional assessments of transgenic performance. In the 
absence of this control, it is desirable to minimise repeated testing to a limited number of test 
days. Between assessments in the foraging task at 6 and 19 months, the APP(V717I) cohort 
had undergone testing with the T-maze and RAWM assessment at 10-11 months of age. 
Including habituation days, the total number of days mice were exposed to testing rooms and 
equipment other than their home cage was 16, which is low considering the age span mice 
were tested at. In support of the argument that environmental enrichment, through repeated 
testing, could have attenuated potential genotypic differences at 19 months, Billings et al. 
(2005) have shown that learning slows the development of Aβ pathology if is occurs at a 
critical early age when assessing the 3xTg-AD model every 3 months from 2-18 months of age 
in the Morris water maze. The lack of behavioural effect is less relevant to the foraging task 
data due to the Billings et al. study using a reference memory design in which the location of 
the escape platform did not change between testing points compared to the foraging task as a 
working memory paradigm. Nevertheless, it is interesting to note that mere exposure to 
repeated testing can alter the development of pathology. In the current study, mice were not 
tested as repeatedly as in Billings et al. (2005). Furthermore, there have been reports of other 
cohorts of APP expressing transgenic lines which show a lack of cognitive profile at old age (24-
26 months) following testing in an extensive battery of tests (Savonenk et al., 2003). 
Importantly, these mice showed a lack of cognitive deficit in parallel longitudinal and cross-
sectional designs. Others have reported comparable spatial memory deficits in PDAPP 
transgenic mice tested extensively in a longitudinal as well as a cross-sectional design (Chen et 
al., 2000). These examples demonstrate that repeated testing need not attenuate age-related 
cognitive decline in APP mutation mouse models.  
Whilst the relative similarity in performance between wild type and transgenic mice at 
19 months could be due to procedural learning following repeated testing, this explanation is 
less likely due to the nature of the task. Firstly, each trial of the foraging task can be 
successfully solved in a number of ways. This means that the animal is not required to learn a 
set pattern of responding in order to obtain rewards. Indeed, the mice change their pattern of 
responding in each trial, such that the required behaviour to successfully complete the task 
changes in each trial based on the locations visited in the earlier part of that trial.  Therefore, 
whilst opportunities to learn about the requirements of a successful trial are available, it is 
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unlikely that mice acquire a defined pattern of responding. Secondly, the foraging task 
involves only 4 test days at each age, with the 2nd and 3rd age points being separated in time by 
13 months. With a stronger spatial working memory deficit indentified at 6 months compared 
to 19 months of age, it seems unlikely that transgenic mice benefitted more than wild type 
mice from repeated testing 13 months later.  
The lack of a spatial working memory deficit in the T-maze is in contrast to the deficits 
identified in aspects of the foraging task, particularly at 6 months of age. It is therefore 
tempting to suggest that the two tasks either differ in the exact form of spatial working 
memory assessed, or in their sensitivity to spatial working memory deficits. Indeed, when 
viewing the total errors made across whole trials in the foraging task, arguably a more global 
measure of performance and potentially more comparable to the T-maze percentage correct 
score, there are no genotypic differences. Genotypic differences were restricted to subtypes of 
error and during parts of trials in the foraging task. Whilst this is not problematic in itself when 
put into the context of the whole task, it points to the versatility the foraging task offers in its 
measures of performance compared to the T-maze. In addition, the range of performance 
success as measured in the T-maze is naturally restricted, as chance performance allows a 
subject to score 50%. This leaves a relatively small window of opportunity for detection of 
genotypic differences.  
The lack of age-related cognitive decline in transgenic APP(V717I) mice in both spatial 
and object recognition memory indicates that Aβ CNS levels were not sufficiently elevated in 
transgenic mice to impair cognition, potentially through an unknown protective factor of the 
C57Bl/6 background as compared to the FVB/N background. Overall, the experiments 
described in Chapter 3 demonstrate that APP(V717I) mutation model does not display 
detectable age-related deficits in learning and memory which could be utilised as a measure of 
the effect of Aβ-modifying treatment on cognition. However, in order to inform the 
behavioural data presented on the APP(V717I) model, the aim of the experiments reported in 
Chapter 4 was to provide a developmental profile of Aβ pathology in transgenic and wild type 
APP(V717I) mice.  
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Chapter 4 
 
Characterisation of Aβ Pathology in the London APP(V717I) Model 
 
4.1 Introduction 
This chapter will present the results of a developmental profile of Aβ pathology in the 
APP(V717I) model. The experiments aimed at identifying the age of onset and progression of 
Aβ pathology in the CNS of transgenic APP(V717I) mice.  
There are a number of reasons why a biochemical characterisation of the APP(V717I) 
model was necessary. Firstly, in models of AD where potential behavioural deficits are thought 
to be driven by manipulations of gene expression and their biochemical effects, it is important 
to characterise the developmental profile of biochemical changes in parallel with the 
assessment of behavioural deficits. Knowledge of both aspects of disease progression within a 
model gives opportunities for increased understanding of how behavioural deficits and 
biochemical changes are linked, as well as increased sensitivity to the potential effects of a 
therapeutic manipulation at different levels of functioning of the CNS. 
Secondly, there are no studies describing the biochemical effects of the introduction 
of the APP(V717I) mutation in C57Bl/6 mice, providing a direct comparison to the current 
cohort. Whilst a range of papers have reported measurements of Aβ in the APP(V717I) model 
(see Chapter 2, Section 2.1.2, Table 2.1 for an overview), all biochemical characterisation work 
has been carried out using the V717I mutation on the FVB/N background. The effect of this 
change is unknown, but studies such as Glazner et al. (2009) have reported differential 
development of Aβ pathology in the TgCRND8 when maintained on different genetic 
backgrounds (also see Savonenko et al., 2003). This further underlines the need to undertake a 
biochemical analysis to assess the compatibility of the data across background stains. 
Thirdly, the importance of assessing the progressive elevation of Aβ was heightened in 
light of the lack of evidence for an age-related cognitive decline in the APP(V717I) model 
(Chapters 2 and 3). In addition, behavioural analysis of the model in Chapters 2 and 3 indicated 
a potential gender difference in expression of the transgenic phenotype, raising the possibility 
that Aβ pathology differs between males and females. Previous literature assessing the 
biochemical profile of the APP(V717I) mutation on the FVB/N background did not consider the 
potential influence of gender. Thus, this chapter presents work aimed to determine the levels 
of soluble and insoluble Aβ40 and Aβ42 as measured using ELISA, as well as the degree of Aβ 
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deposition in APP(V717I) transgenic mice of both genders compared to wild type mice at ages 
3, 6, 9, 12 and 18 months. These ages were chosen in order to provide a direct parallel to the 
ages at which the behavioural work had been carried out.  
On the FVB/N background, the transgenic mice develop elevated soluble Aβ40 and 
Aβ42 levels by 15 months of age, with higher levels of Aβ40 than Aβ42 (Dewachter et al., 
2000; 2002). Some elevation has been reported as early as 3-6 months (Dewachter et al., 
2000), but no plaque formation has been observed in this model until after 12 months 
(Dewachter et al., 2000). Thus, it was predicted that there will be a progressive elevation of 
soluble Aβ levels in transgenic mice compared to wild type mice at ages 3, 6 and 9 months, as 
well as significantly higher levels of soluble Aβ by 12 and 18 months of age. In terms of Aβ 
deposition, high levels of Aβ deposits were expected in transgenic brain tissue at 18 months, 
with a subset of transgenic mice potentially showing Aβ pathology at 12 months. No Aβ 
deposition was expected in wild type tissue at any age or in transgenic tissue at 3, 6, or 9 
months of age. In the event that gender influences Aβ pathology in APP(V717I) mice on a 
C57Bl/6 background, female transgenic mice were predicted to  display elevated Aβ pathology 
compared to male transgenic mice.   
 
4.2 Experiment 8a: Aβ levels in brain homogenate of APP(V717I) mice 
4.2.1 Introduction 
The assessment of Aβ pathology using ELISA allows for the targeted measurement of human 
Aβ in brain homogenates, providing a quantifiable comparison between transgenic and wild 
type tissue at varying ages. Assessment focused on the left cortex as a representative sample 
for the rest of the brain as the APP(V717I) develop extensive pathology across the cortex 
(Dewachter et al., 2000).   
 
4.2.2 Methods  
Subjects 
A total of 37 transgenic and 31 wild type APP(V717I) of both genders at varying age points 
were used, as outlined in Table 4.1. Group sample sizes ranged from 2-5 mice per group, and 
were identical across Aβ40 and Aβ42 analyses. 
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 3 months  6 months  9 months  12 months 18 months 
Tg Male 3/4 3/3 3/3 5/4 4/4 
Tg Female 3/3 3/3 4/4 4/4 4/4 
WT Male 2/2 3/3 2/2 3/3 3/2 
WT Female 2/3 3/3 3/3 4/4 5/5 
Tg total 6/7 6/6 7/7 9/8 8/8 
WT total  4/5 6/6 5/5 7/7 8/7 
Table 4.1: Overview of the number of subjects included in the Aβ ELISA analysis split by gender 
and genotype at 3, 6, 9, 12 and 18 months of age. Soluble and insoluble Aβ sample sizes are 
denoted as soluble/insoluble respectively.  
 
Enzyme-linked immunosorbent assays: General Sandwich ELISA 
Brain dissection 
Mice were culled by cervical dislocation, the brain removed immediately and the hippocampus 
and cortex were dissected bilaterally from the rest of the brain tissue before being snap frozen 
in liquid nitrogen. Samples were stored at -80oC until further processing.  
 
Protein Extraction 
The left cortex sample of each mouse was homogenised in 2% sodium dodecyl sulphate (SDS) 
in dH20 with 1% inhibitor cocktail (Millipore) at 1ml/75mg of wet tissue weight. The samples 
were homogenised using a Precellys 24-Dual (Bertin technologies, Montigny-le-Bretonneux, 
France) at 6000rpm for 2*30 seconds with a 30 second delay. The homogenate was rotated at 
4oC overnight, before being centrifuged at 100 000*g (28 300rpm) for 1 hour at 4oC. The 
supernatant of soluble protein was diluted 1/5 in phosphate buffer (20mM Na2HPO4/NaH2PO4, 
0.2mM EDTA, 0.4M NaCl, 0.2% bovine serum albumin (BSA), 0.05% CHAPS, 0.05% NaN3 at pH 
7) and stored at -20oC. Following removal of the soluble fraction, an insoluble pellet remained 
to which 70% formic acid was added at 1ml/150mg of wet tissue weight. The insoluble pellet 
was centrifuged at 100 000*g (28 300rpm) for 1 hour at 4oC. The supernatant of insoluble 
protein was diluted 1/20 in 1MTris Phosphate buffer (1M Tris, 0.5M Na2HPO4, pH 11) to 
neutralise the sample, and stored at -20oC.  
 
Bicinchoninic acid (BCA) protein assay 
It is necessary to establish the amount of total protein present in each sample to standardise 
levels of individual proteins within a sample. The BCA Protein Assay Reagent bicinchoninic acid 
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kit (Pierce Thermo Scientific) was used to analyse the protein levels in the neat soluble fraction 
obtained in the protein extraction stage. Diluted bovine serum albumin standards (Thermo 
Scientific) were prepared ranging from 2 – 0.01mg/ml in a serial dilution. The standards, 
samples and negative controls were analysed in duplicate on a 96 well plate, with negative 
controls including dH20 and 2% SDS. A volume of 200µl BCA Working Reagent consisting of 50 
parts Reagent A (Pierce Thermo Scientific) and 1 part Reagent B was added, the plate was 
mixed thoroughly for 30 seconds and incubated at 37oC for 30 minutes. The plate was read at 
absorbance 540nm using a spectrophotometer. Protein values in each sample were calculated 
using GraphPad Prism 4.0 from the standard curve.  
 
Sandwich ELISA for soluble Aβ40 
The anti-N-terminal human Aβ monoclonal antibody (MAb) 6E10 (Covance, Princeton, USA) 
was incubated on a 96 well microtitre plate (Greiner Bio-One, Frickenhausen, Germany) at a 
concentration of at a concentration of 0.167µg/ml diluted in carbonate/bicarbonate buffer 
(15mM Na2CO3, 35mM NaHCO3, pH 9.6) overnight at 4
oC. The plate was washed with PBST 
(137mM NaCl, 2.5mM KCL, 8mM Na2HPO4, 1.5mM KH2PO4, 0.05% Tween20) in between each 
stage, and all incubations were at room temperature (RT). Unbound sites were blocked with 
1% non-fat milk powder in PBS for 30 minutes.  Samples, standards and negative controls in 
PBST were incubated at 100µl per well in duplicate for 2 hours. Aβ40 standards (Invitrogen) 
ranged from 10-0.019ng/ml in doubling dilutions. Standards were made up in the identical 
background buffer to that of the samples, with a minimum dilution of 1/8 to that the 
background buffers did not inhibit the target signal. Negative controls included phosphate 
buffer and PBST. The detection antibody, BAM401AP (affinity purified, Autogen Bioclear, 
Calne, UK), an affinity-purified antibody specific to the C-terminal of the Aβ1-40 protein, was 
used as the detection antibody at a concentration of 0.45µg/ml in PBST for 1.5 hours. 
BAM401AP has been verified as specific through western blotting work within the laboratory 
group (Thomas, unpublished data).  The secondary HRP-labelled anti-rabbit IgG (Pierce 
Thermo Scientific) was applied at 0.33µg/ml in PBST for 1 hour. The enzyme substrate, o-
phenylenediamine (OPD), in 0.1M citrate-phosphate buffer (24mM citric acid, 51mM Na2HPO4, 
pH5) was applied and incubated for approximately 20 minutes in the dark. The reaction was 
stopped using 50µl 2.5M H2SO4 and read at 492nm using a spectrophotometer. The ELISA 
protocol provides a lower sensitivity limit of around 0.1ng/ml (Thomas et al., 2006).   
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Sandwich ELISA for soluble Aβ42 
The measurement of soluble Aβ1-42 species from brain homogenate was carried out in an 
identical fashion to that described for the measurement of Aβ1-40 with the exception that the 
detection antibody was the affinity-purified anti-C-terminal human Aβ1-42 antibody (AB5739, 
Millipore, 0.5ug/ml in PBST). This antibody has been verified as specific through western 
blotting work within the laboratory group (Thomas, unpublished data). Aβ1-42 peptide 
standards (Invitrogen) at concentrations 10-0.019ng/ml in doubling dilutions provided a 
standard curve. All other conditions remain identical to that described in for the quantification 
of soluble Aβ40.  
 
Sandwich ELISA for insoluble Aβ40/42 
The measurement of insoluble Aβ1-40/42 species did not differ from the measurement of 
soluble Aβ1-40/42. However, due to the presence of formic acid in the samples, a 1/10 
dilution of the sample was necessary to ensure that the concentration of formic acid did not 
inhibit the signal in the ELISA.  
 
Data Analysis 
Individual Aβ values were standardised to the total protein concentration of each sample, and 
all values are given as ng/mg of total protein. Aβ values were averaged across genotypes 
within each gender and age group. Due to low sample sizes in combination with a clear 
pattern of age-dependent increase in Aβ, which is in keeping with the hypothesised direction 
of effects, no statistical analysis of age was carried out without collapsing across gender.   
 
4.2.3 Results  
Average concentrations of soluble and insoluble Aβ40 and Aβ42 in transgenic samples are 
presented in Table 4.2. Wild type values were at near background levels at every age in both 
males and females. For simplicity, wild type values for each age/gender group are not 
presented, but the average values of each Aβ species for all WT mice are included.  
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Age Gender 
Soluble (ng/mg protein) Insoluble(ng/mg protein) 
Aβ40 Aβ42 Aβ40 Aβ42 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
3 
Male 0.00 0.00 0.10 0.04 0.08 0.04 0.01 0.01 
Female 0.01 0.01 0.02 0.01 0.04 0.01 0.05 0.04 
6 
Male 0.00 0.00 0.06 0.01 0.15 0.09 0.01 0.01 
Female 0.00 0.00 0.04 0.02 0.22 0.03 0.23 0.01 
9 
Male 0.00 0.00 0.03 0.00 0.07 0.03 0.01 0.01 
Female 0.02 0.02 0.03 0.01 0.21 0.09 0.04 0.01 
12 
Male 0.00 0.00 0.03 0.01 0.25 0.05 0.01 0.01 
Female 0.16 0.05 0.11 0.06 0.18 0.08 0.43 0.25 
18 
Male 4.78 4.16 2.34 1.84 0.23 0.05 0.97 0.56 
Female 23.95 8.03 16.69 6.59 3.65 2.54 9.79 6.78 
Mean    WT 0.01 0.01 0.05 0.01 0.11 0.02 0.03 0.12 
 Tg 3.13 1.50 2.10 1.07 0.54 0.30 1.22 0.82 
Table 4.2: Mean soluble and insoluble Aβ40 and Aβ42 concentrations for transgenic 
APP(V717I) mice of both genders at ages 3, 6, 9, 12 and 18 months. Mean WT levels across 
gender and age are provided for comparison.  
 
Given the low levels of Aβ from 3 to 9 months of age, genotypic differences were statistically 
explored at 12 and 18 months only. Values of wild type and transgenic mice aged 18 months 
were collapsed across gender. Transgenic mice displayed significantly higher levels of insoluble 
Aβ40 (U (7, 8) = 7.00, p < .02) than wild type mice at 12 months of age, but no other genotypic 
differences were evident at this age [soluble Aβ40: (U (7, 8) = 17.50, p > .05); soluble Aβ42: (U 
(7, 8) = 25.00, p > .05); insoluble Aβ42: (U (7, 8) = 23.00, p > .05)]. By 18 months of age, 
transgenic mice were found to have higher levels of soluble Aβ40 (U (8, 8) = 4.50, p < .001) and 
Aβ42 (U (8, 8) = 7.00, p < .01), as well as insoluble Aβ42 levels (U (7, 8) = 6.00, p < .01) 
compared to wild type mice. No differences in insoluble Aβ40 levels was detected (U (7, 8) = 
17.50, p > .05). 
 
The effect of age on Aβ levels 
In order to assess whether age influenced Aβ levels in transgenic mice, the data were 
collapsed across gender. Given that levels of Aβ rise in a non-linear fashion at 18 months of 
age, analyses were restricted to pairwise comparisons of the 18 month data with the earlier 
age points. The results are summarised in Table 4.3, and reveal significant differences in 
transgenic mice when comparing levels of insoluble Aβ40 at 3 and 18 months (U (6, 8) = 2.00, 
p > .001). Furthermore, transgenic mice differed significantly in measures of soluble Aβ when 
comparing tissue from 9 month and 18 month old mice [Aβ40: (U (7, 8) = 4.00, p > .002); Aβ42; 
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(U (7, 8) = 1.00, p > .001)], as well as when comparing 12 month and 18 month tissue [Aβ40: (U 
(8, 8) = 6.50, p > .002); Aβ42; (U (8, 8) = 5.00, p > .002)]. 
 
Pairwise 
comparison 
(age in months) 
Soluble Aβ40 Soluble Aβ42 Insoluble Aβ40 
Insoluble 
Aβ42 
U P U p U P U P 
3 vs. 18 3.50 0.004 4.50 0.008 2.00 0.001 10.00 0.03 
6 vs. 18 3.00 0.004 3.50 0.005 11.50 0.11 9.50 0.07 
9 vs. 18 4.00 0.002 1.00 0.001 10.00 0.04 11.50 0.06 
12 vs. 18 6.50 0.002 5.00 0.002 19.50 0.009 15.00 0.04 
Table 4.3: The test statistic and exact significance for the effect of age in transgenic APP(V717I) 
mice on variables from ELISA analysis of Aβ pathology is presented collapsed across gender. 
Significant values are highlighted in bold.   
 
4.2.4 Discussion 
A biochemical analysis of soluble and insoluble human Aβ40 and Aβ42 in transgenic and wild 
type APP(V717I) tissue of both genotypes was carried out using ELISA. The numerical 
measurements of Aβ pathology show genotypic differences in Aβ pathology emerging from 12 
months of age, indicating that Aβ pathology developed in an age-dependent manner in 
transgenic mice.  
Statistical analysis revealed a general increase in transgenic soluble and insoluble Aβ40 
levels compared to wild type mice. This effect was shown to be age-related, with no genotypic 
differences detectable at 3-9 months of age. By 12 months of age, transgenic mice show 
elevation of insoluble Aβ42 levels at 12 months of age. Further genotypic differences emerge 
in soluble Aβ40, soluble Aβ42 and insoluble Aβ40 emerging by 18 months of age. The effect to 
age on Aβ pathology was pronounced in transgenic tissue, with an absence of pathology in 
wild type tissue.  
Comparing the current results to reported levels of Aβ in the APP(V717I) model is 
challenging due to the high variability and lack of gender specification in reported levels of 
soluble and insoluble Aβ40 and Aβ42 (see Chapter 2, Section 2.1.2, Table 2.1). Nevertheless, 
the soluble ELISA results reported in the current work overall appear higher than that of 
previous studies (Dewatcher et al., 2000; Willem et al., 2004; Etcheberrigary et al., 2004; 
Dewacther et al., 2002). This discrepancy emerges from 12 months of age, and is particularly 
evident in the levels of soluble Aβ in female transgenic mice. Only one study reports higher 
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soluble Aβ levels than the presented results (Tanghe et al., 2010). This is likely to be due to 
variations in the measurement protocols, as Tanghe et al. (2010) de-aggregated the Aβ 
samples prior utilising an ultrasensitive assay for increased sensitivity (Amorfix Aggregated 
Abeta Assay A4).  In terms of the ELISA results for insoluble levels of Aβ, the levels presented 
in the current work are comparable to the literature (Tanghe et al., 2010; Willem et al., 2004).  
Overall, the pattern of age-related increase in Aβ pathology in transgenic mice is in 
line with previous literature, where the elevation in Aβ levels has been found to be initiated 
around 12-16 months of age, with near background levels detected prior to that age 
(Dewachter et al., 2000; Willem et al., 2004; Tanghe et al., 2010). This underlines the 
observation that Aβ pathology does not develop until relatively late in this model compared to 
other APP mutation models such as the Tg2576 (Hsiao et al., 1996). This may be due to 
differences in the overexpression levels of APP, as transgenic Tg2576 mice displaying a 5-fold 
increase in hAPP compared to endogenous APP (Hsiao et al., 1996), whilst 
APP(V717I)transgenic mice produce 3-fold hAPP (Moechars et al., 1999b).   
There is evidence of a gender effect in the development of Aβ pathology in APP(V717I) 
transgenic mice, with females displaying numerically higher levels of every species of Aβ 
measured compared to males at 18 months of age. The limited sample size means the value of 
statistical analysis is limited, indicating caution must be taken when interpreting the gender 
patterns observed. As no mention of gender has been made in the APP(V717I) literature, it is 
difficult to assess the way in which this pattern applies to previous work. A further discussion 
of the potential effect of gender on Aβ pathology is provided in the Chapter discussion.  
 
4.3 Experiment 8b:  Aβ deposition in the CNS of APP(V717I) mice 
4.3.1 Introduction 
Whilst analysis of brain homogenates using ELISA allowed for an easily quantifiable 
assessment of Aβ pathology across genotype, gender and age, it provided no information 
regarding the regional distribution of Aβ pathology. Therefore, immunohistochemical staining 
was utilised in parallel with ELISA techniques. 
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4.3.2 Methods 
Subjects 
Coronal brain sections from 6, 9, 12 and 18 month old transgenic and wild type APP(V717I) of 
both genders were used, with an sample size of 2-3 per genotype/gender/age group. Three 
month old mice were not included, as no Aβ deposition is expected at this young age, and 
ELISA results (4.2.3) suggested near background levels of Aβ in 3 month old mice.  
 
Immunohistochemical staining for Aβ40/42 
Mice were perfused as described in Section 3.2, Chapter 3, with the exception that sliced 
sections were stored in cryoprotectant (30% sucrose analytical grade, 30% Ethylene Glycol, 1% 
Polyvinylpyrrolidone in 0.1M PBS, ph 7.4) at -20oC until use. Tissue sections from were rinsed 
three times in 0.1M Tris Buffered Saline (pH 7.4) before each treatment stage, except where 
otherwise specified, and all incubations were carried out at RT. As an antigen retrieval, 
sections were treated with 85% formic acid in dH2O at 25
oC for 10 minutes, followed by 
Quench (10% Methanol, 10% H2O2, 40% dH2O) for 5 minutes to block endogenous peroxidase. 
A 3% Normal Goat Serum (NGS) in TXTBS (0.1% Triton X-100 in TBS) block was applied for 1 
hour. Without washing, this was followed by incubation with either the Aβ1-40 (AB5074P, 
Millipore) or the Aβ1-42 primary antibody (AB5078P, Millipore) at 1µg/ml with 1% NGS in 
TXTBS overnight on a stirrer. These have previously been shown to be specific to the stated Aβ 
species (Kamal et al., 2001). An anti-rabbit secondary antibody (Vector Laboratories Inc, 
Peterborough, UK) was applied at 7.5µg/ml with 1% NGS in TXTBS for 2 hours. The Dako 
Streptavidin ABC Complex (50% Solution A, 50% Solution B with 1% NGS in TXTBS) was applied 
for 2 hours, and two washes in 0.05M Tris buffer (pH 7.4) followed the standard TBS washes 
before sections were exposed to the peroxidase substrate 3,3’-diaminobenzidine (DAB) with 
nickel (Ni2+) until a satisfactory degree of staining was obtained (DAB kit, Vector Laboratories). 
The reaction was stopped with 4oC 0.1M PBS (pH 7.4) and sections were mounted on 
gelatinised slides before air-drying overnight. Slides were coverslipped as described in Section 
3.2, Chapter 3.  
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4.3.3 Results 
For ease of presentation, the full wild type staining profile is not presented due to the lack of 
Aβ40 or Aβ42 stained deposits in any sections at any age point. As illustrations of negative 
controls, 18 month old female wild type sections stained for Aβ40 and Aβ42, as well as an 18 
month old female transgenic section not exposed to primary antibody are presented (Fig. 4.1).  
In addition, the immunohistochemical images from transgenic mice are presented at 12 and 
18 months only, as no or fewer Aβ deposits were present in sections stained for either 
antibody at 6 and 9 months of age (data not shown). 
   
Fig. 4.1: Illustrative photomicrographs of coronal brain tissue sections from 18 month old wild 
type female mice stained for Aβ40 (A) and Aβ42 (B). 5.1C represents a tissue section from an 
18 month old transgenic female mouse not exposed to an anti-Aβ antibody. 
 
Photomicrographs of Aβ40- and Aβ42-stained deposits under high magnification are 
presented for illustration in Fig. 4.2. These are based on the hippocampus of 18 month old 
female transgenic APP(V717I) mice. Note the increased size of Aβ40 stained deposits 
compared to Aβ42, as well as the increased intensity of staining in Aβ40 sections compared to 
Aβ42. 
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Fig. 4.2: Detailed photomicrographs of Aβ40 (A and B) and Aβ42 (C and D) stained sections 
displaying Aβ deposits in the hippocampus of an 18 month old transgenic female mouse.  
 
Representative images of Aβ40 and Aβ42 stained coronal sections of transgenic APP(V717I) 
tissue from males and females at 12 and 18 months of age are presented in Fig. 4.3.  
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Fig. 4.3: Representative immunohistochemical photomicrographs of Aβ40 and Aβ42 stained 
coronal tissue sections of transgenic APP(V717I) from males and females at 12 and 18 months 
of age. 
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As can be seen from Fig. 4.3, Aβ40 stained deposits can be detected in APP(V717I) tissue at 12 
and 18 months of age. Aβ42 stained deposits are less numerous, and are evident mostly at 18 
months of age. Note the presence of Aβ42 staining in 18 month old female transgenic mice, 
but not male transgenic mice.  
 
4.3.4 Discussion 
From the immunohistochemical staining of APP(V717I) brain sections from transgenic and wild 
type mice of both genders at 6 – 18 months of age, it is clear that human Aβ staining is 
restricted to transgenic tissue. In addition, no sections without primary antibody displayed any 
level of staining, suggesting that the clustered dark staining observed in aged transgenic Aβ-
stained sections was Aβ-specific.  
Visual inspection of immunohistochemical sections suggests three conclusions. Firstly, 
Aβ40 deposition is heavier than Aβ42 disposition in transgenic APP(V717I) tissue, as previously 
shown in this model (Dewachter et al., 2000). Secondly, an age-related pattern of Aβ 
pathology is evident, with a higher number of Aβ deposits in tissue from aged mice. This 
pattern is influenced by gender, as female mice show pathology at 12 months of age with 
progressive decline by 18 months of age. In contrast, pathology in male transgenic tissue was 
limited to 18 months of age, indicating a delay in pathology onset compared to female mice.  
 
4.4 Chapter discussion 
This chapter investigated the developmental profile of Aβ pathology in the APP(V717I) model 
with the aim of identifying the age of onset and progression of Aβ pathology in brain tissue 
from transgenic APP(V717I) mice. Taken together, the results of ELISA and 
immunohistochemical analysis of Aβ pathology in the APP(V717I) model indicate that age-
related elevation of Aβ is evident in transgenic mice both in terms of soluble and insoluble Aβ, 
and Aβ deposition, with higher levels of Aβ40 than Aβ42. This pathology is numerically more 
evident is female transgenic than male transgenic mice (although with a low sample size, this 
conclusion is not statistically assessed). This indicates that age is the key variable driving Aβ 
pathology in this APP mutation mouse model of AD-pathology, as would be expected in a 
model of neurodegeneration. Thus, these results are in accordance with the prediction that 
APP(V717I) transgenic mice would show an age-related elevation of Aβ (with higher levels of 
Aβ40 compared to Aβ42) emerging from 12 months of age. Importantly, these conclusions are 
122 
 
consistently supported by both ELISA and immunohistochemical analysis. This internal 
consistency in the evaluation of Aβ pathology increases confidence in the accuracy of the 
results.  
In terms of gender differences, an interesting pattern emerges from the biochemical 
analysis of the APP(V717I) model where female transgenic mice display more extensive Aβ 
pathology than males when matched for age, indicting that female pathology develops earlier. 
Whilst statistical evidence for an effect of gender on the development of Aβ pathology is not 
available in the current study, the pattern has strong support in the literature. Female 
transgenic mice have frequently been reported to display both elevated Aβ pathology and 
impaired cognitive performance compared to transgenic male mice, with no such description 
of a gender difference in the reversed direction available (Sturchler-Pierrat and Staufenbiel, 
2000; Bayer et al., 2003; Callahan et al., 2001; Lewis et al., 2001; Wang et al., 2003; Schuessel 
et al., 2004; Schafer et al., 2007). Remarkably, this effect is stable across APP mutation models 
despite differences in the mutation, promoter, genetic background and methodology used to 
assess cognitive and biochemical changes (Schuessel et al., 2004). This indicates that the 
gender differences observed across these studies is more likely to be linked to underlying, 
central aspects of the factors that differentiate the genders as opposed to artefacts related to 
the generation of one transgenic model (Schuessel et al., 2004). Moreover, these gender 
differences translate to the human clinical population, with females being at higher risk of 
developing AD than men (Fratiglioni et al., 1997; 200; Andersen et al., 1999; Jorm and Jolley, 
1998). Female AD patients also show a different cortical distribution of Aβ plaques as well as 
increased overall levels (Kraszpulski et al., 2001). Whilst a lowering of estrogen in late life has 
been proposed as potentially modulating Aβ pathology in females, recent hormone 
replacement therapy has not supported this (Schafer et al., 2007). In addition, gender 
differences are observed in young female mice prior to a drop in estrogen levels (Schuessel et 
al., 2005; Schafer et al., 2007) suggesting that gender differences in Aβ pathology are unlikely 
to be explained by this factor alone. Recently, differences in male and female oxidative-stress 
response markers have been identified (Schuessel et al., 2004), with female AD patients having 
higher levels of upregulated oxidative stress enzymes than male patients. This could suggest 
that the level of oxidative stress in female AD patients is higher, or that female patients have 
increased sensitivity to oxidative stress resulting in a differential response. Whilst the 
mechanisms behind gender influences on Aβ pathology in AD patients and transgenic mouse 
models are unclear, it is emerging as a consistent factor across the field. Whilst little statistical 
evidence was obtained in the current study to support the interpretation of gender as an 
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influential factor in the development of Aβ pathology, it is worth noting that the numerical 
patterns in APP(V717I) female and male mice are in line with the gender literature in APP 
mutation models.   
Importantly, Aβ pathology in transgenic APP(V717I) mice appears to develop at a 
relatively late stage,  with little evidence of consistent Aβ pathology before 18 months of age. 
Other widely used transgenic APP mutation mouse models such as the Tg2576 model develop 
significant soluble Aβ levels by 6-7 months of age (Kawarabayashi et al., 2001; Westerman et 
al., 2002), with elevated insoluble Aβ levels at 6 and 10 months of age (Westerman et al., 
2002). These differences could be related to a number of factors which are central to the 
development of transgenic models, such as the genetic mutation, promoter and level of 
overexpression of the transgene. Furthermore, differences in the genetic background 
mutations are maintained on have been found to influence Aβ pathology in APP mutation 
models (Galzner et al., 2009; Savonenko et al., 2003). The late development of Aβ pathology in 
the APP(V717I) restricts the use of the model for analysis of Aβ levels for 12-18 months, a 
substantially longer period of time than models such as the Tg2576 (Hsiao et al., 1996). The 
late Aβ phenotype of the APP(V717I) model is relevant in the context of behavioural deficits, 
as no age-related behavioural phenotype was detected between 3 and 19 months in the 
current work. As behavioural deficits are hypothesised to be driven by elevation of Aβ levels, it 
is reasonable to assume that a lack of high Aβ levels at 3 – 12 month is an important factor in 
the lack of a robust spatial memory deficit, or general cognitive phenotype, in this model. 
Furthermore, whilst there is an elevation of Aβ observed from 12 to 18 months in terms of 
both soluble and deposited Aβ, this is not sufficient to lead to robust disruption of cognitive 
processes.  
Assessed across Chapters 2 – 4, the APP(V717I) model did not display consistent age-
related cognitive decline, and the observed anxiety deficits were not found to develop with 
age. Furthermore, the presence of altered anxiety behaviour as early as 3 months of age 
strongly indicates that these changes are not related to Aβ toxicity, as levels of Aβ are near 
zero at this young age. This indicates that the changes in behaviour observed in anxiety 
assessments can be more readily attributed to stable factors which differentiate transgenic 
and wild type mice, such as APP overexpression, as opposed to Aβ pathology.  In addition, the 
APP(V717I) model did not display elevation of Aβ levels until 12 – 18 months of age, a pattern 
consistently detected by both ELISA and immunohistochemistry. Furthermore, the Aβ 
pathology detected at this late age did not disrupt cognitive processes as assessed in Chapters 
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2 and 3, indicating that elevation of Aβ in itself is not sufficient to induce AD-like cognitive 
deficits in this model. Thus, the London APP(V717I) model does not appear to be a suitable 
model in which to assess the effects of 2B3 on both cognition and Aβ pathology. Chapter 5 is 
focused on the behavioural characterisation of an alternative APP mutation mouse model of 
AD-pathology with the aim of identifying deficits in cognition that may lend themselves to 
treatment manipulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
Chapter 5 
 
Behavioural Characterisation of the PDAPP(V717F) Model 
 
5.1 Introduction 
This chapter investigates the nature of cognitive deficits in the PDAPP model of AD-pathology. 
The experiments presented aim to establish the types of learning and memory processes 
which may be affected by Aβ-pathology in the PDAPP model. This was necessary for three 
reasons. Firstly, in order to evaluate 2B3 as a potential Aβ modifying treatment of Aβ 
pathology. It is important that the effect of the antibody treatment is assessed on behavioural 
measures as well as on biochemical markers of Aβ pathology progression. Due to the lack of a 
strong behavioural phenotype in the APP(V717I) model, it was necessary to adopt an 
alternative APP mutation mouse model to achieve this. The PDAPP (V717F) model (Games et 
al., 1995) was chosen due to the location of the APP mutation it carries and its wide use in the 
AD pre-clinical field. Secondly, whilst the PDAPP model is one of the most widely used APP 
murine models in the field, the behavioural characterisation of the model has been limited to 
a few select tasks, with a lack of consistency across laboratory groups. Thirdly, changes in the 
genetic background strain of the V717F line raises issues of variability in the behavioural 
phenotype. Thus, the initial studies focused on characterisation of the behavioural profile of 
PDAPP mice. Experiments 9 and 10 assessed the anxiety behaviour in male PDAPP transgenic 
and wild type mice at 9.5 months of age. Experiment 11 examined spatial working memory at 
9-10 months of age in the T-maze, and Experiment 12 used the foraging task to assess memory 
at 11 and 14 months of age. Finally, Experiment 13 assessed object recognition memory using 
the novel object recognition paradigm at 12 months of age.   
 
5.1.1 PDAPP(V717F) mice 
The transgenic PDAPP mouse model of Aβ pathology was developed by Games et al. (1995) 
and carries the familial autosomal dominant human Indiana APP mutation. This mutation 
manifests itself as a valine to phenylalanine substitution at residue 717 (based on the 770 
isoform) of APP. In the London mutation model, valine is substituted with isoleucine at the 
same residue. The location of the mutation at the γ-secretase cleavage site rather than the β-
secretase cleavage site is critical as it maintains a reduced likelihood of disrupting the 
antibody’s binding capacity to the APP molecule. The transgene in the PDAPP model is driven 
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by the platelet-derived-β growth factor (PDGF-β) and contains a splicing cassette, resulting in 
expression of all three isoforms of hAPP (Games et al., 1995). APP expression levels have been 
indicated to be approximately 10-fold that of endogenous APP (Games et al., 1995). The PDGF-
β promoter is said to target neuronal expression, although levels of both hAPP messenger RNA 
(Games et al., 1995) and hAPP protein levels have been observed in peripheral tissues such as 
the kidneys (Schenk et al., 1999).  
The PDAPP model is frequently reported as being maintained on a triple background 
strain constituting the C57Bl/6, DBA/2 and Swiss Webster background strains (Janus & Eriksen, 
2007), but it has recently been bred onto a pure C57Bl/6 background. Unlike the Tg2576 
transgenic hAPP mouse model (Hsiao et al., 1996), the PDAPP mouse is viable when 
heterozygous and homozygous for the APP(V717F) mutation. The experiments reported in this 
thesis used heterozygous mice, thus the review of the pathological and behavioural profile of 
PDAPP mice will not include contributions from studies on homozygous PDAPP mice. It is 
worth noting, however, that gene dosage does play a role in both Aβ pathology and 
behavioural deficits. These are both more pronounced and present earlier in homozygous 
mice compared to heterozygous mice (Dodart et al., 1999; 2000). 
In terms of pathological makers of disease, PDAPP mice reliably develop Aβ deposits 
with age (Games et al., 1995; Irizarry et al., 1997;   Johnson-Wood et al., 1997; Masliah et al., 
1996; Bard et al., 2000; Chen et al., 2000; Schenk et al., 1999).  In heterozygous animals, no 
pathology is evident at 4-6 months, but deposits of human Aβ in the hippocampus, cerebral 
cortex and corpus callosum begin at 6-9 months of age (Games et al., 1995). Similarly, Dodart 
et al. (2000) reported numerous plaque deposits in transgenic mice in the hippocampus, the 
medial cingulated cortex and the corpus callosum at 6-7 months of age. From 4 to 8 months of 
age, hippocampal Aβ levels increase 17-fold, with a further 500-fold increase in transgenic 
PDAPP mice by 18 months of age (Johnson-Wood et al., 1997). By 12-15 months of age, 
considerable Aβ deposition is observed (Reilly et al., 2003). Whilst the majority of the dense 
and diffuse plaques are focused in the cerebral cortex and hippocampus, plaques have been 
reported in the frontal cortex and the cerebellum (Dodart et al., 2000).  Soluble Aβ40 and 
Aβ42 levels rise from approximately 1600ng/g of cortex tissue at 12 months to 8700 and 
22000ng/g by 15 and 18 months respectively (Schenk et al., 1999). 
Transgenic PDAPP mice show alterations beyond Aβ pathology. Whilst no neuronal 
loss has been observed in PDAPP mice, the pathological profile does include synaptic loss, with 
a reduction in the density of synaptic and dendritic markers in the dentate gyrus (Games et al., 
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1995; Masliah et al., 1996; Dodart et al., 2000). In addition, PDAPP mice display a reduction in 
the size of the hippocampus, the fornix and the corpus callosum (Dodart et al., 2000; Weiss et 
al., 2002; Redwine et al., 2003). Of these, a 25% reduction in the length of the corpus callosum 
appears to be stable across age and evident as early as 6 weeks of age (Redwine et al., 2003). 
The reduction in hippocampal volume is apparent prior to Aβ plaque deposition at 3-4 months 
of age, but not at 6 weeks of age (Dodart et al., 2000; Weiss et al., 2002; Redwine et al., 2003). 
This size reduction could be linked to overexpression of APP or gene dosage, as mice 
homozygous for the APP(V717F) mutation display a larger reduction in size than heterozygous 
mice (Dodart et al., 2000).  
  The PDAPP model is a widely used transgenic line that has undergone behavioural 
characterisation (Eriksen & Janus, 2007), and thus, arguably, could provide a more stable 
behavioural phenotype for drug manipulation. Several groups have investigated behavioural 
impairments in the PDAPP model, with varying results (summarised in Table 5.1). Generally, 
age-independent transgenic deficits in spatial reference memory are present from 3-4 months 
of age (Justice & Motter, 1997 as cited in Kobayashi & Chen, 2005; Brody & Holtzman, 2006; 
Dumas et al., 2008; Guilani, Vernay, Leuba & Schenk, 2009) with some evidence of 
performance decline with age (Huitron-Resendiz et al., 2002). Mirroring this are age-
independent spatial working memory deficits detected 3, 6 and 9-10 months using the radial 
arm maze (Dodart, Meziane, Mathis, Bales, Paul & Ungerer, 1999; Morgan et al., 2000). 
Expanding on the spatial reference and working memory deficits of PDAPP mice, Chen et al. 
(2000) demonstrated that when mice are required to learn a series of spatial locations in the 
Morris water maze (training to criterion), transgenic mice show age-independent deficits in 
learning the first platform location compared to wild type mice. When learning the 
subsequent platform locations, young transgenic mice are not impaired, whilst older mice are, 
suggesting an increased sensitivity to interference or reduced ability to perform the “episodic-
like component of the task” (Chen et al., 2000, p. 975). Thus, it appears transgenic PDAPP mice 
have age-independent deficits in spatial memory from a young age. More demanding spatial 
memory tasks may be sensitive to age-dependent changes in spatial information processing.  
  Object recognition memory has also been investigated in PDAPP mice. However, the 
literature is mixed. Some reports highlight an age-related transgenic deficits emerging at 9 
months (Dodart et al. 1999). In contrast, reports demonstrate normal object recognition 
memory in transgenic mice with delays up to 4 hours between sample and test in mice aged 
18-21 months of age (Chen et al., 2000). Transgenic PDAPP mice display deficits in emotional 
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learning at 11 months of age, where transgenic PDAPP mice show inferior cued fear 
conditioning to wild type controls (Gerlai et al., 2002). There are no published reports 
assessing anxiety behaviour in PDAPP mice.  
Overall, one can conclude that PDAPP mice suffer dysfunction of multiple memory 
systems, including spatial memory and contextual memory, either through damage induced by 
elevated levels of Aβ or APP overexpression. As pointed out by Kobayashi & Chen (2005), the 
variability in the pattern of results in the literature could be related to the hybrid genetic 
background the mutation is maintained on. A differential contribution of each of the three 
genetic lines that makes up the genetic background could result in differences across 
laboratory groups (Dodart et al., 2002).  
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Assessment Construct  Age Deficit Reference 
Morris 
water maze 
Spatial reference 
memory 
3-4 months Tg deficient compared to WT. Tg 
use spatial search strategies less 
than WT mice. 
Justice & Motter 
(1997), Brody & 
Holtzman (2006) 
Morris 
water maze 
Spatial reference 
memory 
3, 6 and 9-
10 months 
Tg deficient compared to WT. Dodart et al. 
(2000) 
Justice & Motter 
(1997), Giuliani et 
al. (2009) 
Morris 
water maze 
Spatial reference 
memory 
6 and   13-
16 months 
Tg impaired at learning a series of 
locations, but not one. At 13-16 
months, Tg deficient at one 
location.  Tg forget learnt locations 
faster than WT. 
Dumas et al. 
(2008) 
Morris 
water maze 
(multiple 
locations) 
Spatial reference 
memory with an 
“episodic-like 
component” 
6-9, 13-15 
and 18-21 
months 
Tg deficient compared to WT at all 
ages. Increased sensitivity to 
interference from 13-15 months of 
age.  
Chen et al. (2000) 
Radial Arm 
Maze 
Spatial working 
and reference 
memory 
3, 6 and 9 
months 
Tg deficient compared to WT mice, 
but no motor activity differences.  
Dodart et al. 
(1999) 
Radial Arm 
Maze 
Spatial working 
and reference 
memory 
11.5 
months 
Tg deficient compared to WT. 
 
Morgan et al. 
(2000) 
Circular 
maze 
Spatial reference 
memory 
3-5 and   
20-26 
months 
Tg mice show inferior use of spatial 
strategy at 3-5 months, and inferior 
use of all available strategies at 20-
26 months. 
Huitron-Resendiz 
et al. (2002). 
Novel 
object 
recognition 
Object 
recognition 
memory 
3, 6 and 9-
10 months 
Tg deficient compared to WT at 9 
months, but not at 3 or 6 months of 
age 
Dodart et al. 
(1999) 
Novel 
object 
recognition  
Object 
recognition 
memory 
6-9, 13-15 
and 18-21 
months 
No Tg/WT differences at any delay 
interval. 
Chen et al. (2000) 
Fear 
conditioning 
Context and cue 
conditioned fear  
11 months Tg show reduced cued, but not 
context, dependent conditioning. 
Gerlai et al. 
(2002) 
Electrophys. 
(in vivo) 
CA1 
potentiation/po
pulation spikes 
3-4.5 and 
24-27 
months 
Altered CA1 potentiation in young 
and aged transgenic mice compared 
to wild type mice.  
Giacchino et al. 
(2000) 
Electrophys. 
(in vitro) 
Hippocampal 
LTP and PPF 
4-5 and 27-
29 months 
Young Tg mice showed enhanced 
PPF and faster LTP decay. Old Tg 
mice showed reduced synaptic 
response, loss of field potentials, 
reduced PPF.  
Larson et al. 
(1999) 
Table 5.1: Summary table of reported behavioural analyses of heterozygous transgenic and 
wild type PDAPP mice at varying ages. Tg = transgenic, WT = wild type, Electrophys = 
electrophysiology, LPT = long term potentiation, PPF = paired-pulse facilitation. Justice & 
Motter, 1997 is referenced as cited in Kobayashi & Chen, 2005. 
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There is need for further characterisation of the PDAPP mutation model for several reasons. 
Firstly, the reported behavioural deficits are based on the mice maintained on the triple hybrid 
background strain of C57Bl/6, DBA/2 and Swiss Webster, whilst the cohort available for the 
current study was on a pure C57Bl/6 background. Given the strong influence background 
strain can have on behavioural phenotypic expression in transgenic models, it is important to 
establish whether the reported deficits remain once the mutation is moved to a single strain 
background (Savonenko et al, 2003; Crawley et al., 1997; Bucan & Abel, 2002; Wolfer & Lipp, 
2000; Võikar et al., 2001). Secondly, the majority of the reported deficits in the PDAPP model 
appear to the age-independent, with some indication of a decline in performance with age. In 
order to assess the effect of 2B3 on cognition, it is essential that a cognitive deficit is selected 
that is likely to be driven by Aβ pathology rather than factors such as overexpression of APP.   
 
Introduction Summary and Experimental Hypotheses 
The aim of the experiments presented in this chapter is to provide a profile of changes in 
anxiety-related behaviour and cognitive functioning of PDAPP(V717F) transgenic mice at 9 – 
14 months of age. No behavioural analysis was conducted at younger ages because younger 
mice were unavailable. The experiments presented test the hypotheses that the APP(V717F) 
mutation would lead to a reduction in anxiety-behaviours  in transgenic mice compared to 
wild type controls when assessed in the marble burying task and EPM (Experiments 9 and 10 
respectively), as well as inferior spatial working memory as assessed using the T-maze FCA 
(Experiment 11) and the foraging task (Experiment 12). In terms of object recognition memory, 
a mixed literature prevents a clear prediction, but given that the testing paradigm utilised in 
the current project resemble that of Chen et al. (2000) rather than Dodart et al. (1999), no 
object recognition memory deficit was predicted to be present in transgenic PDAPP mice at 
any delay interval in the novel object recognition task (Experiment 13).   
 
5.1.2 Assessment of anxiety in PDAPP(V717F) model 
Assessments of anxiety differences between transgenic and wild type mice in pre-clinical 
mouse models disorders are important due to the potential effect anxiety differences can play 
in learning and memory performance as assessed in other tasks. Galvan et al. (2008) reported 
transgenic PDAPP were more likely than wild type mice to show a lack of motivation to swim, a 
behaviour that could be linked to the water environment eliciting less anxiety in the transgenic 
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mice compared to the wild type mice. However, no information is available in the literature 
regarding direct measures of anxiety-like behaviours in the PDAPP model. Thus, in order to aid 
interpretation of behavioural results, the anxiety phenotype of transgenic PDAPP mice was 
compared to wild type controls.  
 
5.2 General Method: Maintenance of the PDAPP(V717F) mouse model  
The PDAPP(V717F) Indiana mutation is traditionally maintained on a triple mixed background 
compromising C57Bl/6, DBA and Swiss Webster (Eriksen &Janus, 2007). However, the colony 
used throughout this work was obtained directly from Eli Lilly (UK) and were maintained on a 
C57Bl/6 background. A colony of 18 heterozygous transgenic males and 22 wild type 
littermate male controls were a generous gift from Eli Lilly at the age of 9 months. Mice were 
housed as they were delivered, in a mix of group and single housing. A tail sample was 
collected at the end of the experimental procedures to verify genotype. In our hands, no 
observations of elevated aggression or general health issues were made. In terms of body 
weight, wild type mice were significantly heavier than transgenic mice from arrival at 9 
months of age (t (38) = 2.74, p < .05). Attrition in wild type mice was 0% throughout, compared 
to an attrition rate of 10% in transgenic mice on ad libitum access to food and water. When 
food deprived to 90-95% of ad libitum body weight, the attrition rate of transgenic APP(V717F) 
mice increased to 16.7%. Locomotor activity was measured in an open arena at 9 months, with 
no differences between transgenic and wild type mice in the percentage of time spent moving 
(F (1, 35) = 2.29, p > .05), in the distance travelled (F (1, 35) = 3.23, p > .05) or in the average 
speed (F (1, 35) = 3.26, p > .05).    
 
Polymerase Chain Reaction (PCR) for APP(V717F) 
Two sets of primers were used in the APP(V717F) PCR master mix to target APP and Actin. This 
enabled the identification of carriers of the APP(V717F) mutation alongside identification of 
amplifiable genomic material in all samples. The primers 2010 (Eurofins MWG Operon; 5’-
ATCTGGCCCTGGGGAAAAAAG-3’) and 2011 (5’ –GATGTCCTTCCTCCTCTGTTC-3’) were utilised to 
target the APP(V717F) mutation, whilst the primers MusA-ActinF1 (5’-
CACCACACCTTCTACAATGAGCTG-3’) and MusA-ActinR1 (5’–TCATCAGGTAGTCAGTGAGGTCGC-
3’)  targeted Actin (Eurofins MWG Operon).  A master mix solution made up of 2.5µl of 10x 
buffer (BIOTAQ Red DNA Polymerase, Bioline), 0.5µl of 50x MgCl2 (Invitrogen), 1.25µl of 10mM 
dNTPs (GE Healthcare), 0.05µl of each primer at a concentration of 100pmol each, 1.5µl of Taq 
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Red (Bioline), 14.05µl of DNAse- and RNAse-free H20 was combined per sample, with 5µl of 
DNA. The thermocycling conditions and band visualisation was identical to that utilised for the 
APP(V717I) PCR (Section, 2.2, Chapter 2). The APP(V717F) transgene DNA product is 
approximately 900bp and appears in transgenic samples only, whilst the Actin DNA product 
appears as a band at approximately 500bp in every sample with genomic DNA (see Fig. 5.1).  
  
Fig. 5.1: Representative image displaying an electrophoresis gel of amplified genomic material 
from APP(V717F) transgenic and wild type mice. Lane 1 = DNA ladder displaying bp 1000 to 
150. Lane 2 = ~500bp fragment representing the endogenous actin gene in a known wild type 
mouse sample. Lane 3 = ~500bp fragment representing the endogenous actin gene and 
~900bp fragment representing the transgenic APP(V717F) mutation in a known transgenic 
control sample. Lane 4 and 5 = wild type samples. Lane 6 = nuclease free water control.  
 
An overview of the order of experiments and the sample size for APP(V717F) mice is presented 
in Fig. 5.2. 
 
 
 
 
 
 
 
Fig. 5.2: Experimental time line indicating the age at which each test carried out in APP(V717F) 
mice, as well as details of the sample sizes. The cohort of mice used for marble burying and 
elevated plus maze testing differed from those tested on the T-maze. This is a full overview of 
the tasks administered to this cohort of mice up to 14 months of age.   
9.5 months: 
MB/EPM 
10 months: 
T-maze 
Tg = 10 
WT = 10 
(Cohort 1) 
 
Tg = 7 
WT = 11 
(Cohort 2) 
Tg = 14 
WT = 21 
(Cohort 
1&2) 
 
Age and task 
N numbers Tg = 14 
WT = 21 
(Cohort 
1&2) 
 
 
 
11 months: 
Foraging 
task 
Tg = 14 
WT = 21 
(Cohort 
1&2) 
 
 
14 months: 
Foraging 
task 
12 months: 
Object 
recognition 
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5.3 Experiment 9:  Marble Burying 
The marble burying task is an anxiety task based on the natural neophobic response mice 
exhibit when exposed to novel objects, as described in Section 2.3, Chapter 2. Briefly, mice are 
exposed to 20 marbles, and their level of anxiety towards the marbles is measured as the 
number of marbles the mice bury during the 30 minute test time.  
 
5.3.1 Method 
Design 
PDAPP model male mice were assessed at 9.5 months of age. For anxiety testing, delivery of 
test (marble burying and EPM) was counterbalanced across subject groups and conducted in 
novel testing rooms. The contribution of gender to the transgenic behavioural phenotype was 
not assessed, as female transgenic mice were not available for testing. For the same reason, 
the effect of age on anxiety behaviours in the model was not assessed.  
 
Subjects 
Ten transgenic male PDAPP mice aged 9 months with 10 littermate wild type controls were 
utilised.  
 
Apparatus  
The apparatus utilised was identical to that used for the APP(V717I) mice described in Section 
2.3, Chapter 2. 
 
Method 
The testing procedure was identical to that used for the APP(V717I) mice described in Section 
2.3, Chapter 2. 
 
Scoring and data analysis 
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The approach taken to scoring and data analysis was identical to that used for the APP(V717I) 
mice described in Section 2.3, Chapter 2. 
 
5.3.3 Results  
The number of marbles buried by the mice was averaged within each genotype group (Fig. 
5.2). Based on visual inspection, wild type mice appear to bury more marbles than transgenic 
mice. In order to test whether genotype affected the number of marbles buried, a Mann-
Whitney U test was carried out. There was a significant effect of genotype (U (10, 10) = 22.0, p 
< .05), with wild type mice burying more marbles than transgenic mice.  
 
 
Fig. 5.2: The mean number of marbles buried for male PDAPP transgenic and wild type mice at 
9.5 months of age. Error bars ±1 S.E.M. * = p < .05. 
 
5.3.4 Discussion 
It was predicted that wild type mice would bury more marbles than transgenic PDAPP mice at 
9.5 months of age. The data supports this prediction, indicating that transgenic mice of this 
model display deficits in anxiety compared to wild type mice. Whilst no direct measure of 
anxiety behaviour in transgenic PDAPP mice is available in the literature, the present data may 
support the interpretation of the tendency of transgenic mice to show a lack of motivation to 
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swim in the Morris water maze (Galvan et al., 2008) as linked to the water environment 
eliciting less anxiety in the transgenic mice compared to the wild type mice.  
 As discussed in Section 2.3, Chapter 2, the marble burying task is controversial due to 
the undefined nature of the behaviour measured. Therefore, assessment of behaviour across 
two independent anxiety tasks was conducted in order to increase confidence in 
interpretation of the data presented in the marble burying task.  
 
5.4 Experiment 10: EPM  
5.4.1 Introduction 
In order to validate the data obtained in the marble burying task, the EPM was administered in 
parallel. The validation of the EPM as a measure of anxiety-behaviour is presented in Chapter 
Section 2.4, Chapter 2. 
 
5.4.2 Method  
Design 
The assessment of anxiety, as expressed as avoidance of novel, exposed spaces, was 
conducted in parallel with measures of neophobia using the marble burying task. Therefore, 
male mice were assessed at 9.5 months of age.  
 
Subjects 
Ten transgenic male PDAPP mice aged 9.5 months with 10 littermate wild type controls were 
utilised, as described in Section 5.3, Chapter 5.  
 
Apparatus  
The EPM apparatus used was identical to that described in Section 2.4, Chapter 2. 
 
Method 
The testing procedure adopted was identical to that described in Section 2.4, Chapter 2. 
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Scoring and data analysis 
The approach taken to scoring and data analysis was identical to that described in Section 2.4, 
Chapter 2. 
 
5.4.3 Results  
As can be observed through inspection of Fig. 5.3, transgenic mice spent more time in the 
open arms as a percentage of time spent in any arm than WT mice (F (10, 10) = 18.94, p 
<.0001). The mean and S.E.M. values for the ratio variable are presented in Table 5.2.  
 
Fig. 5.3:  The mean time spent in the open arms as a percentage of time spent in any arm for 
male PDAPP transgenic and wild type mice at 9.5 months of age. Error bars ±1 S.E.M. **** = p 
< .0001. 
 
For simplicity of presentation, the time spent in the open and closed arms in seconds is not 
presented in graphs as the pattern of results mirrors that of the ratio variable. However, the 
means and S.E.M. values are presented for information in Table 5.2, and show a preference for 
the closed over the open arms in the wild type mice which is not present in the transgenic 
mice. Statistical analysis using ANOVA confirmed a significant main effect of arm type (F (1, 18) 
= 10.00, p < .005) in which more time was spent in the closed arm compared to the open arm. 
This measure interacted with genotype (F (1, 18) = 20.16, p < .0001), with wild type mice (but 
not transgenic mice, p > .05) spending significantly more time in the open compared to the 
closed arms (p < .0001).     
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Variable Genotype Mean S.E.M. 
Time in open arms 
Tg 133.77 24.36 
WT 29.50 11.88 
Time in closed arms 
Tg 97.92 22.37 
WT 236.24 17.98 
Ratio of time in open/closed arms 
Tg 57.24 8.80 
WT 12.21 5.44 
Table 5.2: The mean and S.E.M. values for the time spent in the open and closed arms (s), as 
well as the ratio of time spent in the open arms as a percentage of time spent in any arm.  
 
5.4.4 Discussion 
The results from the elevated plus maze test of anxiety at 9.5 months of age shows an anxiety 
phenotype in transgenic mice, with transgenic animals spending more time in the open, 
exposed arms than wild type mice. This result is both in line with the hypothesis and the data 
from the marble burying test, suggesting that reduced anxiety in PDAPP transgenic mice 
compared to littermate controls is a phenotype that can be observed across test paradigms 
with different response requirements.  
 
5.5 Experiment 11:  T-maze forced choice alternation non-matching to position task 
5.5.1 Introduction 
The T-maze task measuring spatial working memory has been described in Section 3.4, 
Chapter 3. It has been widely used to assess hippocampal function (Deacon & Rawlings, 2006), 
and results from Experiment 5b demonstrate disruption of wild type performance on the task 
following bilateral hippocampal lesions.  
 
5.5.2 Method 
Design 
In order to assess the effect of the APP(V717F) mutation in PDAPP mice, transgenic and wild 
type mice were assessed on the standard T-maze forced choice alternation task using the non-
matching to position paradigm. A set of trials in which a visual cue signalled reward was then 
administered. This was designed to assess whether a potential transgenic deficit performance 
could be ameliorated if rewards could be obtained without requiring the use of recent spatial 
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information to distinguish between previously visited and unvisited locations. Mice were 
assessed at 10 months of age. 
 
Subjects 
Eighteen male PDAPP mice were used, of which 7 were heterozygous to the APP(V717F) 
mutation and 11 were non-transgenic littermate controls.  
 
Apparatus  
The apparatus utilised in the standard trials of the T-maze FCA task was identical to that 
described in Section 3.4.3, Chapter 3. In the visually cued trials, a laminated, black and white 
vertically striped card of dimensions 12.7cm*8.5cm (see Fig. 5.4) was used. Each stripe was 
0.95cm wide. 
   
Fig. 5.4: A visually cued and baited reward well (A), with (B) demonstrating the T-maze 
apparatus with one baited and visually cued reward well in place.   
 
Method 
Mice received 8 test days of standard T-maze testing as described in Section 3.4.3, Chapter 3. 
Following a one day break from testing, 8 test days of visually cued trials were administered. 
The visually cued trials differed from standard trials only in the presence of a striped card 
inserted behind the well in the goal arm used on the sample trial. In the test trial, the visual 
cue was moved to the unvisited, baited goal arm. Thus, the mouse was not required to rely on 
A B 
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extramaze and/or intramaze cues or information regarding which arm was previously visited, 
as simply tracking the visual cue was consistently rewarded on each trial. This relies on the 
mouse forming an association between the reward and the visual cue. 
 
Scoring and data analysis 
Data was collected, scored and analysed as described in Chapter 4, Section 4.3.2.  
 
5.5.3 Results  
The average percentage correct responses (see Fig. 5.5) were analysed using a repeat 
measures ANOVA with test day and cue presence as within-subject factors, and genotype as a 
between-subjects factor. This revealed a significant difference in transgenic and wild type mice 
scores, with transgenic mice scoring lower than wild type mice in both visually cued and 
standard trials (F (1, 16) = 1115.541, p < .0001). There was a significant effect of cue presence 
in the direction of improved performance in visually cued trials compared to standard trials (F 
(1, 16) = 19.87, p < .0001), but transgenic and wild type mice did not differ in their response to 
the introduction of the visual cue [cue presence*genotype (F (1, 16) = 0.27, p > .05)].  
 
Fig. 5.5: Mean percentage correct across standard test days followed by visually cued test days 
for PDAPP transgenic and wild type mice at 10 months of age. Error bars ±1 S.E.M. *** = p < 
.0001. 
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There was a significant effect of test day mirroring an improvement in performance across test 
days (F (7, 112) = 2.54, p < .02; see Table 5.3), which was driven by significantly higher correct 
scores on test days 8 compared to test days 1 (p < .05). There were no interactions between 
test day and any other factor [genotype*test day: (F (7, 112) = 0.95, p > .05), test day*cue 
presence: (F (7, 112) = 0.98, p > .05), test day*cue presence*genotype: (F (7, 112) = 0.32, p > 
.05)].  
Test 
day 
                             Standard                                                                 Visual cue 
WT Tg WT Tg 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
1 50.01 5.40 50.00 5.03 68.17 4.74 61.90 5.99 
2 66.66 6.48 54.76 5.50 75.75 5.67 59.51 6.14 
3 68.17 7.05 57.13 6.13 75.75 5.67 59.51 10.83 
4 63.64 4.81 50.00 4.39 78.78 5.54 59.53 4.95 
5 68.18 3.92 57.14 4.17 83.33 5.02 57.14 8.02 
6 60.61 6.07 50.00 5.16 83.33 5.02 66.67 8.13 
7 72.73 7.41 57.16 6.46 77.26 6.06 69.04 7.65 
8 66.67 7.05 57.16 5.95 87.87 3.95 66.66 6.29 
Mean 64.58 2.21 54.17 2.32 78.78 3.62 62.50 5.04 
Table 5.3: The mean percentage correct score (with S.E.M. values) for individual test days in 
transgenic and wild type PDAPP mice given 8 days of standard T-maze trials followed by 8 days 
of visually cued trials.   
 
5.5.4 Discussion  
The results from the T-maze study utilising standard trials followed by visually cued trials 
showed two general patterns. Firstly, wild type mice outperform transgenic mice regardless of 
the task difficulty level. Secondly, mice of both genotypes show improved performance in 
visually cued trials. This is in line with predictions that transgenic PDAPP mice would display 
impaired spatial working memory compared to littermate controls at 10 months of age, and 
that providing a visual cue to guide behaviour (thus removing the need to utilise recently 
acquired spatial information) would improve performance in both genotypes.  
However, it is worth noting that in visually cued trials, wild type mice continued to 
outperform transgenic mice. Thus, transgenic mice appeared to benefit less from the 
introduction of the visual cue than wild type mice. This can be interpreted several ways. 
Firstly, in order for the visual cue to be efficient in lowering the task difficulty level, mice were 
required to form an association between the visual cue and the reward. Whilst this learning 
requirement is arguably less demanding than the use of recently acquired position information 
to locate rewards, it nevertheless requires learning. Thus, transgenic mice may be deficient in 
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learning simple associations compared to wild type mice. Alternatively, and perhaps more 
parsimoniously, transgenic mice may suffer from visual deficits that may limit their ability to 
encode the discriminative stimulus. As it is not possible to discount either of these 
explanations based on this data, it is necessary to treat transgenic PDAPP mouse performance 
deficits in behavioural tasks with caution until further information is available regarding the 
function of their visual system.     
 
5.6 Experiment 12: Foraging task 
5.6.1 Introduction 
Based on results from the spatial working memory assessment of APP(V717I) mice presented 
in Section 3.3, Chapter 3, the foraging task appeared to be more sensitive to spatial working 
memory deficits compared to the T-maze task. Thus, PDAPP mice were also assessed on the 
foraging task to establish the generality of the behavioural phenotype across tasks. 
 
5.6.2 Methods 
Design 
The initial stages of habituation were identical to that described in Section 3.3, Chapter 3, but 
an unforeseen adverse effect of food deprivation in this model restricted the further use of an 
identical methodology. Attrition in transgenic mice increased from 10% to 16.7% during food 
deprivation to 90-95% of ad libitum body weight, compared to 0% of wild type mice. The task 
was therefore altered from a food-reward to a liquid reward based task, as no such adverse 
effects of water-deprivation were observed when administering the T-maze task.  
The liquid reward version of the foraging task was conducted in three phases. Phase A 
was identical in design to that described in Section 3.3, Chapter 3, with 8 liquid rewarded pots. 
This was carried out at 11 months of age. In phase B, the task difficulty level was lowered with 
a reduction in the number of pots from 8 to 6. This was carried out in an attempt to establish 
the level of task difficulty sensitive to a performance deficit in transgenic mice. A longitudinal 
assessment was conducted at 11 and 14 months of age in order to assess whether the 
presence of the APP(V717F) mutation led to higher error scores in the transgenic than wild 
type mice in an age-dependent manner. Phase C consisted of a control task in which only one 
pot was presented. The latter task served to assess whether transgenic and wild type mice 
142 
 
differed in their motivation or willingness to engage with the pots. This was carried out at 11 
months of age.    
 
Subjects 
Thirty-five male PDAPP mice were used, of which 14 were heterozygous to the APP(V717F) 
mutation and 20 were non-transgenic littermate controls. One wild type mouse was excluded 
after 7 days of testing due to a lack of engagement with the task, and consistent inability to 
visit each pot in the arena. One transgenic mouse was excluded at the point of data analysis 
(see Section 5.6.4, Chapter 5). The data obtained from these mice were excluded from all 
analyses. 
 
Method and Apparatus 
Phase A 
The colony was maintained on ad libitum access to food, but were water deprived to 90% of 
their body weight and given daily access to water for 2 hours. Eight pots which contained 
nothing except one drop (approximately 30µl) of sweetened, condensed milk (50:50 with 
dH2O) were placed in the arena (Fig. 5.6) in an identical pattern to that utilised when testing 
the APP(V717I) mice (Section 3.3, Chapter 3). Using wooden cubes, pots were raised 8 cm 
above the level of the sawdust in order for the mice to be unable to visually locate the reward 
without climbing onto the edge of the pot, allowing the experimenter to score reward 
searching behaviour (Fig. 5.7). Mice were required to visit all pots and retrieve the rewards in 
order for the task to be completed. The mice were tested over 5 consecutive days, with one 
trial on each day. 
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Fig. 5.6: The 8-pot liquid version of the foraging task.  
 
 
Fig. 5.7: The elevated reward pots in the liquid version of the foraging task.  
 
Phase B 
Immediately following 5 days of training in the 8 pot version of the liquid foraging task, the 
task difficulty level was reduced by decreasing the number of pots from 8 to 6. The pattern of 
the pots was altered to avoid locating pots in the centre of the arena in an attempt to 
minimise the effect variations in genotypic anxiety levels could play on task performance (see 
Fig. 5.8). Mice received 4 consecutive test days, with one trial on each day. 
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Fig. 5.8: The 6-pot liquid version of the foraging task.  
 
Phase C 
Immediately following testing in the 6-pot version of the foraging task, a control task was 
administered in which all but one rewarded pot was removed from the arena (see Fig. 5.9). 
Following consumption of the reward, subjects were left in the arena for 4 minutes. The 
number of errors made was recorded (returns to the single pot).  
 
 
Fig. 5.9: The foraging control task.  
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Scoring and data analysis 
The dependent variables of the task were scored and analysed as described in Section 3.4, 
Chapter 3 with the following changes. An error was defined as jumping onto the edge of a pot 
and lowering the head into the pot below the edge of the pot, as opposed to being defined by 
digging behaviour. For Phase C, only errors were analysed (as all errors were by definition also 
return and consecutive errors).  
 
5.6.3 Results 
One transgenic mouse was excluded from all analysis (Phase A, B and C) as an outlier due to 
performance scores being more than three standard deviations higher than the transgenic 
group mean. As all variables violated the assumptions of normality and homogeneity of 
variance which was not improved using transformations, they were analysed using Mann 
Whitney U and Wilcoxon Signed Ranks for between and within-subject analyses respectively.  
 
Phase A: Error 
(Returning to a previously visited pot) 
Inspection of Fig. 5.10 suggests a slight increase in error scores across trials in PDAPP mice 
compared to the wild type group. However, statistical analysis revealed no significant 
differences between transgenic and wild type mice on error scores across trials (U (13, 21) = 
107.50, p > .05) or during the first half of the trials when averaged across test days (U (13, 21) 
= 100.00, p > .05).  
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Fig 5.10: The mean error scores across trials and in the first half of the trials at 11 months of 
age for transgenic and wild type PDAPP mice. Error bars ±1 S.E.M. 
 
Phase A: Repeat error  
(Returning to a previously visited pot more than once) 
As with the error scores, the repeat errors of transgenic PDAPP mice are numerically higher 
than wild type mice (see Fig. 5.11).  However, there were no significant differences between 
transgenic and wild type mice on error scores across trials (U (13, 21) = 101.50, p > .05) or 
during the first half of the trials when averaged across test days (U (13, 21) = 83.50, p > .05).  
 
Fig. 5.10: The mean repeat error scores across trials and in the first half of the trials at 11 
months of age for transgenic and wild type PDAPP mice. Error bars ±1 S.E.M. 
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Phase A: Consecutive error 
 (returning to a previously visited pot twice or more without visiting any other pots in 
the interval between those errors) 
The pattern of numerically superior wild type performance is also evident in the consecutive 
error scores (see Fig. 5.12).  There was a non-significant trend towards wild type error scores 
being significantly lower than those of transgenic mice (U (13, 21) = 75.00, p = .055), and 
analysing consecutive error scores in the first half of the trials revealed no significant 
differences (U (13, 21) = 81.50, p > .05).  
 
Fig. 5.12: The mean consecutive error scores across trials and in the first half of the trials at 11 
months of age for transgenic and wild type PDAPP mice. Error bars ±1 S.E.M. 
Phase B 
For simplicity of presentation, an overview of the statistic and p value for all dependent 
variables is presented in Table 5.4 prior to a summary of analysis of each type of error 
measure.  
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Variable 
Genotypic difference 
U P 
11 months of age 
Error 78.0 0.073 
Error first half of the trials 68.0 0.025 
Repeat error  84.5 0.118 
Repeat error first half of the trials 100.0 0.097 
Consecutive error 80.5 0.079 
Consecutive error first half of the trials 99.0 0.115 
 Error in control task 90.0 0.178 
14 months 
of age 
Error 53.5 0.005 
Error first half of the trials 35.5 0.001 
Repeat error  45.5 0.002 
Repeat error first half of the trials 32.0 0.001 
Consecutive error 49.5 0.003 
Consecutive error first half of the trials 33.0 0.001 
Table 5.4: The test statistic and exact significance for variables from the foraging task is 
presented at 11 and 14 months of age analysed for genotypic differences. Significant values 
are highlighted in bold.  
 
Phase B: Error 
From visual inspection of Fig. 5.13, transgenic mice appear to make more errors than wild type 
mice across the task and in the first half of the trials at both 11 and 14 months of age. 
Statistical analysis confirms that at 11 months, transgenic and wild type mice differed 
significantly in their error scores in the first half of the trials (U (12, 21) = 68.00, p < .05), but 
not in error scores across trials (U (12, 21) = 78.00, p > .05). At 14 months of age, transgenic 
mice made significantly more errors than wild type mice both across trials (U (12, 21) = 53.50, 
p < .005) and in the first half of the trials (U (12, 21) = 35.50, p < .0001).  
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Fig. 5.13: Mean total error (A) and error in the first half of the trials (B) across test days for 
transgenic (dark grey bars) and wild type mice (light grey bars) at 11 and 14 months. Error bars 
±1 S.E.M. * = p < .05, ** = p < .005, *** = p < .0001. 
 
Within-subject comparisons of error scores at 11 and 14 months did not reveal significant 
increases in errors across trials (χ2 (33) = -1.77, p > .05) or in the first half of the trials (χ2 (33) = 
-1.51, p > .05) when collapsed across genotype. When analysing the within-subject changes in 
error scores from 11 to 14 months by genotype, no significant changes were observed in wild 
or transgenic mice across the task [wild type: (χ2 (21) = -1.24, p > .025); transgenic: (χ2 (12) = 
1.22, p > .025)] or in the first half of the trials [wild type: (χ2 (21) = -0.34, p > .025); transgenic: 
(χ2 (12) = -1.83, p > .025)].  
 
Phase B: Repeat error 
From visual inspection of Fig. 5.14, transgenic mice appear to make more repeat errors than 
wild type mice across the task and in the first half of the trials at both 11 and 14 months of 
age. At 11 months, these differences are not significant across trials (U (12, 21) = 84.50, p > 
.05) or in the first half of the trials (U (12, 21) = 100.00, p > .05). At 14 months however, 
statistical analysis confirms that transgenic and wild type mice differed significantly in their 
repeat error scores across the task (U (12, 21) = 45.50, p < .002) and in the first half of the 
trials (U (12, 21) = 32.00, p < .0001). 
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Fig. 5.14: Mean total repeat error (A) and repeat error in the first half of the trials (B) across 
test days for transgenic (dark grey bars) and wild type mice (light grey bars) at 11 and 14 
months. Error bars ±1 S.E.M. ** = p < .002, *** = p < .0001. 
 
Within-subject comparisons of repeat error scores at 11 and 14 months did not reveal 
significant increases in repeat errors across trials (χ2 (33) = -1.03, p > .05), but there was a 
general increase in repeat error scores in the first half of the trials at 14 months of age (χ2 (33) 
= -2.96, p < .002). When analysing the within-subject changes in repeat error scores from 11 to 
14 months by genotype, no significant changes were observed in wild type mice across the 
task (χ2 (21) = -0.22, p > .025) or in the first half of the trials (χ2 (21) = -1.13, p > .025). 
Transgenic mice however displayed significantly higher levels of repeat errors in the first half 
of the trials at 14 months compared to 11 months of age (χ2 (12) = -2.70, p < .002), but no 
significant difference in repeat errors across the task was observed (χ2 (12) = -1.25, p > .025).  
Phase B: Consecutive error 
Fig. 5.15 illustrates the elevated levels of consecutive error scores in transgenic mice 
compared to wild type mice across measures. Statistical analysis reveals that genotypic 
differences are not significant across the task (U (12, 21) = 80.50, p > .05) or in the first half of 
the trials (U (12, 21) = 99.00, p > .05) at 11 months of age. Transgenic and wild type mice differ 
significantly in their consecutive error scores at 14 months of age, both across trials (U (12, 21) 
= 49.50, p < .0001) and in the first half of the trials (U (12, 21) = 33.00, p < .0001).  
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Fig. 5.15:  Mean total consecutive error (A) and consecutive error in the first half of the trials 
(B) across test days for transgenic (dark grey bars) and wild type mice (light grey bars) at 11 
and 14 months of age. Error bars ±1 S.E.M. *** = p < .0001. 
 
Within-subject comparisons of consecutive error scores at 11 and 14 months did not reveal 
significant increases in consecutive errors across trials (χ2 (33) = -0.87, p > .05) or in the first 
half of the trials (χ2 (33) = -1.55, p > .05) when collapsed across genotype. When analysing the 
within-subject changes in consecutive error scores from 11 to 14 months by genotype, no 
significant changes were observed in wild type mice across the task (χ2 (21) = -0.42, p > .025) 
or in the first half of the trials (χ2 (21) = -0.001, p > .025), nor in transgenic mice across the task 
(χ2 (13) = -1.79, p > .025) or in the first half of the trials (χ2 (13) = -1.72, p > .025).  
 
Phase C: Error 
There were no significant differences between transgenic and wild type mice in the number of 
times they returned to the single, foraged pot during the 4 minute time interval (U (12, 21) = 
90.00, p > .05; see Fig. 5.16). 
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Fig. 5.16:  Mean error for transgenic and wild type mice at 11 months of age in the one pot 
control task. Error bars ±1 S.E.M.  
 
5.6.4 Discussion 
It was hypothesised that the APP(V717F) mutation would result in lower spatial working 
memory performance compared to non-transgenic mice. Whilst limited evidence of genotypic 
differences in spatial working memory was evident in Phase A, support for the hypothesis was 
obtained in the critical stages of the experiment, namely Phase B, where the number of pots 
was reduced from 8 to 6. The lack of a difference in the number of errors made in the control 
task (Phase C) indicates that the performance differences observed between the transgenic 
and wild type group on the foraging task is not likely to be due to differences in hyperactivity, 
or differences in their general motivation to engage with the pots or consume the reward.  
Using an appropriate level of task difficulty, the performance of transgenic mice 
decreased between 11 and 14 months, indicating that the task was sensitive to age-related 
deterioration of spatial memory. This cognitive decline was detected clearly in the first half of 
the trials, arguably the less demanding phase of the trials. Thus, wild type mice are able to 
perform the first half of the trials with limited errors at both 11 and 14 months. In contrast, 
the performance of transgenic mice deteriorated markedly in the first half of the trials by 14 
months of age. Thus, the foraging task appears to be a suitable task for assessing the effect of 
2B3 on cognitive performance in the PDAPP model, as a clear transgenic performance deficit 
can be measured which appears to be based on inferior cognitive processing in an age-
dependent manner.  
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5.7 Experiment 13: Assessment of object recognition memory in PDAPP (V717F)  
5.7.1 Introduction 
Following evidence to suggest that transgenic PDAPP mice display impairments in spatial 
working associated with hippocampal function, the question of the degree to which deficits in 
learning and memory are restricted to this system becomes of interest. The literature on 
object recognition memory or visual novelty detection in the PDAPP model is varied, with 
reports of both age-dependent object recognition memory deficits (Dodart et al., 1999) and 
intact processing of visual novelty at 18-21 months of age (Chen et al., 2000). This discrepancy 
may be due to differences in the testing paradigm utilised by the two laboratory groups, with 
Dodart et al. (1999) introducing a spatial novelty aspect in the test phase by using a single item 
in the sample phase. As the testing procedure utilised in the current work aimed at isolating 
novel object recognition processes as opposed to a conjunction of novel object and novel 
place recognition, the procedure adopted was identical to that described in Section 3.5, 
Chapter 3 and similar to that of Chen et al. (2000).    
 
5.7.2 Method 
Design 
PDAPP mice were assessed either with a 3 hour delay interval between the sample and the 
test phase, or with a 5 minute delay. The assessment of object recognition memory was 
carried out at 12 months of age, an age beyond that in which object recognition deficit can be 
detected as indicated by Dodart et al. (1999), and at which point Aβ plaque pathology is 
established (Reilly et al., 2003).  
 
Subjects 
In the 5 minute delay condition, 17 male PDAPP mice were used of which 7 were heterozygous 
APP(V717F) mice and 10 were non-transgenic littermate controls. In the 3 hour delay 
condition, 7 transgenic and 11 wild type littermate control mice were used.  
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Apparatus 
The apparatus utilised in assessing object recognition memory in the PDAPP model was 
identical to that utilised when assessing the APP(V717I) model in Section 3.5.2, Chapter 3, with 
the exception of the objects used. As the mice were trained during the foraging task to jump 
onto objects to obtain a reward, the current experiment used taller objects (such as 
approximately 20cm tall bottles and ceramic figures) than those used with the APP(V717I) 
mice in an attempt to avoid mice climbing onto the objects.  
 
Method 
The testing procedure was identical to that described in Section 3.5.2, Chapter 3, with two 
exceptions. Firstly, only two delay intervals were used: 5 minute delay or 3 hours delay. 
Secondly, only one day of habituation to the arena with an object not used in future testing 
was employed, due to significant recent exposure to the test room and general arena testing 
through the foraging task.  
 
Scoring and data analysis  
The scoring and data analysis did not differ from that described in Section 3.5.2, Chapter 3. 
  
5.7.3 Results  
The contact times averaged across the two identical objects in the sample phase are 
presented in Table 5.5. In order to assess whether there was any sampling bias between 
groups, effect of genotype on contact time in the sample phase was analysed, with delay as a 
factor. Whilst there was no main effect of genotype (F (1, 29) = 1.04, p > .05), there was a main 
effect of sampling trials, in which contact time in sampling phase 1 was significantly higher 
than in sampling phase 2 (F (1, 29) = 10.98, p < .005). This effect appears to be driven by a 
trials*genotype interaction (F (1, 29) = 5.60, p < .05), in which transgenic mice explored the 
objects significantly more in sample phase 1 than in sample phase 2 (F (1, 31) = 13.707, p < 
.001). No further significant genotype*trials differences emerged [closest to significance: 
genotype difference in sampling phase 1 in the direction of increased sampling by wild type 
mice compared to transgenic littermates: (F (1, 31) = 3.90, p > .05)].  
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There were no differences in the sample contact times in the different delay groups (F 
(1, 29) = 0.67, p > .05), nor any interaction with delay and other factors [delay*genotype: (F (1, 
29) = 0.70, p > .05), trials*delay: (F (1, 29) = 0.32, p > .05), trials*genotype*delay interaction: (F 
(1, 29) = 1.07, p > .05).   
  Contact time (s) in sample phase 
  Wild Type Transgenic 
Trial Delay Mean S.E.M. Mean S.E.M. 
1 5 minute 
delay 
22.10 3.75    27.46      5.25 
2   16.06      2.32 13.50 4.45 
1 
3 hours 
  18.61      2.20     34.73     10.25 
2   20.43      2.33     17.68      3.78 
Table 5.5: The mean contact time in seconds for transgenic and wild type mice when faced 
with a pair of novel objects over two habituation days (novel pairs presented on each day).  
 
The mean contact time for the novel and familiar object at each delay interval during the test 
phase is presented in Table 5.6. A repeat measures ANOVA confirmed that transgenic and wild 
type mice did not significantly differ in the contact time at test (F (1, 31) = 0.10, p > .05), nor 
was there a genotype*delay interaction (F (1, 31) = 1.11, p > .05). 
There was a main effect of object type, in which the novel object was explored 
significantly more than the familiar object (F (1, 31) = 5.86, p < .05), but genotype did not 
influence the amount of time spent exploring the novel and familiar objects [genotype*object: 
(F (1, 31) = 0.22, p > .05)]. Similarly, there were no interactions between delay, genotype and 
object type [object*delay: (F (1, 31) = 2.21, p > .05), object*delay*genotype: (F (1, 31) = 0.14, p 
> .05)]. 
Delay 
Novelty 
status 
Contact time (s) in test phase 
Wild Type Transgenic 
Mean S.E.M. Mean S.E.M. 
5 minute 
delay 
Novel 14.90 2.37     15.80      2.34 
Familiar    12.46      2.07 15.66 1.93 
3 hours 
Novel    19.58      3.05     20.64      4.33 
Familiar    14.06      1.59     15.39      5.03 
Table 5.6: The mean contact time in seconds for transgenic and wild type mice when faced 
with a novel and a familiar object in the test phase (averaged across two trials).  
 
Fig. 5.17 shows the mean discrimination ratio for transgenic and wild type mice. Inspection of 
this figure suggests there are no differences in performance between transgenic and wild type 
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mice in their ability to discriminate between the novel and the familiar object as measured in 
the discrimination ratio averaged across test days. ANOVA analysis confirmed that there was 
no main effect of genotype (F (1, 31) = 0.37, p > .05), delay (F (1, 31) = 1.66, p > .05), or a 
significant interaction between the two (F (1, 31) = 0.79, p > .05). When comparing 
discrimination ratios against chance, neither wild type nor transgenic mice differed 
significantly from 50% at the 5 minute delay (wild type: (F (1, 21) = 2.44, p > .05); transgenic: (F 
(1, 13) = 0.01, p > .05). When given a three hour delay, only wild type mice differed 
significantly from chance (wild type: (F (1, 21) = 4.65, p < .05); transgenic: (F (1, 13) = 2.62, p > 
.05). 
 
Fig. 5.17: Discrimination ratio (total time novel/total time any object*100) displayed for 
transgenic (Tg) and wild type (WT) mice at delay intervals 3 hours and 5 minute delay. Error 
bars ±1 S.E.M.    
 
5.7.4 Discussion 
The results obtained from the novel object recognition task suggests that harbouring the 
APP(V717F) mutation does not lead to differential performance at 12 months of age compared 
to wild type controls. The lack of a transgenic deficit compared to wild type mice is not a result 
of genotypic variations in the level of exploration of objects in the sample phase, but may be 
masked by a lack of discrimination between the novel and familiar object by wild type 
controls. This indicates that the object recognition memory of transgenic PDAPP mice is not 
disrupted by Aβ pathology at 12 months of age, despite reports of extensive plaque pathology 
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by this age (Dodart et al., 2000; Reilly et al., 2003). It is important to note however that the 
onset and degree of Aβ pathology may vary between colonies of PDAPP mice in different 
laboratories. In addition, it is possible that transgenic PDAPP mice would display a novel object 
recognition deficit compared to wild type controls in the event that wild type mice showed a 
stronger novelty preference.   
This result is in line with those of Chen et al. (2000), who did not detect any 
differences between wild type and transgenic mice at any delay interval using a paradigm 
generally comparable to the current experiment. In contrast, Dodart et al. (1999) detected an 
age-related deficit in object recognition memory emerging at 9-10 months in transgenic 
PDAPP mice. However, Dodart et al. (1999) utilised a paradigm where one object is presented 
in the sample phase, followed by two objects in the test phase. In this scenario, spatial novelty 
is a factor in addition to object novelty. The novelty of the spatial location of an object has 
been shown to influence exploration in the Tg2576 model (Hale & Good, 2005; Good, Hale & 
Staal, 2007). Thus, Dodart et al. (1999) utilise a testing procedure with a lowered novelty 
detection difficulty level, which may disproportionately benefit wild type mice.  
Whilst both Chen et al. (2000) and the current data point to a lack of genotypic 
differences in object novelty detection, there are differences between the data sets. Notably, 
the transgenic mice in the current study do not show a novelty preference in when there is a 5 
minute delay, with transgenic mice spending a comparable amount of time exploring the novel 
and familiar object. No transgenic deficit is detected in this condition, arguably due to a 
relatively poor performance level of wild type mice. This is not observed in Chen et al. (2000), 
where both transgenic and wild type mice show a novelty preference in the no delay 
condition, which deteriorates at a comparable rate as the delay is increased. One explanation 
for this difference in general performance level could be variations in the sample phase. Whilst 
the current study allowed subjects 10 minutes to explore the objects in the sample phase, 
Chen et al. (2000) used a criterion of 20s of accumulated exploration time (maximum 20 
minutes). However, this difference is unlikely to account for the relatively large differences in 
the results, as the average sample time for testing conditions listed in Table 5.13 reveal similar 
exploration levels to the 20s criterion of Chen et al. (2000). A second factor that differs 
between the current experiment and that of Chen et al. (2000) is the genetic background of 
the PDAPP mice. This factor is a continuing source of variation, and has been highlighted by 
Kobayashi & Chen (2005) as a potential explanation for differences between Chen et al. (2000) 
and Dodart et al. (1999) on the object recognition memory profile of the PDAPP model. The 
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change from a hybrid triple background to a pure C57Bl/6 background as in the current project 
offer increased potential for alterations to the behavioural phenotype of transgenic and wild 
type mice.  
The performance of PDAPP and APP(V717I) mice described in Chapter 3 on the novel 
object recognition task differ in the degree of novelty preference, which was higher in 
APP(V717I) mice, despite the exploration times in the sample and test phase being higher for 
PDAPP mice. There are several factors which may influence the performance of wild type mice 
of both models in this task. As mentioned previously, the genetic background of both models 
is C57Bl/6. Nevertheless, neither model is likely to be congenic, and have arisen through a 
different mix of inbred strains. Furthermore, the objects used when testing the PDAPP model 
were not those utilised with the APP(V717I) mice. This was due to the novel object recognition 
task being administered after the liquid reward foraging task in PDAPP mice, resulting in 
PDAPP mice being trained to jump onto objects in an arena to obtain reward. It was therefore 
desirable to avoid objects which could be climbed, which was possible with the objects used to 
test APP(V717I) mice. This change in object characteristics could well have influenced 
performance in the task, as it has been shown that discrimination ratios are higher when mice 
can climb onto objects during exploration compared to objects which can only be touched 
(Heyser & Chemero, 2011).   
 
5.8 Chapter discussion 
The aim of this chapter was to provide a profile of potential changes in anxiety-related 
behaviour and memory of PDAPP(V717F) transgenic mice at 9 – 14 months of age. A predicted 
reduction in anxiety-behaviour was observed in 9.5 month old transgenic mice which was not 
evident in littermate controls (Experiment 9 and 10). In terms of spatial working memory, both 
the T-maze (Experiment 11) and the foraging task (Experiment 12) indicate transgenic deficits 
at 11 and 14 months respectively. In contrast, no genotypic differences in object recognition 
memory were observed, with the general performance level of novelty detection being 
relatively low across genotypes (Experiment 13).  
In terms of anxiety behaviour, there are no direct data available in the literature on 
anxiety changes in transgenic PDAPP mice. Interestingly, the pattern of results observed is 
comparable to that observed in the APP(V717I) model (Chapter 2), as well as other models of 
Aβ pathology such as the Tg2576 line (Lalonde et al., 2003; Ognibene et al., 2005). This general 
trend towards lowered anxiety in transgenic APP mutation models suggests either that a range 
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of mutations in the APP protein exhibit a similar effect on anxiety behaviour through elevation 
of Aβ levels, or that overexpression of APP drives changes to anxiety behaviour without the 
involvement of Aβ pathology. A third alternative could involve a combination of both these 
factors. The observation that anxiety deficits in transgenic APP(V717I) mice are age-
independent lend support to the notion that overexpression of APP may play a greater role 
than Aβ pathology. As no analysis of anxiety in the PDAPP model at a young age was possible, 
no conclusions can be drawn regarding the effect of age on changes in anxiety behaviour in 
this model based on the current data set. The novel object recognition task did not appear to 
be a sensitive task to assess object recognition memory in the PDAPP model, as limited novelty 
preference was evident in both transgenic and wild type mice.  
The T-maze FCA and the foraging task revealed poorer performance in aged PDAPP 
mice. The detection of transgenic deficits across two separate tasks demonstrates that the 
behavioural deficit is not task-specific, whilst manipulations of the task difficulty level in the 
foraging task suggest that the lowered performance of transgenic PDAPP mice is related to 
deficits in spatial working memory as opposed to a general motivational or activity-related 
issue. It is important to note however that the continued deficit in transgenic mice following 
the introduction of the visual cue in the T-maze task could indicate a transgenic-specific issue 
with the visual system. Indeed, such issues have been reported in the Tg2576 model, and 
appear to be linked to a retinal degeneration gene found in 20% of inbred mouse strains 
(Garcia et al., 2003). When homozygous, the gene causes near blindness in carriers, 
confounding behavioural measures of cognitive performance (Garcia et al., 2003). Whilst this 
is an issue that one cannot dismiss based on the current data, the lack of a deficit in the 
recognition memory task would indicate that gross visual impairments are an unlikely 
explanation for spatial memory deficits in PDAPP mice.  Furthermore, a number of previous 
studies of PDAPP mice in which visually cued platform locations have been utilised in the 
Morris water maze have found no genotypic differences in latency after 3 days of training, 
indicating intact sensorimotor function (Brody & Holtzman, 2006; Dumas et al., 2008). 
Interestingly, transgenic deficits in visually cued trials are evident on day 1 and 2, indicating 
that transgenic mice are impaired at learning the association between the cue and the 
platform, but the transient nature of this deficit does not implicate the visual system. In 
addition, whilst visually cued trials in the Morris water maze and the T-maze both rely on the 
ability of transgenic mice to form an association between the cue and the trial end point, the 
deficit in the appetitive task may reflect the nature of the prior training (alternation or position 
bias) or the nature of the reward.  
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When interpreting demonstrations of age-dependent spatial working memory deficits 
in transgenic APP mutation mouse models in the context of the amyloid cascade hypothesis, 
the prediction is that such deficits are related to elevations in Aβ levels in the CNS. Reports of 
pathological and biochemical analysis of PDAPP transgenic brain tissue confirms the elevation 
of soluble Aβ levels by 8 months of age (Johnson-Wood et al., 1997), with Aβ plaque 
deposition by 12-15 months of age (Reilly et al., 2003). It is therefore possible that the 
performance deficit detected in the foraging task in transgenic PDAPP mice at 14 months is 
related to Aβ pathology, although onset and degree of pathology in transgenic models may 
vary greatly between laboratories. Nevertheless, it is possible that the task could be utilised to 
assess the ability of 2B3 to reduce Aβ pathology and cognitive deficits in vivo. The aim of the 
experiments reported in Chapter 6 is to assess whether 2B3 can lower Aβ production and 
reduce spatial working memory deficits when administered to PDAPP transgenic mice.  
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Chapter 6
 
The effects of 2B3 in vitro and in vivo 
 
6.1 Experiment 14: The effect of 2B3 in primary neuronal cell cultures  
6.1.1 Introduction 
The aim of immunotherapy in AD research is to reduce the underlying pathology as well as the 
cognitive and behavioural symptoms of the disease using antibodies. Whilst several attempts 
at reducing Aβ pathology and cognitive deficits in transgenic mouse models have been 
successful using anti-Aβ antibodies (Schenk et al., 1999; Sigurdsson et al., 2001; Janus et al., 
2000; Wilcock et al., 2004; Morgan et al., 2000), there has been limited success associated 
with translating the approach to human patients (Orgogozo et al., 2003; Gilman et al., 2005; 
Holmes et al., 2008). This is due both to a tendency for anti-Aβ antibodies to induce 
meningoencephalitis in patients, as well as to a lack of observed cognitive benefit associated 
with Aβ plaque clearance. As excess Aβ is deposited in insoluble plaques in the extracellular 
space, it is possible that antibodies which bind to Aβ excessively activate the immune system. 
An alternative approach is to use an antibody that binds to the β-secretase cleavage site of 
APP, a protein which can undergo proteolytic cleavage in a number of ways, to inhibit Aβ 
production through steric hindrance.  
The use of anti-APP β-secretase cleavage site antibodies has been limited to date, but 
when assessed has proved successful both in vitro and in vivo. Rakover et al. (2007) 
demonstrated that administration of such an antibody to transgenic Tg2576 mice reduced 
deficits in the object recognition task, but without the hypothesised lowering of soluble or 
insoluble Aβ levels in the CNS. Thomas et al. showed that two different types of anti-APP β-
secretase cleavage site antibodies, 2B12 (Thomas et al., 2006) and 2B3 (Thomas et al., 2011), 
could reduce Aβ40 and Aβ42 production in cell culture by 63% and 78% respectively. However, 
the effect was obtained using the human MOG-G-UVW and SH-SY5Y cell lines, which are not 
neuronal. It was therefore essential to determine whether the Aβ reducing effects of 2B3 
could be replicated in primary neuronal cell cultures. By extending the types of cell systems 
the treatment has been tested in to one that more closely mimics neuronal cells, it is possible 
to assess whether the effects of 2B3 generalise across cell types. The main aim of this 
experiment was to use a primary neuronal murine culture to assess whether 2B3 reduced Aβ 
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production. Thus, primary neuronal cultures were developed using cortical tissue from foetal 
C57Bl/6 wild type mice.  
 
6.1.2 Methods 
The protocol for the generation, growth and differentiation of embryonic cells into neurons 
was based on methods generously provided by Dr. Kelly and Dr. Vinh, whilst the execution 
relied heavily on the expertise of Dr. Thomas, all at Cardiff University.  
 
Generation and collection of foetal cortical tissue 
Female C57Bl/6 mice were time-mated before being sacrificed at gestational day E16.5. Foetal 
cortical tissue was dissected from each hemisphere and the meninges were removed. Tissue 
was kept on ice in HBSS (Hank’s Buffered Salt Solution) cell culture media.  
 
Extraction, expansion and maintenance 
Tissue samples were washed in media [DMEM (Dulbecco’s Modified Eagle Medium), 1% 
Penicilin, 1% Streptomycin, 1% Fungizone] and centrifuged twice at 1000rpm for 3 minutes. 
After removal of excess media, 500µl of Trypsin (Worthington, Lakewood, USA, 10mg in HBSS) 
was added. The samples were incubated for 20 minutes at 37oC, before 500µl of Trypsin 
inhibitor (Sigma-Aldrich, 20µg/ml in HBSS) and 500µl of DNAase (Worthington, 50µg/ml in 
HBSS) was added. Following 5 minutes incubation at 37oC, 10ml of media was added before 
samples were centrifuged at 1000rpm for 3 minutes. Excess media was removed before 200µl 
expansion media [DMEM/F12 1:1, 2% B27, 20ng/ml Fibroblast Growth Factor (FGF), 20ng/ml 
Epidermal Growth Factor (EGF), 1% Penicillin, 1% Streptomycin, 1% Fungizone] was added. 
Cells were triturated lightly 3 times and counted, and were maintained at 37oC in 24-well 
plates.  
Cells were encouraged to proliferate whilst being regularly fed and passaged until 
approximately 25ml of cell-containing media was available. Cells were fed by replacing 40-50% 
of the media with fresh expansion media. The passaging procedure was identical to the 
extraction procedure from the first centrifugation onwards. 
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Neuronal differentiation 
Once approximately 25ml of media with confluent cells was obtained, cells were 
differentiated. Glass coverslips were baked at 180oC for 2 hours before one coverslip was 
added per well to a 24-well cell culture plate. Five hundred µl of 20µg/ml of poly-L-lysine made 
up in dH2O was added to each well and incubated for 24 hours at 37
oC. Wells were washed 3 
times in media (DMEM, 1% Penicillin, 1% Streptomycin, 1% Fungizone), excess media 
removed, then placed under UV light for 45 minutes. Following a 2 hour drying period, the cell 
passaging method was applied, using differentiation media (DMEM/F 12 1:1, 1% FBS, 2% B27, 
1% Penicillin, 1% Streptomycin, 1% Fungizone) rather than expansion media. Approximately 75 
000 cells in 40-50µl differentiation media were applied to each well and incubated for 4 hours 
at 37oC before 500µl of differentiation media was added. Experimental manipulation of cells 
was carried out 24 hours after differentiation.  
 
Neuronal detection using immunocytochemistry 
In order to ensure differentiation of primary foetal cells into neurons, immunocytochemical 
staining using the neuronal marker Neuronal Specific Enolase (NSE) was carried out. In 
addition, a marker for glia cells (glial fibrillary acidic protein; GFAP) was used to assess the 
number of non-neuronal cells present in the culture. Immunocytochemical staining was 
carried out as described in Thomas et al. (2006).   
Immunocytochemical staining using neuronal-specific markers confirmed the presence 
of multiple successfully differentiated neuronal cells. Whilst GFAP staining for glia cells showed 
labelling of some individual cells, the majority of the cell population was identified to be 
neuronal (data not shown).  
 
Production of 2B3 
2B3 is a monoclonal mouse IgG which binds to the β-secretase cleavage site of APP, the 
development of which has been described elsewhere (Thomas et al., 2011). The following 
sections will outline the methods adopted to produce 2B3 from 2B3-producing hybridoma 
cells stored in liquid nitrogen. This will include details of cell culture methods, concentration, 
purification, dialysis and quantification of IgG.  
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Cell culture 
The 2B3-producing hybridoma cells were thawed in a 56oC water bath before approximately 
1.5ml of cell culture medium [RPMI1640 (Sigma-Aldrich, Dorset, UK), 2mM Glutamine, 10% 
Fetal Bovine Serum, 1% Penicillin, 1% Streptomycin] was added and resuspended prior to the 
addition to a further 30ml of media. The solution was centrifuged at 1000rpm for 5 minutes at 
room temperature (RT) and the supernatant subsequently removed. One ml of warm medium 
was added to the cell pellet and following resuspension, the cells were transferred to one well 
of a 24-well cell culture plate and grown at 37oC in 5% CO2. Cells were passaged when 
confluent by resuspension before the volume was divided between several wells with the 
addition of an appropriate volume of cell culture media depending on the size on the well or 
flask (Corning Incorporated, NY, USA) used for expansion.     
When cells were grown to confluence, the media containing 2B3 was collected when 
approximately 50% of the cells were viable. The media was centrifuged at 1000rpm for 5 
minutes at RT and the supernatant was collected and stored at -20oC until use.  
 
Concentration 
Following filtering using 45µm Super Acrodisc 32 filters (Pall Life Sciences, Ann Arbor, USA), 
cell media of 2B3-producing hybridomas was concentrated using Amicon Ultra-15 centrifugal 
filter units (Millipore, Billerica, USA) with a 100 000 molecular weight cut off. Fifteen ml of 
media was centrifuged in a JS7.5 swing out rotor at 3000g at 4oC. Following 1 hour of 
centrifugation, filtered media was discarded, and 15ml of fresh media was added to the top 
chamber to be centrifuged. This pattern continued until approximately 75ml had passed 
through one centrifugal filter unit. Several units were employed simultaneously, and the 
concentrated antibody was pooled after completion of centrifugation. Distributing media 
across several centrifugal units was carried out in an attempt to avoid high viscosity in the 
concentrated sample.    
 
Purification 
Concentrated media supernatant containing 2B3 was purified using an affinity 
chromatography MAb TrapTM Kit (GE Healthcare) with the aim of both purifying and further 
concentrating the IgG solution. A sequence of buffers as well as the antibody sample was put 
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through a HiTrap Protein G column containing recombinant protein G which binds mouse IgG, 
but is genetically altered to lack the ability to bind albumin. Buffers were diluted 1:10 with 
sterilised dH2O, excluding the neutralising buffer. The column was washed with sterilised dH2O 
to clear ethanol residues following storage at approximately 1 drop per second, the constant 
rate throughout the procedure. The column was equilibrated with 3ml of binding buffer 
before the sample was applied. The supernatant from the column was collected in a 
numbered series of Eppendorf tubes containing 75µl neutralising buffer to preserve IgG 
activity.  Ten ml of binding buffer was administered to remove molecules other than the 
antibody, before 5ml of elution buffer was passed through the column to release the antibody. 
A protein assay (see section 2.6.3) was carried out on the supernatant fractions in order to 
identify the fractions containing the antibody.  
 
Dialysis 
The antibody was dialysed in PBS (137mM NaCl, 2.5mM KCL, 8mM Na2HPO4, 1.5mM KH2PO4, 
pH7.2) to ensure compatibility with the Tris and Glycine-based buffers of the MAb TrapTM Kit. 
Slide-A-Lyzer Dialysis Cassettes (Pierce Thermo Scientific, Rockford, USA) of 0.5-3ml sample 
volume with a 10 000 molecular weight cut off were utilised. Cassettes were rotated in 2 litres 
of PBS at 4oC overnight.  
 
Quantification of 2B3 using ELISA 
The methods utilised to measure 2B3 in cell culture media were based on the procedure used 
by Thomas et al. (2006, 2011) and was identical to that outlined in Section 4.2.2, Chapter 4 
with the following exceptions. The 96-well plate was coated in an sheep anti-mouse IgG at a 
concentration of 1/4000 diluted in carbonate/bicarbonate buffer (15mM Na2CO3, 35mM 
NaHCO3, pH 9.6). Standards ranged from 210-0.10ng/ml in doubling dilutions. Doubling 
dilutions of the 2B3 sample were applied, from 1/1000 to 1/32,768,000. The detection 
antibody, HRP-labelled anti-mouse IgG (Pierce Thermo Scientific) was used at 1/6000 and 
incubated for 1 hour.  
 
Administration of 2B3 to differentiated primary neurons and measurement of Aβ40 
levels in media 
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Following differentiation, equal volumes of primary neurons from 4 independent embryos 
were passaged and placed into 3 conditions in a 24 well cluster plate and allowed to attach 
overnight. Cells were then incubated in differentiation media (DMEM/F 12 1:1, 1% FBS, 2% 
B27, 1% Penicillin, 1% Streptomycin, 1% Fungizone) only, or differentiation media containing 
2B3 or an irrelevant mouse IgG (Sigma Thermo Scientific) at 10µg/ml at 37oC for 48 hours at 
37oC. Media was collected and Aβ40 and Aβ42 levels were measured using ELISA methods as 
described in Thomas et al. (2006). Briefly, media was immunoprecipitated overnight at 4oC 
using BAM401S (Alpha Diagnostics Int.) at 1:2000. This was followed by a 2 hour incubation 
with Protein A (Santa Cruz Biotechnology, Santa Cruz, USA) and 3 rounds of CHAPS buffer 
wash (150 mM NaCl, 50 mMTris, 1mM EDTA, 10mM CHAPS) and centrifugation at 3275g. 
Samples were washed in PBS and boiled for 5 minutes at 95oC and centrifuged again at 3275g. 
The supernatant was used to measure Aβ40 using the same ELISA methodology as described 
in Section 4.2.2, Chapter 4. 
 
Data analysis 
The concentration of Aβ40 per sample was calculated in GraphPad Prism4.0 by the fitting of a 
non-linear regression curve to standard values and calculating unknown values from the curve. 
Individual Aβ values were standardised to the total protein concentration of each sample, and 
all values are given as ng/mg of total protein. ANOVA and post hoc analysis with Bonferroni 
correction was used to analyse the data, reflecting the independence of each primary cell 
preparation. 
 
6.1.3 Results 
Levels of Aβ40 following administration of either 2B3 or the negative controls are presented in 
Fig. 6.1. Inspection of this figure indicates a reduction in Aβ40 following 2B3 administration 
compared to controls. Statistical analysis confirmed a significant effect of treatment (F (2, 6) = 
13.86, p < .005), with 2B3-treated levels significantly different from both the IgG (p <.05) and 
media control condition (p <.001). There was a 64.41% reduction in levels of Aβ40 in 2B3 cells 
compared to the cells treated with the irrelevant IgG, and a 73.96% reduction when comparing 
Aβ40 levels in 2B3-treated and media treated cells. There was no significant difference in Aβ40 
levels between IgG and media treated cells (p >.05). Unfortunately, levels of Aβ42 were too 
low to be detected.  
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Fig 6.1: Levels of Aβ40 from primary murine cortical neurons after incubation with 2B3 or an 
irrelevant mouse IgG (10µg/µl) for 48 hours (ng/mg of total protein). *= p < .05, *** = p < .001. 
Error bars ±1 S.E.M.   
 
6.1.4 Discussion 
The results from the present experiment showed a significant reduction in Aβ40 levels 
following 2B3 administration compared to that either of an irrelevant IgG or a media control. 
This pattern of results is in line with predictions that neuronal cells will produce less Aβ if an 
anti-β-secretase APP antibody is present. Furthermore, the level of downregulation is highly 
comparable to that obtained using 2B3 and 2B12 in human astrocytoma and neuroblastoma 
cell lines (Thomas et al., 2006; 2011). In relation to the Aβ measurements obtained in aged 
APP(V717I) tissue in Chapter 4 (Section 4.2.3), the Aβ levels of the media-treated neurons are 
lower, as expected in wild type neurons not overexpressing APP. The lower Aβ levels in wild 
type APP(V717I) brain homogenate compared to that of primary neuronal cultures reflects a 
basic difference in tissue and cell culture preparations, as well as a difference in the 
concentration of the media obtained from primary neurons following immunoprecipitation. 
The experiment further demonstrated the need for an antibody that binds specifically at the β-
secretase cleavage site of APP, as an irrelevant IgG does not produce a significant 
downregulation of Aβ40.  
This is an important result as it is the first demonstration that the ability of 2B3 to 
reduce Aβ levels is transferrable from immortalised human cells to a primary mouse neuronal 
culture system. Thus, the antibody has been demonstrated to be effective in mouse neurons, 
suggesting that the application of the treatment to transgenic APP mutation models may be 
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equally successful in downregulating Aβ. Such a replication in vivo would open the possibility 
of assessing the effect of the antibody treatment on cognitive function, a central aspect of 
disease progression in humans. It is therefore an important measure against which to assess 
the potential utility of an anti-β-secretase cleavage site antibody to inhibit disease progression 
in transgenic APP mutation models.   
 
6.2 Experiment 15: The effect of 2B3 on cognition and Aβ levels 
6.2.1 Introduction 
The hypothesis relating to in vivo 2B3 administration predicts a reduction in both Aβ levels and 
associated Aβ-related behavioural deficits following treatment. In order to test this 
hypothesis, PDAPP mice were administered 2B3 and tested on the foraging task described in 
Chapter 5.  
Transgenic PDAPP mice aged 15 months of age were utilised in the current experiment 
for two interconnected reasons. Firstly, the treatment of AD at a time when the Aβ pathology 
is established represents more clinically relevant assessment than preventative treatment at a 
younger age, as AD diagnosis is not provided until the disease is established. Secondly, the use 
of aged transgenic mice offers model mice with AD-like symptoms in the form of a decline in 
cognitive function, allowing the assessment of potential changes on both biochemical and 
behavioural measures following 2B3 treatment. 
The general aim of Experiment 15 was to evaluate whether 2B3 could inhibit Aβ 
production in transgenic PDAPP mice as detected by a lowering of Aβ levels in the CNS. 
Furthermore, the ability of 2B3 to reduce spatial working memory deficits of aged transgenic 
PDAPP mice in the foraging task was assessed. Eighteen 9 month old transgenic and 22 wild 
type littermate control PDAPP mice were generously provided by Eli Lilly to support this work. 
At the starting point of the current experiment, the colony had aged to 15 months. However, 
due to high attrition, the number of transgenic PDAPP mice available to partake in the 
experiment had been reduced to 12. With such a low sample size, the experiment should be 
considered a pilot study.  
A central issue in immunotherapy which targets the CNS is access. The blood-brain 
barrier is a highly regulated membrane with tight junctions separating the central nervous 
system from the periphery. Whilst there are several transport routes across this barrier such 
as diffusion of lipid-soluble agents, receptor-mediated endocytosis and transport proteins 
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(Tam & Watts, 2010), the ability of IgG molecules to cross the membrane is a matter of 
debate. IgG levels in the CSF have been shown to be approximately 0.12% of that in serum 
(Felgenhauer, 1974). In order to assess the ability of 2B3 to inhibit β-amyloid production in 
vivo, it is essential that a method was adopted that ensured delivery of the antibody to its 
target, APP, within the CNS. Thus, a pilot experiment was carried out with the aim of assessing 
whether intracerebroventricular infusions using osmotic minipumps (Alzet, Cupertino, USA) 
could be used as a reliable method of antibody delivery to the brain.  
 
6.2.2 Method 
Design 
A pilot study comparing the intensity and pattern of mouse IgG-related staining obtained 
through intracerebroventricular infusions using osmotic minipumps was conducted. One 
mouse received infusions of 2B3, whilst a control mouse received PBS infusions. In addition, 
the infusion cannula was placed into the left lateral ventricle only, leaving the right 
hemisphere as a within-subject control. An increase in non-specific mouse IgG related staining 
around the infusion site due to a potential inflammatory response would be detectable in 
tissue from both conditions, whilst 2B3-specific staining would be limited to the 2B3 condition.  
In order to assess the effect of 2B3 on spatial memory in PDAPP mice, transgenic and 
wild type PDAPP mice were assessed in the 6-pot liquid version of the foraging task at 14 
months of age prior to the surgical fitting of osmotic minipumps to allow for pre- and post-
treatment performance measures. Transgenic mice were treated with 2B3 or a vehicle 
solution of differentiation media (DMEM/F 12 1:1, 1% FBS, 2% B27, 1% Penicillin, 1% 
Streptomycin, 1% Fungizone) concentrated and purified in an identical fashion to 2B3-
containing differentiation media. Treatment was continuous for 14 days before Aβ levels were 
measured. In addition, four wild type mice were treated with vehicle to assess whether the 
presence of the osmotic minipump would alter their performance in the foraging task. On the 
10th to the 13th day of treatment, spatial memory was assessed using the liquid reward version 
of the foraging task (see Chapter 5, Section 5.6.2). It was hypothesised that PDAPP transgenic 
mice treated with 2B3 would display lower Aβ levels than transgenic mice treated with vehicle 
and show an improvement in performance in the foraging task.  
 
Subjects 
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Two C57Bl/6 male mice aged 6 months were utilised in the osmotic minipump pilot study, with 
one mouse in each treatment condition.  
In the 2B3 treatment experiment, 19 wild type and 12 transgenic PDAPP (V717F) mice 
were assessed in the liquid version of the foraging task at 14 months of age (as reported in 
Chapter 5, Section 5.6.2). At 15 month of age, 12 male transgenic PDAPP mice underwent 
surgical fitting of osmotic minipumps. Half these mice were treated with 2B3 and half with 
vehicle. In addition, four wild type mice were treated with vehicle. Two of these wild type mice 
were utilised in biochemical analyses as negative controls.  
 
Apparatus and method for the osmotic minipump pilot 
2B3 was concentrated and purified to 1.35mg/ml, whilst PBS buffer served as the vehicle 
solution. Detailed methods relating to 2B3 production are outlined in Chapter 2, Section 2.3.  
 Treatments were administered using osmotic minipumps (Alzet, 1002) infusing 0.25µl 
of solution per hour continuously for 9 days. Pumps were filled and primed at 37oC overnight. 
Mice were anaesthetised with isoflurane carried by O2 during stereotaxic surgery. A 28G 
cannula from the brain infusion kit (Alzet, 0004760) was inserted into the left lateral ventricle 
at 3.4mm posterior, 10mm lateral and 3mm ventral from bregma. A 1.5cm long catheter 
linked the cannula to the pump positioned subcutaneously at the neck of the animal. 
Cyanoacrylate glue followed by dental cement secured the cannula to the skull before the 
wound was stitched. The mouse was given a subcutaneous injection of glucosaline to aid 
rehydration and was placed in a warm, secure environment to recover under monitoring. Mice 
were perfused on day 9 following surgery. 2B3 was detected in coronal sections by 
administering a 30 minute quench followed by a biotinylated anti-mouse IgG (Vector) at a 
concentration of 7.5µg/ml with 1% normal horse serum for 2 hours at RT. Incubation in the 
Dako Streptavidin ABC Complex and DAB staining was carried out as described in Section 4.3.2, 
Chapter 4. 
 
Apparatus and method for the assessment of the effect of 2B3 in vivo 
Assessment of spatial working memory as measured using the 6-pot liquid version of the 
foraging task was carried out described in Section 5.6.2, Chapter 5. Following 4 days of testing, 
mice were rested with ad libitum access to food and water for 3 days ensuring the return to ad 
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libitum weight prior to surgical fitting of osmotic minipumps. The minipumps were primed and 
implanted in an identical fashion to that described in the osmotic minipump pilot study 2B3 
was concentrated to 1.98mg/ml, with the vehicle solution consisting of differentiation media 
(DMEM/F 12 1:1, 1% FBS, 2% B27, 1% Penicillin, 1% Streptomycin, 1% Fungizone) 
concentrated and purified alongside 2B3. After 7 days of recovery, mice were water deprived 
to 95% of their body weight. On day 9 following surgery, mice were given one habituation 
session of 10 minutes in the arena with two baited pots. This was followed by 4 test days in 
the foraging task on day 10 - 13 following surgery using the same methodology as that 
adopted in the test days prior to surgery. After completing all behavioural testing, mice were 
given ad libitum access to water and food and culled for tissue collection fourteen days 
following surgery.         
 
Data collection and analysis for the assessment of the effect of 2B3 in vivo 
Performance in the foraging task was coded as described in Section 5.6.2, Chapter 5. Brain 
tissue was dissected to isolate the left cortex and hippocampus (as described in Section 4.2.2, 
Chapter 4), as these structures were located nearest the infusion site. Soluble and insoluble 
Aβ-40 and -42 were measured using ELISA (see Section 4.3.2, Chapter 4). 
 
6.2.3 Results 
Osmotic minipump administration pilot 
As can be observed from Fig. 6.2, infusion of 2B3 resulted in considerable intense staining 
around the infusion site than PBS infusions, in which only a limited increase in staining was 
detected. In addition, the mouse IgG staining in the 2B3 condition was detectable at large 
distances from the infusion site, with bilateral staining of subcortical structures including the 
hippocampus. No staining was evident throughout the cortex beyond the infusion site, 
including the frontal cortex. In contrast to the 2B3 condition, little staining was observed in the 
PBS infused tissue. At high magnification (x200), the staining in the 2B3 condition appears 
cellular, suggesting an internalisation of 2B3. This is not evident in the PBS condition, where 
the staining under high magnification is more general and appears to focus mainly on the 
extracellular matrix (Fig. 6.3).  
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A B 
No evidence of 2B3- or PBS-
related staining in the frontal 
cortex  
Stronger subcortical staining 
following 2B3 infusion compared 
to PBS infusion.   
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Fig. 6.2: Coronal sections of tissue infused with 2B3 (A) and PBS (B) via osmotic minipumps 
stained with an anti-mouse IgG secondary antibody. 
Staining in 2B3-infused tissue 
evident in the ventral 
hippocampus   
Staining in 2B3- and PBS-infused 
tissue is absent in the cortex, but 
is evident in the dorsal 
hippocampus and other 
subcortical structures in 2B3-
infused tissue   
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Fig. 6.3: Coronal section of cortical tissue infused with 2B3 (A) or PBS (B, C) using an osmotic 
minipump. A and B are comparable locations medial to the infusion site, whilst the PBS 
infusion site is displayed in C. All sections were stained with an anti-mouse IgG secondary 
antibody. 
 
Behavioural results 
One transgenic mouse was excluded from all analysis as an outlier due to performance scores 
being higher more than three times higher than the transgenic group mean. All variables were 
analysed using Mann Whitney U and Wilcoxon Signed Ranks for between and within-subject 
analyses respectively due to violations of the assumption of homogeneity of variance and 
normality which were not rectified by transformation. Mean and S.E.M. values for all 
conditions are presented in Tables 6.1-6.3.   
 
Control groups 
Firstly, the data were analysed to assess whether surgical implantation of osmotic minipumps 
altered wild type performance in the foraging task. Both between- and within-subject analysis 
of performance revealed no significant influence of osmotic minipumps infusing a vehicle on 
performance compared to pre-infusion performance or non-surgical wild type control mice 
(see Table 6.1). Thus, for comparison of transgenic and wild type performance, wild type mice 
were collapsed across control conditions.  
 
 
A B C 
5 µm 
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Variable 
Treatment 
difference  
  Within-subject changes 
 No pump WT Vehicle WT 
U p  U P U P 
Before 
treatment  
Error 22.50 0.718  
Before 
vs. 
During 
-1.01 0.331 -1.21 0.313 
Error first half of the trials 15.00 0.189  -0.80 0.425 -1.47 0.250 
Repeat error  21.00 0.600  -0.04 0.985 -1.21 0.313 
Repeat error first half of 
the trials 
24.00 1.000 
 -0.01 1.000 -1.00 1.000 
Consecutive error 22.00 0.786  -0.30 0.801 -1.30 0.375 
Consecutive error first 
half of the trials 
24.00 1.000 
 -0.45 1.000 -1.00 1.000 
During 
treatment 
Error 22.50 0.724       
Error first half of the trials 25.50 1.000       
Repeat error  24.50 0.885       
Repeat error first half of 
the trials 
24.00 1.000 
      
Consecutive error 16.00 0.250       
Consecutive error first 
half of the trials 
24.00 1.000 
      
Table 6.1: The test statistic and exact significance for between- and within-subject analysis of 
variables of wild type performance from the foraging task is presented analysed for treatment 
differences. No pump WT = 15, vehicle WT =4.  
 
Pre-treatment genotypic differences 
Secondly, performance scores at 14 months (before treatment scores) as first presented in 
Section 5.6.3, Chapter 5, Phase B were analysed for genotypic differences of each transgenic 
treatment condition compared to wild type controls. This was carried out to ensure the 
continued significance of the transgenic impairment on the foraging task compared to wild 
type littermates following the subdivision of the transgenic mice.  Between-subject analysis of 
genotypic differences was split by treatment, and revealed significant transgenic impairments 
on a subset of measures (see Table 6.2). The measures that remain sensitive to genotypic 
differences appear to be focused on the first half of the task, where the task difficulty is low 
compared to the second half.  
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Variable 
Difference compared to WT 
controls 
Tg 2B3 Tg Vehicle 
U P U P 
Before 
treatment  
Error 28.00 0.112 26.50 0.089 
Error first half of the trials 19.00 0.018 7.50 0.001 
Repeat error  28.50 0.119 22.50 0.045 
Repeat error first half of the trials 19.00 0.003 4.00 0.001 
Consecutive error 33.50 0.234 10.00 0.002 
Consecutive error first half of the trials 19.00 0.005 2.00 0.001 
Table 6.2: The test statistic and exact significance for between- and within-subject analysis of 
variables of wild type performance from the foraging task is presented analysed for treatment 
differences. WT n=16, Tg Vehicle n= 6, Tg 2B3 n=6. Significant differences are highlighted in 
bold.  
 
Analysis of treatment effects: Error 
(returning to a previously visited pot) 
Fig. 6.4A shows the average error scores of transgenic mice treated with 2B3 or vehicle prior 
to treatment, and following the surgical implantation of osmotic minipumps. Fig. 6.4B shows 
the errors during the first half of the trial. These suggest a decrease in error scores in 
transgenic mice treated with 2B3 that is not present in vehicle-treated mice.  
In terms of pre-treatment values, no significant differences between the transgenic 
groups were present for total error scores (U (6, 6) = 17.00, p > .05) or error scores in the first 
half of the trial (U (6, 6) = 14.50, p > .05). In terms of measures taken during treatment, 
statistical analysis did not detect any significant differences between 2B3 and vehicle-treated 
mice on error scores across trials (U (6, 6) = 15.00, p > .05) or during the first half of the trials 
when averaged across test days (U (6, 6) = 15.00, p > .05). Average values across test days with 
S.E.M.s are presented in Table 6.3. 
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Fig 6.4: The mean error scores across trials (A) and in the first half of the trials (B) at 14-15 
months of age for transgenic PDAPP mice prior to and during administration of 2B3 or vehicle. 
Error bars ±1 S.E.M.  
 
In order to analyse the potential within-subject change in error scores before and during 
treatment, vehicle and 2B3-treated transgenic mice were analysed separately. This analysis did 
not reveal any significant difference in the before and during treatment scores of vehicle-
treated transgenic mice across trials (χ2 (6) = -0.31, p > .0125) or in the first half of the trials (χ2 
(6) = -0.11, p >.0125). Similarly, 2B3-treated animals did not differ significantly between before 
and during treatment performance on either the across trials (χ2 (6) = -1.15, p >.0125) or first 
half measure (χ2 (6) = -1.58, p >.0125). Analysis of the within-subject change in performance in 
wild type mice treated with vehicle revealed no significant changes (Across trials: χ2 (4) = -0.73, 
p > .0125; in the first half of the trial: χ2 (4) = -1.09, p > .0125). Similarly, wild type mice who 
did not undergo osmotic pump fitting did not significantly alter their performance across the 
two test trials (Across trials: χ2 (14) = -0.60, p > .0125; in the first half of the trial:  χ2 (14) = -
1.02, p > .0125).  
Genotype Treatment 
Before treatment During treatment 
Error across 
trials 
Error in the first 
half of the trials 
Error across 
trials 
Error in the first 
half of the trials 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
Tg 2B3 5.29 0.84 1.46 0.40 4.04 0.78 0.71 0.25 
Tg      Vehicle 5.21 0.96 1.14 0.24 5.61 2.34 1.18 0.44 
WT      Vehicle 3.75 1.13 0.44 0.06 3.19 0.89 0.31 0.06 
WT     No pump 3.80 0.39 0.42 0.16 4.38 0.71 0.52 0.16 
Table 6.3: The mean error scores across trials and in the first half of the trials at 14-15 months 
of age for transgenic and wild type PDAPP mice prior to and during administration with 2B3 or 
vehicle.   
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Analysis of treatment effects: Repeat Error  
(returning to a previously visited pot more than once) 
In terms of pre-treatment values, no significant differences between the transgenic groups 
were present for total error scores (U (6, 6) = 16.50, p > .05) or error scores in the first half of 
the trial (U (6, 6) = 17.00, p > .05). As observed in the error scores, the trend for a reduction in 
repeat error scores during treatment with 2B3 (see Fig. 6.5) was not statistically significant 
compared to the performance of vehicle-treated mice across trials (U (6, 6) = 15.00, p > .05) or 
during the first half of the trials when averaged across test days (U (6, 6) = 16.00, p > .05). 
Average values with S.E.M. are presented in Table 6.4.  
 
Fig 6.5: The mean repeat error scores across trials (A) and in the first half of the trials (B) at 14-
15 months of age for transgenic PDAPP mice prior to and during administration of 2B3 or 
vehicle. Error bars ±1 S.E.M. 
 
Within-subject analysis of changes in behaviour following administration of 2B3 or vehicle did 
not detect any significant differences between pre- and post-treatment in any condition. 
Specifically, vehicle-treated mice did not significantly alter their levels of total repeated error 
scores (χ2 (6) = -0.11, p > .05) or repeated errors in the first half of the task (χ2 (6) = -0.74, p > 
.05). Similarly, 2B3-treated mice showed no significant changes in total repeated error scores 
(χ2 (6) = -1.58, p > .05) or repeated errors in the first half of the trials (χ2 (6) = -1.84, p > .05). 
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Genotype Treatment 
Before treatment During treatment 
Repeat error 
across trials 
Repeat error in 
the first half of 
the trials 
Repeat error 
across trials 
Repeat error in 
the first half of 
the trials 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
Tg 2B3 2.32 0.64 0.54 0.21 1.07 0.32 0.18 0.12 
Tg      Vehicle 2.21 0.68 0.36 0.11 2.68 1.23 0.43 0.29 
WT      Vehicle 1.38 0.58 0.00 0.00 0.88 0.33 0.00 0.00 
WT     No pump 1.10 0.25 0.08 0.06 1.17 0.34 0.07 0.05 
Table 6.4: The mean repeat error scores across trials and in the first half of the trials at 14-15 
months of age for transgenic and wild type PDAPP mice prior to and during administration 
with 2B3 or vehicle.   
 
Analysis of treatment effects: Consecutive Error 
(returning to a previously visited pot twice or more without visiting any other pots in 
the interval between those errors) 
Prior to administration of 2B3 or vehicle, the two transgenic groups did not differ in total error 
scores (U (6, 6) = 13.50, p > .05) or error scores in the first half of the trial (U (6, 6) = 16.00, p > 
.05). During treatment, no significant reduction in consecutive error scores was observed in 
2B3-treated compared to vehicle-treated mice in total consecutive error scores (U (6, 6) = 
12.00, p > .05) or during the first half of the trials when averaged across test days (U (6, 6) = 
15.00, p > .05; see Fig. 6.6). Average values with S.E.M.s are presented in Table 6.5.  
 
Fig. 7.6: The mean consecutive error scores across trials (A) and in the first half of the trials (B) 
at 14-15 months of age for transgenic PDAPP mice prior to and during administration of 2B3 or 
vehicle. Error bars ±1 S.E.M. 
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No significant within-subject changes were detected for vehicle or 2B3-treated transgenic 
mice in the total consecutive error scores [Vehicle: (χ2 (6) = -0.68, p > .05) 2B3: (χ2 (6) = -0.74, p 
> .05)] or the consecutive errors scores isolated from the first half of the task [Vehicle: (χ2 (6) = 
-1.16, p > .05) 2B3: (χ2 (6) = -1.84, p > .05)].  
Genotype Treatment 
Before treatment During treatment 
Consecutive 
error across 
trials 
Consecutive 
error in the first 
half of the trials 
Consecutive 
error across 
trials 
Consecutive 
error in the first 
half of the trials 
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M. 
Tg 2B3 0.89 0.39 0.43 0.19 0.36 0.12 0.07 0.07 
Tg      Vehicle 1.21 0.41 0.29 0.07 1.14 0.48 0.39 0.30 
WT      Vehicle 0.25 0.10 0.00 0.00 0.13 0.13 0.00 0.00 
WT     No pump 0.38 0.11 0.03 0.02 0.37 0.11 0.07 0.05 
Table 6.5: The mean consecutive error scores across trials and in the first half of the trials at 
14-15 months of age for transgenic and wild type PDAPP mice prior to and during 
administration with 2B3 or vehicle.   
 
Biochemical results 
Analysis of treatment effects: Cortex  
Measures of soluble Aβ40 and Aβ42 extracted from the left (treated) cortex are presented in 
Fig. 6.7, with insoluble values presented in Fig. 6.8. With a high level of individual variability in 
Aβ levels in transgenic mice regardless of treatment condition, there is no evidence of a 
systematic lowering of Aβ levels in 2B3-treated compared to vehicle-treated transgenic mice. 
Statistical analysis confirmed that neither soluble Aβ40 (U (6, 6) = 11.00, p > .05) nor Aβ42 (U 
(6, 6) = 11.00, p > .05), nor insoluble levels of cortical Aβ40 (U (6, 6) = 15.00, p > .05) or Aβ42 
(U (6, 6) = 15.00, p > .05) levels differed significantly in transgenic mice following 2B3/vehicle 
administration.  
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Fig. 6.7: Aβ40 and Aβ42 soluble values (pg/mg of total protein) from the left cortex of 2B3-and 
vehicle-treated PDAPP mice displayed as individual values with the mean denoted as a black 
line. Tg = transgenic, WT = wild type.  
 
  
Fig. 6.8: Aβ40 and Aβ42 insoluble values (pg/mg of total protein) from the left cortex of 2B3 
and vehicle-treated PDAPP mice displayed as individual values with the mean denoted as a 
black line. Tg = transgenic, WT = wild type.  
 
Analysis of treatment effects: Hippocampus 
Hippocampal measures of soluble Aβ40 and Aβ42 are presented in Fig. 6.9, with insoluble 
values presented in Fig. 6.10. As with cortical measures, statistical analysis provided no 
evidence for a lowering of Aβ levels in transgenic mice treated with 2B3 as compared to 
transgenic mice treated with vehicle [soluble Aβ40 (U (6, 6) = 11.00, p > .05; soluble Aβ42 (U 
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(6, 6) = 11.00, p > .05; insoluble Aβ40 (U (6, 6) = 15.00, p > .05; insoluble Aβ42 (U (6, 6) = 15.00, 
p > .05]. 
   
Fig. 6.9: Aβ40 and Aβ42 soluble values (pg/mg of total protein) from the left hippocampus of 
2B3 and vehicle-treated PDAPP mice displayed as individual values with the mean denoted as 
a black line. Tg = transgenic, WT = wild type.  
 
  
Fig. 6.10: Aβ40 and Aβ42 insoluble values (pg/mg of total protein) from the left hippocampus 
of 2B3 and vehicle-treated PDAPP mice displayed as individual values with the mean denoted 
as a black line. Tg = transgenic, WT = wild type.  
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The relationship between Aβ levels and behavioural measures 
Non-parametric correlations were used to assess whether a relationship could be detected 
between measures of spatial working memory during treatment and Aβ pathology assessed by 
ELISA. As can be seen in Table 6.6, cortical measures of soluble Aβ40 were found to correlate 
positively with a subset of performance measures. In contrast, no significant relationship was 
observed between measures of spatial working memory in the foraging task and further 
measures of Aβ pathology. 
Variable (during 
treatment) 
Cortex 
Sol 
Aβ40 
Cortex 
Sol 
Aβ42 
Cortex 
Insol 
Aβ40 
Cortex 
Insol 
Aβ42 
HPC Sol 
Aβ40 
HPC 
Sol 
Aβ42 
HPC 
Insol 
Aβ40 
HPC 
Insol 
Aβ42 
Error 0.443 0.137 0.125 0.262 0.229 0.015 -0.132 0.023 
Error first half of the 
trials 
0.406 0.219 0.176 0.191 0.125 0.250 0.058 0.024 
Repeat error  0.357 0.109 0.063 0.190 0.264 0.171 -0.229 -0.047 
Repeat error first 
half of the trials 
0.520 0.148 0.342 0.318 0.074 0.074 0.178 0.082 
Consecutive error 0.493 0.001 0.202 0.282 0.230 -0.033 -0.184 -0.025 
Consecutive error 
first half of the trials 
0.270 0.045 0.368 -0.165 -0.180 0.090 0.240 -0.066 
Table 6.6: Overview of the relationship between performance measures in the foraging task 
and ELISA measures of Aβ pathology as tested using Kendall’s tau (τ). Significant correlations 
are highlighted in bold (p < .05). Sol = soluble, Insol = insoluble, HPC = hippocampus.   
 
6.2.4 Discussion 
The results from the administration pilot study indicate that intracerebroventricular infusion 
using osmotic minipumps offers a successful route of 2B3 administration. After 9 days of 
continuous infusion, 2B3 was detectable bilaterally across the subcortical structures, with no 
such staining evident in the PBS condition. Furthermore, whilst the administration method 
involved invasive surgery, animals tolerated the procedure exceptionally well and pilot work 
carried out at a different time point indicated no changes in behaviour or willingness to 
engage with behavioural tasks in animals with an osmotic minipump in place (data not shown).  
The biochemical and behavioural results from Experiment 15 are in accordance with 
each other, with neither outcome measure identifying a significant effect of 2B3 
administration. In terms of behavioural measures, no significant within-subject or between-
subjects changes were observed, and measures of cortical and hippocampal Aβ levels did not 
reveal significant downregulation of Aβ in 2B3-treated mice compared to those receiving 
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vehicle. Aβ pathology appears to be positively related to a number of measures of spatial 
working memory performance, although this effect was restricted to cortical Aβ40. A larger 
sample size may have aided detection of connections between these measures.     
There are a number of limitations with the present pilot study that may have 
influenced the pattern of results. Firstly, the sample size is a serious limitation, with low 
numbers in each treatment condition. However, it was considered a necessary and informative 
initial step in the evaluation of the antibody on a mouse line that displayed a robust 
behavioural phenotype. Nevertheless, it must be acknowledged that the low number of 
subjects limits the statistical power available to detect potential treatment effects. There are 
some interesting   numerical trends in the behavioural data that warrant comment.  
Consistently across the foraging task measures, and in particularly those from the first 
half of the test, the performance level of 2B3-treated transgenic mice is numerically very 
similar to wild type level. This was not the case for vehicle-treated transgenic mice, and 2B3-
treated mice consistently made fewer errors than vehicle-treated mice. It is therefore possible 
that with an increased sample size, the behavioural pattern of improved performance in the 
foraging task in PDAPP mice treated with 2B3 would achieve reveal significant treatment 
effects. To investigate this, a post hoc power analysis carried out using StudySize2.0. Analysis 
indicated that on the basis of within-subject average error scores, the power of the present 
experiment  was .31. Whilst this provides evidence that the current study is seriously 
underpowered, it is important to note that an increase in the sample size does not necessarily 
mean that the result would be significant. 
A second factor that is worth considering is that of the age of the animals. The pre-
treatment deficit in spatial working memory of transgenic mice may have been more 
pronounced had the cohort been older at testing. Whilst 14 month old wild type mice 
significantly outperformed transgenic mice in the foraging task, a larger numerical difference 
in performance scores would have offered a larger window of opportunity to detect significant 
treatment effects of varying magnitude. As a parallel to this point, Aβ pathology in 15 month 
old PDAPP transgenic mice was surprisingly low, with a high level of variability. This raises the 
possibility that a floor effect could mask treatment effects of 2B3. Verification of these results 
was sought both through re-genotyping and ELISA testing of samples at a range of 
concentrations, confirming accurate genotyping and assay sensitivity. As with the phenotypic 
profile of cognitive deficits, it is possible that further aging of the cohort would have resulted 
in higher levels of Aβ against which one could evaluate treatment effects. 
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 In addition, questions have been raised regarding intracerebroventricular infusions 
and its status as a direct delivery method to the CNS. Pardridge (2005) points both to the slow 
diffusion of drugs to the brain parenchyma and the rapid absorption of substances in the CSF 
into the bloodstream to suggest that intracerebroventricular infusion should be classified as 
slow intravenous infusion as opposed to a direct delivery method to the CNS. Clearly, an 
antibody which does not reach its target cannot be expected to influence the processing of 
that target. However, pilot work showing a distribution of 2B3 across the infused hemisphere 
suggests success of delivery despite limitations of the speed of diffusion. Whilst 
immunohistochemical methods do not allow for assessment of the concentration of 2B3 in 
perfused brain tissue, the intensity of the staining indicates that a considerable volume of 2B3 
was present in the hemisphere following 9 days of continuous infusion. It is therefore unlikely 
that delivery problems were an issue.  
The duration of treatment in the current study was restricted as a result of the 
administration method. As such, the pilot study should be viewed as an acute treatment study. 
It is possible that significant treatment effects would have been detected had subjects 
received 2B3/vehicle administration for a longer period of time. Furthermore, it should be 
noted that wild type mice did not receive 2B3 infusion in the current study. As as pilot study, 
transgenic mice served as subjects in order to assess whether the administration of 2B3 would 
alter biochemical or behavioural measures in a system over-expressing APP and Aβ, as 
lowering Aβ levels in a healthy, balanced system such as wild type mice may be detrimental. In 
future work, the addition of 2B3-treated wild type controls would be desirable in order to 
assess whether any potential effect of 2B3 in transgenic mice is specific to elevation of Aβ 
levels as opposed to acting through a non-specific process comparable in wild type and 
transgenic mice.      
 
6.3 Conclusion 
This chapter investigated whether 2B3, an anti-APP β-secretase cleavage site antibody, could 
lower Aβ levels in primary murine neurons and whether such an effect could be replicated in 
vivo.  Importantly, the effects of 2B3 on cognitive deficits in aged, transgenic PDAPP mice was 
also assessed, as potential AD therapeutics require alterations at the biochemical level to 
translate to cognitive and behavioural symptoms in order to be considered effective. 
Experiment 14 replicated the findings of Thomas et al. (2011) in demonstrating the ability of 
2B3 to downregulate Aβ in vitro, and further established that such effects of 2B3 are not cell-
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specific. Experiment 15 established the ability of osmotic minipumps to successfully deliver 
murine IgGs to the CNS, thereby bypassing potential restriction of access as determined by the 
BBB. In addition, the first attempt at assessing the effects of 2B3 in vivo was presented. 
Despite demonstrations of a downregulation of Aβ levels in primary murine neuronal culture, 
the lack of treatment effects of 2B3 in vivo does not support the hypothesis that an anti-APP 
β-secretase cleavage site antibody can lower Aβ pathology and associated cognitive deficits. 
To date, no study has showed a lowering of both Aβ levels and cognitive deficits, with 
the only in vivo demonstration of the effect of an anti-APP β-secretase cleavage site antibody 
coming from Rakover et al. (2007). They succeeded in lowering impairments in novel object 
recognition following preventative, systemic administration of treatment with an 
accompanying reduction in inflammatory markers. Despite this, no Aβ-related alterations were 
observed. This indicates that alterations in Aβ pathology detectable using traditional ELISA and 
immunohistochemistry are not a necessary prerequisite to alterations in cognitive function. It 
follows therefore that anti-APP β-secretase cleavage site antibodies could provide benefits in 
terms of cognitive function following only small alterations in Aβ levels, as the synaptic deficit 
theory of AD would predict. This interpretation is in line with results from studies by Janus et 
al. (2000) and Morgan et al. (2000) who detected a reduction in spatial reference memory 
deficits in transgenic mice following active immunisation with Aβ42, but observed only limited 
alterations in Aβ levels. Similarly, passive immunisation studies using transgenic mouse models 
have encountered a parallel trend with a number of studies establishing ameliorating effects 
on cognitive deficits with smaller or non-detectable effects on Aβ pathology, particularly if the 
treatment duration was reduced to 1-2 months  (Dodart et al., 2002; Wilcock et al., 2004).  
 There are a number of limitations of the in vivo experiment described in the current 
chapter. These include a limited sample size, a lack of range in terms of administration 
methods, duration of treatment, and the age of treated mice. In addition, alternative 
biochemical and behavioural outcome measures assessing the wider effects of 2B3 
administration would be informative. Despite these limitations, a non-significant numerical 
trend was observed in the behavioural data with 2B3-treated mice showing indications of 
potential changes in spatial working memory following exposure to the antibody, despite the 
limited treatment period. Thus, the pilot study investigating the effects of 2B3 in transgenic 
PDAPP mice offers an interesting starting point for the further assessment of 2B3 in vivo. The 
potential future directions of this work will be discussed further in Chapter 7.  
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Chapter 7 
  
General Discussion 
7.1 Overview 
The main goal of this thesis was to provide a characterisation of two transgenic APP murine 
models of Aβ pathology with the aim of assessing the effect of 2B3, an anti-APP β-secretase 
cleavage site antibody, on Aβ pathology and associated cognitive deficits in these models. A 
brief overview of the results is provided followed by a more detailed description and 
discussion of the research findings. 
 
7.2 Summary of findings 
Currently available treatments for AD are symptomatic only, and do not succeed in altering 
disease progression in terms of age-related neurodegeneration or decline in cognitive 
function. Pre-clinical studies using transgenic mouse models of AD-like pathology have 
successfully lowered Aβ levels by targeting various steps in the Aβ cascade of pathology, but 
several of these approaches have either not translated successfully to clinical trials or could 
have a number of serious side effects due to a lack of specificity in the selected targets. Due to 
the large-scale health problem AD poses to society, there is great need for the development of 
novel disease-modifying treatments.  
An anti-APP β-secretase cleavage site antibody (2B3) which is able to reduce Aβ levels 
in vitro could provide a disease-modifying treatment with fewer of the side effects observed in 
pre-clinical studies and human trials. Recent work has shown downregulation of Aβ levels in 
human non-neuronal cell lines following 2B3 administration (Thomas et al., 2011). It was 
therefore hypothesised that 2B3 administration in vivo would limit β-secretase processing of 
APP, lower Aβ levels in the CNS and reduce cognitive impairments. Prior to evaluating this 
hypothesis, it was necessary to identify and characterise a suitable APP transgenic mouse 
model. The London APP(V717I) and the PDAPP (V717F) models of AD-like pathology were 
characterised with the aim of identifying cognitive decline that could be related to escalating 
Aβ pathology with age. The work presented in this thesis is therefore based on two main 
hypotheses. Firstly, that aging of transgenic APP mutation mice would lead to impairments in 
measures of cognitive function associated with elevations of Aβ levels and secondly, that 
administration of 2B3 to aged transgenic mice would lower both Aβ levels and cognitive 
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impairments. The results of these investigations lend only partial support to the first of these 
predictions.   
The analysis of anxiety-like behaviour in APP(V717I) mice as described in Chapter 2 
aimed at establishing a developmental profile to assess whether potential genotypic 
differences were age-related. Due to the lack of available information regarding the influence 
of gender on phenotypic expression of genotypic differences, both male and female 
APP(V717I) mice were included throughout both behavioural and biochemical analyses. The 
results contradicted earlier reports of increased anxiety levels in transgenic mice, with wild 
type mice consistently displaying more anxiety-like behaviours than transgenic mice across 
age in two separate tasks. The contribution of gender was task-specific and largely 
independent of genotype, with female mice displaying lower anxiety levels than males in the 
marble burying task only. It was suggested that the differences in the pattern of results 
compared to available literature was most likely due to changes in the genetic background 
strain. Importantly, the emergence of anxiety deficits in transgenic mice at 3 months of age, 
prior to the development of Aβ pathology, suggested the influence of APP overexpression on 
marble burying and elevated plus maze performance. It was therefore necessary to widen the 
behavioural characterisation in order to identify an age-related cognitive phenotype in the 
APP(V717I) model against which 2B3 could be assessed.  
 Chapter 3 describes a set of experiments designed to detect potential transgenic 
deficits in spatial working memory, spatial references memory and object recognition 
memory. Moechars et al. (1999b) identified a spatial reference memory deficit at 3-6 months, 
but the developmental effects of the APP(V717I) mutation on spatial cognition were unknown. 
Across various age points and three tasks, there is little evidence to suggest that the 
APP(V717I) leads to impairments in spatial memory. On the T-maze, 11 month old transgenic 
mice outperformed wild type littermate controls, and inferior transgenic performance on 
selected variables in the foraging task at 6 months can be considered at best transient and 
task-specific. Furthermore, no genotypic differences in object recognition memory were 
detected. It was concluded that aging to 18 months of age did not result in impairments in 
spatial and object recognition memory in APP(V717I) transgenic mice on a C57Bl/6 
background. This pattern of results may indicate that areas of the temporal and frontal lobe 
are not functionally impaired in this model. This interpretation is based on a combination of 
control experiments reported in Chapter 3, in which hippocampal lesioned mice were found to 
be impaired on the RAWM and the T-maze non-matching to position task, as well as 
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interpretation of published literature. The hippocampus is likely to be implicated in the 
foraging task given the spatial nature of the task in combination with evidence that 
performance is disrupted by lesions to the hippocampus in pigeons (Pearce et al., 2005). The 
T-maze non-matching to position paradigm has been shown to be sensitive to the prefrontal 
cortex in rats, indicating a similar sensitivity might be present in mice (Dias & Aggleton, 2008). 
In contrast, the contribution of the prefrontal cortex to performance on the foraging task has 
not been evaluated. A validation study of the foraging task using hippocampal and prefrontal 
manipulations would be desireable, and add strength to the conclusion that APP(V717I) mice 
do not display functional impairments in the hippocampus or prefrontal cortex. The lack of 
deficit in the object recognition task further underlines the intact nature of the medial 
temporal lobe in terms of the perirhinal cortex in this model. If one were to draw parallels to 
cognitive assessments of patients, the types of cognitive functions assessed across these tasks 
could be said to broadly relate to recognition and recall of objects and space, over long or 
short periods of time. It is possible that the differences in anxiety as reported in Chapter 2 
could influence the performance in the tasks described. However, the use of both appetitive 
(T-maze, foraging task) and aversive (RAWM) task motivation should limit the degree to which 
such differences influence the overall performance profile. Furthermore, habituation for 
appetitive tasks was conducted until wild type mice, the more anxious of the genotypes, were 
reliably interacting with the testing apparatus without indication of fearfulness. Furthermore, 
it is unlikely that the longitudinal nature of testing in the foraging task would attenuate a 
cognitive deficit given that the task is one in which performance rather than acquisition is the 
outcome measure. Furthermore, the exact pattern of actions for successful performance is 
different on each trial, such that the effect of repeated testing is minimised. In light of these 
points, it is argued that the lack of cognitive deficits in APP(V717I) mice described in Chapter 3 
are not artefacts of the choice of tests or the nature of testing.   
 The developmental profile of Aβ pathology in APP(V717I) was investigated in Chapter 
4 in an attempt to inform the lack of age-related cognitive changes observed in the 
behavioural assays described in Chapter 2 and 3. Interestingly, there was evidence of elevated 
levels of Aβ in female transgenic mice compared to age-matched transgenic males. This is a 
common observation in the transgenic APP mutation model literature (Sturchler-Pierrat and 
Staufenbiel, 2000; Bayer et al., 2003; Callahan et al., 2001; Lewis et al., 2001; Wang et al., 
2003; Schuessel et al., 2004; Schafer et al., 2007) which mirrors a trend in the current work 
towards female transgenic mice displaying a stronger behavioural phenotype than males. In 
terms of the developmental profile of Aβ pathology, the APP(V717I) model does not lead to 
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elevation of Aβ levels in transgenic males until 18 months, with females showing a comparable 
level at 12 months. This is relatively late compared to more established models such as the 
Tg2576 (Kawarabayashi et al., 2001; Westerman et al., 2002), and could explain the absence of 
detectable cognitive deficits prior to 12 months of age. However, several assessments of 
cognitive function were carried out between 14-19 months of age without transgenic deficits 
emerging. Overall, the results from Chapter 4 indicate that the level of Aβ pathology 
developed by 18-19 months of age in APP(V717I) transgenic mice on a C57Bl/6 background is 
not sufficiently extensive to disrupt spatial and/or object recognition memory. Interpreted in 
the context of the amyloid cascade hypothesis, the APP(V717I) model does not support the 
notion that elevation in Aβ levels is sufficient to initiate the pathological cascade resulting in 
cognitive decline when modelled in the mouse, possibly due to an interaction between 
protective features of the genetic background and the level of APP overexpression. The lack of 
an age-related behavioural phenotype in the APP(V717I) model highlighted the necessity for 
introducing an alternative APP transgenic model to the project.  
 Chapter 5 focused on the behavioural characterisation of the PDAPP APP(V717F) 
model of AD-like pathology. Whilst transgenic mice did not differ from wild type controls at 12 
months of age on a measure of object recognition memory, genotypic differences were 
detected in both spatial tasks. A decrease in performance from 11 to 14 months of age 
indicated that the foraging task was sensitive to age-dependent deficits in cognitive function in 
transgenic PDAPP mice. Table 7.1 summarises the range of behavioural assessments carried 
out on both the APP(V717I) and the PDAPP model, and the presence or absence of transgenic 
deficits on each task.  
Psychological/cognitive 
construct 
Test 
APP(V717I) PDAPP(V717F) 
Deficit Age  Deficit Age  
Anxiety-like behaviour  
EPM √ 3/6/19m √ 9.5m 
Marble burying √ 3/6/19m √ 9.5m 
Spatial working memory 
Foraging task × /√/× 3/6/19m √ 11/14m 
T-maze FCA × 11m √ 10m 
Spatial reference memory Radial Arm Water Maze × 10m n/a n/a 
Object recognition memory Object recognition × 18m ? 12m 
Table 7.1: Summary of the impact of APP overexpression and/or Aβ pathology on cognition 
and behaviour in transgenic APP mutation mice as detected using a range of tasks in the 
current thesis.  √ = pathology or APP overexpression causes deficit in the given task. × = no 
difference between transgenic and wild type mice on performance in the given task. ? = 
limited conclusions can be drawn due to poor wild type performance. n/a = not applicable as 
the task was not administered.  
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With a behavioural paradigm which is sensitive to PDAPP transgenic deficits, it was possible to 
assess the effect of 2B3 on cognitive decline and Aβ levels in aged transgenic mice, as 
described in Chapter 6. The ability of 2B3 to modulate Aβ pathology using murine neurons was 
established prior to intracerebroventricular infusions. Thus, proof of principle was obtained 
that 2B3 had the desired effect in cells comparable to those in the CNS of PDAPP mice. Despite 
this, acute treatment of 2B3 in aged transgenic mice at a point where cognitive decline was 
established did not result in significant changes in behaviour or Aβ levels. As this does not lend 
support to the prediction that 2B3 will alter Aβ pathology and associated cognitive deficits in 
APP mice, one is required to accept the null hypothesis that 2B3 was ineffective in vivo.  
The lack of an effect of 2B3 in vivo could be based on experimental issues that resulted 
in sub-optimum conditions for the detection of significant effects. These include the 
concentration of 2B3, the duration of treatment, the administration method, the assay 
sensitivity to changes in Aβ concentration and the task sensitivity to changes in cognitive 
functioning. Perhaps most importantly, the limited sample size would have considerably 
reduced the statistical power. The second potential explanation for the lack of significant 
change following 2B3 treatment surrounds the efficacy of the antibody itself. The efficacy of 
2B3 could be reduced if it was inhibited from binding APP at the cell surface, or was not 
internalised with APP to allow steric hindrance of β-secretase at the multiple intracellular 
sites, such as the endosomal/lysosomal system, where this cleavage is thought to occur 
(Thomas et al., 2006; Haas et al., 1992; Koo & Squazzo, 1992; Hartmann et al., 1997). However, 
the success reported by Rakover et al. (2007) in demonstrating biochemical and behavioural 
changes following administration of an anti-APP β-secretase antibody argues against such an 
interpretation. 
It is important to highlight that the work with evaluating 2B3 in vivo is in its initial 
stages, and that the distance from pre-clinical studies to treatment of AD patients is clearly 
great. Beyond optimising conditions for the detection of significant effects of 2B3 in vivo, a 
number of challenges require attention. These include the degree of immune system 
activation and inflammation following 2B3 treatment and other potential side effects, the 
challenge of humanising the antibody, the administration method in human patients, the point 
in disease progression at which the treatment should be delivered to have optimum effect and 
the dosing regime in order to achieve safe efficacy. There are strong trends in the AD field that 
indicate that early intervention is considered key to clinical trial success, an approach which is 
supported by the continuing increase in focus on early biomarkers of AD to aid early diagnosis 
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or preventative treatment. The methods of administration in patients will clearly require 
another approach than surgical implantation as is possible in preclinical models. Whilst the 
degree to which antibodies can naturally pass the blood-brain-barrier is under discussion, the 
technical advances in bioengineering are demonstrating that bispecific antibodies (Atwal et al. 
(2011) and peptides capable of carrying large, hydrophobic cargo across the blood-brain-
barrier (Skrlj et al., 2012). Such advances should be utilised by the AD research community to 
optimise peripheral administration of antibody therapies. Overall, there are substantial issues 
which will require attention should the antibody prove promising in pre-clinical work. 
Nevertheless, as a first step in a pre-clinical pilot, Experiment 15 offers some encouraging 
numerical trends.  
 
7.3 Theoretical Implications 
The utility of transgenic mutation models of AD-like pathology 
The two APP mutation models analysed in this thesis are based on familial autosomal 
mutations in the same gene. Nevertheless, the profile of behavioural changes induced by the 
mutations is very different in the two lines. Whilst the PDAPP(V717F) model develops deficits 
in spatial working memory which were age-dependent, no such robust or age-related deficits 
were detected in the APP(V717I) model. The variety in the phenotypic expression of familial 
autosomal APP mutations in transgenic mouse models suggests that transgenic mouse models 
of AD-like pathology suffer from a level of variability that threatens their validity in the pre-
clinical field. To support this argument, the genetic background strain on which the mutations 
are maintained have repeatedly been shown to strongly influence the phenotypic profile both 
in terms of behavioural deficits and pathological hallmarks of disease (Crawley et al., 1997; 
Võikar et al., 2001; Savonenko et al., 2003). Indeed, the numerous transgenic models vary in 
promoters, genetic background and the number and location of mutations. Nevertheless, they 
represent the most clinically relevant pre-clinical disease models available to the field and 
have been invaluable in examining AD-related disease progression, the temporal relationship 
between Aβ/tau aggregation and cognitive decline, the utility of intervention at varying stages 
of disease progression and the relationship between Aβ levels in the CNS and the plasma 
(Chapman et al., 1999; Oddo et al., 2003; Tanzi, 2005; Walsh et al., 2002; Mucke et al., 200; 
Klein, Krafft & Finch, 2000). In addition, the ability to isolate disease-related factors such as Aβ 
and tau pathology in separate models allows for the assessment of their individual 
contributions in the absence of any potential bilateral escalation. It has therefore been argued 
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that transgenic APP mutation mouse models of AD-like pathology are highly valuable for the 
pre-clinical study of disease mechanisms and progression, as well as the evaluation of novel 
therapeutic interventions (Wilcock et al., 2004; 2006; Schenk et al., 1999; Janus et al., 2000; 
Rakover et al., 2007; Eriksen & Janus, 2007). Essential to the successful use of transgenic 
models, however, is the careful analysis and selection of a model which best replicates the 
aspects of disease under consideration. 
 Whilst mouse models of AD-pathology have clear value, it is worth highlighting the 
issues in translating preclinical research to the patient population. Clearly, there are great 
species differences between mouse and man which place basic limitations on the degree to 
which preclinical conclusions can be applied to patients. Further discrepancies between 
transgenic mouse models of AD pathology and human patients emerge due to the way in 
which the transgenic mouse models are generated. Overexpression of APP is not a known 
feature of AD (with the exception of trisomy 21) and the subsequent Aβ pathology in mice 
could differ from human AD in important, aetiological ways. Indeed, overexpression of wild 
type APP has been shown to be sufficient to cause comparable cognitive deficits to those of 
mutant APP overexpression (Moechars et al., 1999b). This indicates that there are phenotypic 
elements to the transgenic mouse models which are a biproduct of model generation rather 
than a translationally-relevant disease feature. Furthermore, the lack of a mouse model which 
encompasses the full spectrum of AD pathology, including extensive neuronal loss with age, 
may be an important limitation if the interaction between separate pathological features is 
important for understanding drug effects in humans.  
 The nature of the behavioural outcome measures in preclinical work are also likely to 
differ from those used in clinical trials. The choice of task used to measure animal cognition in 
preclinical work are based on an attempt to measure dysfunction of specific area of the brain 
and/or a particular psychological construct which is relevant to the disease studied. However, 
these tasks have emerged from the animal literature in general rather than as specific 
preclinical tools in drug discovery and disease-related work, and as such do not necessarily 
have implicit translational value. Indeed, a number of the tools used as primary endpoints [e.g. 
Alzheimer’s Disease Assessment Scale-cognition (Rosen, Mohs & Davis, 1984); Clinician 
Interview Based Impression of Severity-plus (Schneider et al., 1997); Blessed Dementia Scale 
(Erkinjuntti, Hokkanen, Sulkava & Palo, 1988) in clinical trials are heavily focused on the 
proficient use of language, with recall and recognition tasks often being word based or 
involving the naming of household objects. Clearly, the assessment of cognitive function using 
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language is not a translationally relevant concept. Other measures are based on the ability to 
function in daily living (such as turning on and off lights, self-feeding and maintaining hygiene 
standards). The measurement of deficits in spatial cognition is limited to the drawing of 
geometric shapes and limited questions regarding the ability of the patient to navigate familiar 
locations such as the neighbourhood and their homes. This spatial navigation can be more 
clearly linked to tasks such as water maze paradigms assessing spatial reference memory, but 
serve only a small part of patient assessment. Another aspect of patient testing which it may 
be possible to translate to preclinical work is the measurement of long term, autobiographical 
recall related to episodic memory (see Section 7.4 for a further discussion on the assessment 
of episodic memory in rodents). Overall, one could argue that the discrepancy between the 
results of clinical trials and preclinical data may be related to a discrepancy between the types 
of cognitive and behavioural testing carried out at the two stages of drug assessment.    
 
Age-independent deficits in APP Models 
As referred to in previous chapters, is important to establish the developmental profile of 
cognitive deficits in APP mutation mouse models of Aβ pathology prior to their use in pre-
clinical studies. APP mutation models are based on the hypothesis that the overexpression of 
APP leads to elevated levels of Aβ with age, which is causative in the emergence of 
behavioural deficits. Due to the confounding variable of APP overexpression, it is problematic 
to link cognitive impairments with elevation of Aβ without analysing the temporal nature of 
the behavioural deficits. As observed in Chapters 2 and 3, an anxiety deficit in APP(V717I) mice 
was detected at 3 months, an age where ELISA and immunohistochemical methods do not 
detect Aβ pathology. The lack of escalation of that deficit with age, as also observed in the 
foraging task, makes a stronger case for the causative role of APP overexpression as opposed 
to increases in Aβ concentration. This highlights the need to assess the change in cognitive 
function with age in APP models. In addition, the use of control wild type mice overexpressing 
endogenous APP offers a method for dissociation of APP- and Aβ-driven behavioural changes. 
Indeed, Moechars et al. (1999b) demonstrated that both APP(V717I) transgenic and wild type 
APP overexpressing mice showed a similar profile of anxiety deficits and spatial reference 
memory impairments that was not present in non-overexpressing wild type mice. It is argued 
that a more widespread use of control mice overexpressing endogenous APP would offer an 
improvement of the current project, in addition to being beneficial to the field in general.  
Immunotherapy as a treatment option for AD 
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If one accepts the proposal that a replication of Experiment 15, in which the conditions of 2B3 
efficacy are optimised, would reveal improved memory in PDAPP mice, then along with the 
study conducted by Rakover et al (2007), this could be an important innovation in the field of 
immunotherapy for AD. The initial enthusiasm in the field regarding immunotherapy for AD 
was tempered by the failed clinical trials (Orgogozo et al., 2003; Nicholl et al., 2003; Pfeifer et 
al., 2002). The main issues were meningoencephalitis and a lack of cognitive benefit despite 
successful Aβ plaque clearance (Holmes et al., 2008). As 2B3 binds APP as opposed to Aβ, its 
substrate is arguably less permanent than deposited Aβ, as APP can undergo cleavage by α-
secretase in the absence of β-secretase cleavage. The lack of binding to a substrate deposited 
in immunoreactive, extracellular plaques may hypothetically result in a reduced inflammatory 
response compared to traditional immunotherapy. The reduction in inflammatory markers 
observed by Rakover et al. (2007) following treatment of Tg2576 mice with an anti-APP β-
secretase cleavage site antibody supports this argument.  
The antibody approach used in this thesis offers an earlier intervention than other 
immunotherapy strategies through the inhibition of Aβ production, as opposed to post-
production clearance of excess Aβ. 2B3 may therefore offer further cognitive protection 
through the inhibition of Aβ toxicity, which is thought to peak in the soluble Aβ form, prior to 
plaque deposition (Walsh et al., 2002; Mucke et al., 200; Klein, Krafft & Finch, 2000). It is 
possible that the issues observed in clinical trials using anti-Aβ antibodies will be reduced or 
absent using an anti-APP β-secretase antibody. Undoubtedly other issues will present 
themselves, such as the detection of AD at an early (presymptomatic) stage. Overall, 
immunotherapy as an approach for AD treatment remains in its initial stages, and requires 
extensive investment of research to further optimise efficacy and reduce side effects. As such, 
2B3 and other anti-APP β-secretase antibodies remain potentially promising candidates.  
 
7.4 Future directions 
2B3 (or an alternative Aβ production downregulator) in vivo 
The work carried out to test the central hypothesis of this thesis is in its infancy. There is 
clearly a need for optimisation and replication of Experiment 15 in order to assess whether the 
numerical trends observed in the behavioural measures can be replicated. To further this 
work, a range of treatment time points should be employed, in which preventative action in 
young transgenic mice is contrasted against the more clinically relevant late-stage treatment 
intervention. This relates to the issue of reversibility of Aβ-induced synaptic damage as 
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highlighted by Tanzi (2005). The question of whether cognitive function can be restored in 
neurons which have been exposed to Aβ-induced impairments, and at what time point 
intervention is necessary to inhibit the initiation by Aβ of apoptotic signalling cascades has not 
yet been answered.  
The current work did not assess the effects of downregulating Aβ production on 
biochemical measures beyond Aβ levels. A range of biochemical markers of CNS functioning 
are available which could be utilised in future study. This may assess the effect of inhibition of 
Aβ production on inflammatory markers such as TNF-α, IL-1β, and S-100B (Craft, Watterson & 
van Eldik, 2005) as well as markers of synaptic density such as synaptophysin, synapsin, 
microtubule-associated protein-2 (Dawson et al., 1999), PSD-95 (El-Husseini et al., 2000) and 
neuronal calcium binding proteins such as calbindin D-28k and parvalbumin (Celio, 1990). This 
may provide a broader understanding of the direct effects of downregulation of Aβ production 
following varying durations of Aβ suppression. Furthermore, measures of products of 
proteolytic cleavage of APP by α-secretase (C83, sAPPα. P3, ICAD) in mice treated with 2B3 
compared to controls would support the interpretation that a potential lowering of Aβ is the 
result of inhibition of BACE1 and subsequent enhancement of non-amyloidogenic cleavage.  
As discussed in Chapter 1, Section 1.5.2, there is growing evidence to suggest that Aβ 
and NFT pathology are closely linked. King et al. (2006) suggests a mechanism by which an 
increase in soluble Aβ causes tau-dependent disassembly of microtubule proteins, placing tau 
downstream of Aβ in the disease cascade. Assuming the conditions under which 2B3 delivery 
could be optimised in vivo to replicate the knockdown of Aβ levels as observed in the primary 
neuronal cultures, it would be interesting to assess the effect of 2B3 in a model system which 
encompasses both Aβ and NFT pathology, such as the 3xTg model (Oddo et al., 2003). This 
would test whether modifications of Aβ levels could reduce both types of pathology despite 
only directly modifying APP processing. In addition, preventative action vs. treatment 
comparisons should be made evaluating the optimum intervention point for minimising or 
reversing the pathological interaction between Aβ and NFT. 
Furthermore, it would be beneficial to expand the range of cognitive assessments of 
treated APP mutation transgenic mice and controls to assess whether a potential reduction in 
cognitive deficits can be generalised across various memory and learning paradigms. 
Alternatively, demonstrations of beneficial effects being restricted to select functions could 
indicate differences in the degree of reversibility of Aβ induced neuronal or synaptic damage 
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across structures and neuronal populations. The benefits of expanded cognitive assessment of 
transgenic mouse models are discussed further below.    
 
Expanded cognitive assessment 
The utility of transgenic APP mutation models could be increased through the expansion of the 
range of cognitive tests traditionally used and the increased use of translational cognitive tests 
that map more closely onto patient-based tests. In addition, the cognitive developmental 
profile should be established through both longitudinal and cross-sectional assessment. These 
points apply both to the field generally and the work presented in the current thesis.  
The assessment of cognitive function in transgenic APP mutation models frequently 
utilises the Morris water maze, the radial arm maze and the object recognition task for the 
assessment of spatial reference-, spatial working- and object recognition memory respectively. 
Bussey et al. (2012) make a convincing case for the use of a cognitive battery of tasks assessing 
a variety of cognitive function, with a selection of tasks measuring similar processes. The 
administration of these tasks through the same touch-screen test chambers reduces the 
influence of the experimenter and apparatus variables on performance, and allows more 
direct comparison between tasks. When using this methodology, the order of administration 
of tasks must be carefully planned in order to avoid generalisation and transfer effects 
between tasks. A combination of longitudinal and cross-sectional design would be desirable.  
 In addition, attempts should be made to target aspects of cognitive decline that most 
accurately reflect the cognitive impairment observed in human AD patients. As an example, 
episodic memory deficits are an early diagnostic sign of AD in humans, and are assessed in 
tests such as CANTAB (Fray & Robbins, 1996). Episodic memory, the ability to recall an event in 
terms of its content and its temporal-spatial characteristics (Tulving, 1972), is thought to 
involve an element of conscious recall which calls into questions its application to animal 
cognition. Nevertheless, an analogue of episodic-like memory can be measured in rodents. 
These tasks require the recollection of “what” happened “where” and “when”, with the 
condition that all three aspects of an encountered event must be recalled (representing an 
integrated memory). Examples include an adaptation of the object recognition paradigm 
(Good, Hale & Staal, 2007) and a configural fear conditioning paradigm (Iordanova, Good & 
Honey, 2008) where temporal and spatial components are included. Thus, a greater focus on 
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the development of behavioural paradigms in mice with greater construct validity could offer 
a better platform on which to evaluate therapies.  
  
7.5 Summary 
Whilst work to develop disease-modifying treatments for AD has not been without obstacles, 
immunotherapy remains a promising possibility for the treatment of AD. The success and 
promise of immunotherapy up to this point is largely based on murine pre-clinical models, 
highlighting the essential role they have played in the field.  
The work presented in Chapters 2 – 5 extends the current understanding of the 
behavioural phenotypes of the APP(V717I) and PDAPP(V717F) models, allowing a more 
comprehensive picture to emerge in terms of the developmental profile of cognitive and 
anxiety-like behavioural impairments. The evaluation of 2B3 as a treatment for Aβ-related 
pathology progressed with the novel demonstration of successful downregulation of Aβ 
production in primary murine neuronal cultures. The impact of 2B3 on the behavioural deficits 
in PDAPP mice revealed at best only numerical improvements. Clearly, a more extensive study 
is required to assess the impact of 2B3 on cognition in APP mice. Overall, however, the results 
are an important first step in the evaluation of novel immunotherapeutic approaches.  
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